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Summary:
Proteoglycans and glycosaminoglycans are implicated in a wide range of 
biological processes and phenomenom. Perhaps most importantly, the are 
attributed with a role in the modulation and maintenance of the 
physiochemical properties and integrity of the extracellular matrix, and in 
mediating cell adhesion and growth.
Our understanding of the role of proteoglycans and glycosaminoglycans in 
tumorigenesis and metastatic spread is limited. Few proteoglycans have 
been determined to possess specific biological functions. Other studies 
have tried to correlate changes in the synthesis and properties of 
proteoglycans and glycosaminoglycans with metastatic potential and 
progression, but many of the observations have proved to be somewhat 
conflicting. Therefore the effects and relevance of changes in the 
properties of and alterations in the biosynthesis of these molecules have 
not been fully elucidated.
In this study, the proteoglycans and glycosaminoglycans isolated from a 
series of B16 melanoma cell lines that differed in metastatic potential 
(as measured by lung colonization) were analyzed, and their chemical 
properties determined using ion exchange and size exclusion 
chromatography. In addition, the cell phenotypes of the cell lines were 
partially characterized, with cell adhesive and proteolytic responses 
being measured. Chemical agents, acknowledged as being capable of 
modifying glycosaminoglycan biosynthesis, were employed to modify the 
chemical properties of these molecules. The aim was to determine 
whether changes in the charge properties and the size of the GAG chains 
influence the ability of these cells to form lung metastases after 
intravenous inoculation, and whether a change or consistant alteration in
the properties of the proteoglycans and glycosaminoglycans could be 
identified as being related with metastatic potential.
Cell adhesion is a central process in many phases of the metastatic 
cascade. Many tumour cell types can be demonstrated as possessing 
adhesive preferences for extracellular matrices or isolated matrix 
proteins in vitro. The B16 cell lines were therefore assayed for such 
preferences and whether or not chemical modulation of the biochemical 
properties of the proteoglycans and glycosaminoglycans synthesized 
influenced their adhesive responses.
No consistent adhesive preference could be identified that appeared to be 
related to metastatic potential for all of the cell lines tested. Modulation 
of the chemical properties of the glycosaminoglycans synthesized by the 
cell lines also appeared not to correlate with changes in metastatic 
potential. Differences in the composition and properties of the 
glycosaminoglycans synthesized did not appear to influence the level of 
cell adhesion either. In conclusion, preferential adhesion to complex 
matrices and individual matrix proteins did not appear to be related to the 
metastatic potentials of the B16 melanoma cell lines used in this study, 
and alterations in the chemical properties of the glycosaminoglycans 
synthesized also did not appear to influence lung colonization.
Two consistant relationships were however identified. The ability to 
release 35S-isotope from metabolically labelled subendothelial matrix 
and an increased expression of cell surface glycosaminoglycans correlated 
with high levels of lung colonization. Increased cell surface 
glycosaminoglycans may be related to an increase in the number or size of 
the of the glycosaminoglycan chains polymerized onto proteoglycan core
protein, whereas increased 35S-releasing activity may represent an 
increase in the ability of more metastatic cell lines to penetrate 
basement membrane-like structures, a rate regulating step in the process 
of metastasis. The relevence of these two parameters is discussed in 
more detail within the text.
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(1): Fig.1 : Tumour cell metastasis
The Proteoglycans of Metastatic and Non-Metastatic B16
Murine Melanomas
1.1.1. Neoplasia and Metastatic Disease
The development of secondary neoplastic disease rather than the primary 
neoplastic lesion is often the major cause of cancer morbidity. Secondary 
disease originates through the dissemination of malignant tumour cells 
resulting in the establishment of cancerous deposits in dispersed 
anatomic locations. This process of metastasis is a complex, multi-step 
process involving an interplay between the biological properties of tumour 
cell and host (Fig.1): malignant tumour cells detach from the primary 
tumour and invade adjacent tissue, and may also disseminate by 
intravasation into the microvasculature or lymphatics. The interactions 
between tumour cells within the vasculature or lymphatics and the 
constituents of blood and lymph influence the outcome of the metastatic 
event. Upon lodgement in an organ, tumour cells extravasate from the 
microvasculature and gain access to the organ parenchyma which, if 
suitable, supports tumour cell proliferation and the establishment of 
secondary tumours.
Fig.1: Tumour Cell Metastasis-(reproduced from Fidler^l99Q).
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Conventional therapies have failed to overcome or limit the problems 
associated with metastatic disease. The dispersed distribution of 
metastatic lesions, the heterogeneity of cell phenotype within a lesion, 
and the common biological properties shared by both normal and 
neoplastic cells contribute to this failure. Attention has focussed upon 
determining, early on in the course of the disease, the aggressiveness and 
metastatic potential of individual tumours thereby permitting the 
appropriate stage-specific therapies to be devised. Advances in the 
identification and characterization of the biochemical markers and 
factors specific to tumour cells, and in particular to malignant celis, have 
been made with the aim of providing improved strategies for the earlier 
identification and treatment of tumours and their metastases.
Melanoma, a malignant tumour of melanocytes, is the leading cause of 
death among diseases of the skin and its incidence continues to rise 
(Liotta etal., 1987; Herlyn, 1990). Melanocytes are responsible for skin 
pigmentation, and are derived from neural crest cells (Herlyn, 1990) that 
migrate during embryogenesis into the embryonic skin and organs. In 
normal skin, melanocytes are found distributed amongst the basal 
keratinocytes in the epidermis and are separated from the dermis by the 
epithelial basement membrane.
The prognosis of melanoma has been correlated with clinical and 
histological features, the most important being tumour thickness 
(Breslow, 1970). Primary malignant melanomas develop fundamentally as 
a single pathological process but with different clinical, histological, and 
biological expressions (Ackerman & Su, 1979; Herlyn, 1990). The current 
criteria used for the prognosis of melanoma are useful in predicting the
2
aggressiveness of a melanoma in a population but cannot accurately 
predict the aggressiveness of an individual's melanoma. There is therefore 
a need for highly accurate biochemical markers.
1.1.2. Tumour Induction
The failure of cells to respond to those signals that regulate cell growth 
and phenotype can result in neoplasia. Neoplasms are believed to originate 
as focal and probably clonal proliferative lesions (Fidler & Talmadge,
1986). Initially, primary tumours are most probably benign, and this stage 
tends not to be life-threatening, with many such lesions regressing 
spontaneously. The loss of growth regulation results in tumorigenesis and 
the development of the primary lesion. Subsequent lesions with abnormal 
form and cytology and the biological properties of cancer appear later.
The development of a malignant, life-threatening, phenotype is separate 
and distinct from tumorigenesis, and gives rise to metastasis. 
Tumorigenesis is an early event in cell transformation and is a 
prerequisite for metastasis (Newbold etal. 1982). These two events are 
controlled by separate genetic elements. Cell hybrids generated from 
fusions between (metastatic x non-metastatic cells) and (metastatic x 
normal cells) separated tumorigenic ability from metastatic competence. 
Tumorigenic, non-metastatic but not non-tumorigenic, metastatic hybrids 
could be isolated. Metastatic revertants which arose from non-metastatic 
hybrids possessed karyotypic alterations including the loss of genetic 
elements or whole chromosomes (Weiner etal., 1974; Stanbridge etal.,
1981). Chromosomal abnormalities have been detected in chromosomes 1, 
6 , and 7 of malignant melanomas and in vertical growth phase (VGP) 
melanomas which are predisposed to metastasize (Herlyn etal.,1985), and 
alterations in oncogene status, including the overexpression of N-myc
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(Bauer etal., 1990), the deletion or translocation of c-myb (Meese etal., 
1989), and mutations in K-ras (Shukla etal., 1989) have all been detected 
in human melanomas.
The genetic instability of hybrids has minimised their potential in 
analysing the genetic events underlying the metastatic process. This 
problem has been circumvented by the cloning of cell lines differing in 
metastatic potential from primary tumours, metastases and established 
tumour cell lines. (Fidler, 1973a; Fidler & Hart, 1982; Poste etal., 1982a). 
Tumour cells of increasing metastatic capacity have been isolated from 
successive metastases after intravenous or subcutaneous inoculation 
(Fidler, 1973a; Poste etal., 1982a), and cell lines isolated in this manner 
have provided greater population stability for the analysis of the events 
underlying and contributing to the metastatic process. Various selection 
procedures have demonstrated the heterogeneity in cell phenotype that 
exists in primary and secondary tumours and in cultured tumour cell 
populations (Fidler, 1973a; Frost & Kerbel, 1981; Poste etal., 1982b; 
Garbisa etal., 1988).
1.1.3. The origin and nature of metastasis
Tumour populations are heterogeneous, containing cells of differing 
metastatic potentials. In addition to in vivo and in vitro selection 
procedures, tumour cell subpopulations can be selected on the basis of 
particular cellular characteristics which may be important in the 
metastatic process. These include lectin-binding (Schirrmacher etal., 
1982; Lotan etal., 1989), resistance to natural killer (NK) cells and 
macrophages (Hanna, 1985; Mantovani, 1990), interactions with blood 
components and the microvasculature (Gasic, 1984; Weiss etal., 1989), 
adhesion to extracellular matrices and their components (Liotta etal.,
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1986b; Juliano, 1987), and drug resistance (Bradley etal., 1988). Each of 
these factors constitutes a selective pressure, implying that metastasis 
is a non-random process.
Metastasis is a selective event, dependent upon specific cellular 
properties which enable the cell to successfully complete each stage of 
the process (Nicolson, 1982a, 1988a; Nicolson etal., 1982). Poorly 
metastatic cells have little probability of successful metastasis, 
whereas highly metastatic cells have a high probability. Even when highly 
metastatic cells are injected intravenously, not every cell survives to 
proliferate at a distant site, indicating that all metastatic cells do not 
have an equal chance to produce a metastasis (Price etal., 1986; Fidler, 
1989).
Malignant cells constitute small subpopulations within the primary 
tumour but become dominant in metastases through the actions of 
selective pressures. Although metastasis formation represents a cloning 
process (Talmadge etal., 1982; Fidler & Talmadge, 1986; Price etal., 
1986), the cell population within a metastasis is susceptible to 
phenotypic drift. Primary neoplasms are often assumed to be monoclonal 
in origin but the generation of different cell subpopulations within the 
tumour occurs through time. Cell heterogeneity develops in rapidly 
expanding clonal populations of tumour cells (Poste & Fidler, 1980; Poste 
etal., 1982b; Raz, 1982). Cells isolated from metastases and clonal 
populations do not possess equal metastatic ability. The majority of 
spontaneous metastases that originate are clonal in origin (Poste etal., 
1982b; Talmadge etal., 1982; Nicolson, 1984b; Hu etal., 1987), and within 
individual metastases, variant clones arise which further diversify the 
phenotype (Raz, 1982; Chambers etal., 1984).
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Metastasis appears to be a transient phenomenon, possibly in response to 
changes in intratumour environment dependent upon both tumour and host 
factors. Alterman etal. (1989) described a B16 melanoma which was 
non-metastatic in young mice but spontaneously metastasize in aged or 
hyperimmunized young mice. Similar altered cellular responses to 
intratumour environment are also observed when tumour cells are exposed 
to hypoxic conditions. The resultant increase in metastatic potential may 
be a consequence of an increase in the ploidy of the affected cells (Young 
etal., 1988; Hill, 1990; Young & Hill, 1990). Hypoxic conditions arise in 
poorly vascularized tumours and metastasis may therefore be a response 
to such stress conditions (e.g. hypoxia, nutrient depletion, immune cell 
infiltrates, and necrosis) which develop within growing tumours. Once 
cells metastasize and the conditions of stress have diminished, they may 
lose their acquired metastatic potential which may only be reacquired 
when conditions of stress develop once more. The development of cell 
heterogeneity within a tumour therefore appears to be modulated by 
environmental factors and conditions.
1.2 .1. The Three-Step Theory of Tumour Cell Invasion 
Tumour cell invasion of the extracellular matrix (ECM) is not a 
consequence of the mechanical aspects of uncontrolled cell growth forcing 
cells into adjacent tissue. Cell invasion can occur without cell 
proliferation and is an active process requiring ongoing protein synthesis 
and proteolysis. Tumour cell invasion and metastasis can be blocked or 
inhibited by both natural and synthetic inhibitors of cell adhesion, protein 
synthesis and proteolysis (Thorgeirsson etal., 1982; Iwamoto etal., 1987; 
Humphries etal., 1988b; McCarthy etal., 1988; Reich etal., 1988a; 
Hoyhtya etal., 1990).
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In malignant tumours, cell proliferation is followed by local invasion of 
the adjacent host tissues. Invasion is preceded by local degradation and 
remodelling of the ECM surrounding the tumour cells. Three sequential 
biochemical events appear to underlie tumour cell invasion of the tissue 
matrix (Liotta, 1986): cell adhesion, matrix degradation, and cell 
locomotion .
1.2.2. Tumour Cell Adhesion to the ECM
The ECM places both physical and biochemical constraints upon cells by 
providing positional and behavioural information and by influencing cell 
phenotype (Liotta, 1986; Patel & Lodish, 1987; Hay, 1989). The response of 
tumour cells within a matrix often differs to the response exhibited by 
normal or benign tumour cells which may shift into a resting or 
differentiated state. ECM alterations can therefore induce alterations in 
both cellular characteristics and behaviour (Fairbairn etal., 1985; lozzo, 
1985; Boyd etal., 1988; Noel etal., 1988; Starkey, 1990).
Malignant cells invade local tissue either as individual cells or as small 
cell aggregates. This requires that the invading tumour cells adhere to 
some component(s) of the ECM. Cell attachment to a substrate is a 
necessary step for cell-mediated matrix degradation. Increased adherence 
to specific matrix components, and to naturally occurring and 
reconstituted matrices, can correlate with the metastatic behaviour of 
some tumour systems (Terranova etal., 1984; Liotta, 1986; Chung etal., 
1988; Hunt, 1989; Hutchinson etal., 1989; Lichtner etal., 1989; Tullberg 
etal., 1989). The ECM also influences and modulates the secretion and 
activities of the enzymes responsible for its degradation 
(Turpeenniemi-Hujanen etal., 1986; Nabeshima etal., 1986; Emonard et
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al., 1990).
1.2.3. Matrix Degradation
Matrix dissolution can occur through several mechanisms. Tumour cells 
can directly secrete specific proteinases into the local environment or 
utilize surface- or matrix-bound proteinases (Moscatelli & Rifkin, 1988; 
Zucker, 1988). Proteinases can then directly degrade the matrix or 
alternatively, activate other proteinases present within the matrix.
Matrix lysis most likely occurs at the region close to the tumour cell 
surface where the concentration of protease can outweigh the natural 
protease inhibitors present in matrix and in serum (Beckerle etal., 1987; 
Pollanen etal., 1988; Estreicher etaL, 1990), and ECM destruction and the 
presence of elevated levels of proteinases can correlate with metastatic 
potential (Liotta etal., 1977; Sloane etal., 1981, 1982).
Liotta etal. (1980,1982) proposed that invading tumour cells secreted 
matrix degrading enzymes. Collagens are the major structural component 
of ECMs and tumour cell-derived collagenases have in some instances 
correlated with both tumour aggressiveness and metastatic potential 
(Salo et al., 1982; Turpeenniemmi-Hujanen etal., 1985,1986; Emonard et 
al., 1990). Additionally, tumour cells can degrade the non-collagenous 
components of the ECM. The production of heparanase (Ricoveri & 
Cappalletti, 1986; Vlodavsky etal., 1988), plasminogen activators (Wang 
et al., 1980; Borgenmann & Jones, 1983), cathepsins (Sloane et al., 1981,
1982), and the ability of cells to utilise matrix-bound proteases has also 
been demonstrated to correlate with metastatic potential.
Traversal of the vascular basement membrane (BM) is a vital step for the 
haematogeneous dissemination of tumour cells, an important route for
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metastatic spread. Several studies have described the loss or disruption 
of host BM adjacent to the invasive front of in situ tumours, but the 
significance of these abnormalities in the pathology of the disease 
remains unclear, and may be one consequence of the process of 
dedifferentiation that many tumour cells undergo (Hayman etal., 1982; 
Barsky etal., 1983; Gabbert, 1985; Forster etal., 1986; Gusterson etal., 
1988). Local modification of the membrane may be necessary for the 
migration of tumour cells to occur through this structure, and it is 
possible that tumour cells that intravasate are those subpopulations of 
cells selected for their ability to degrade vascular BMs.
1 .2.4. Tumour Cell Locomotion
Tumour growth and invasion stimulates both angiogenic and immune 
responses, allowing tumours to recruit endothelial cells and lymphocytes 
to their vicinity (Gabbert, 1985). The generation of a capillary network 
and cellular immune response are natural, invasive mechanisms. Factors 
produced by tumour cells and by invading lymphocytes and endothelial 
cells may facilitate the spread of malignant cells by remodelling the 
matrix and by stimulating cell growth and directed locomotion (Gasic,
1984; Shing etal., 1984; Hanna, 1985; Nabeshima etal., 1986; 
Gospodarowicz etal., 1987; Savion etal., 1987; Terranova etal., 1989; 
Weiss etal., 1989; Blood & Zetter, 1990). Matrix dissolution destabilizes 
the physical constraints on malignant cells permitting cell migration. The 
final step in the invasion process is tumour cell locomotion into the 
region of proteolytically modified matrix.
Tissue invasion continues by repetition of the adhesion, degradation and 
locomotion steps. Tumour cells may also migrate in response to ECM and 
BM components and their degradation products (Fligiel etal., 1986; Furcht
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etal., 1986; Liotta, 1986; Nabeshima etal., 1986; Blood etal., 1988; 
Humphries etal., 1989; Hunt, 1989) and to motility factors (Liotta & 
Schiffman, 1988; Kohn etal., 1990), and these may interact to direct cell 
locomotion and influence the specificity of metastases.
Many tumours have associated oedema, necrosis and immune cell 
infiltrates (Gabbert, 1985). Oedema causes distension and loss of the 
regular structure in the ECM, increasing the intercellular spaces and 
producing a more porous tissue which may more readily permit tumour 
cell invasion. Tumours themselves have no lymphatics but lymph has been 
detected to flow from the centre of the tumour towards its periphery and 
invasion front. Invading cells at the invasion front of tumours tend to 
exist as single cells or as small cell clusters, and this flow of lymph may 
passively assist the invasive process by physically directing cells 
towards the lymphatics.
1.3.1. Organ Colonization
Certain tumour types appear to preferentially metastasize to specific 
body sites (Nicolson, 1988a; Fidler, 1989). The patterning is often 
determined by the tumour site and can be influenced by the mechanical and 
physical forces acting on the tissue. However, this does not explain all 
patterns of metastasis. Even when tissue fragments are transplanted to 
ectopic sites, tumour cells exhibiting an organ preference still 
preferentially colonize the displaced tissue (Poste & Fidler, 1980; Hart & 
Fidler, 1981). This homing response is not due to a preferential 
accumulation of cells within the tissue. The intravenous administration of 
radiolabelled tumour cells into animals demonstrated that there was no 
bias in the distribution of tumour cells to specific organs or tissues 
(Fidler, 1989). Tumour cells were detectable in all organs tested, even
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those in which the tumours rarely or never occurred. It can be concluded 
that the concept of tumour cell homing is two-step: tumour cells must 
initially lodge and subsequently grow at specific organ sites. The 
predictability of the pattern of metastasis for tumours of defined 
histological type indicates that metastasis contains non-random 
elements.
The pattern of metastasis distribution cannot be predicted from the 
pattern of initial tumour cell arrest. Similar numbers of cells from a 
K-1735 murine melanoma cell lines were found to initially lodge in the 
lungs of experimental animals immediately after intravenous inoculation, 
irrespective of the metastatic potential (Price etal., 1986). Rather, the 
tumour cell survival rate appears to be a major determinant of 
colonization pattern. At 24 hours, non-metastatic cells had a lower 
survival rate than metastatic cells, and after 3 days only metastatic cells 
were still viable. Paget (1889) suggested that certain tumour cells might 
possess an affinity for the environment provided by certain organs, and 
this might account for the non-random distribution of tumour metastases. 
The organ-specificity colonization exhibited by various tumour cell lines 
may be dependent upon factors produced within the organs which may 
induce homing responses (Liotta & Schiffman, 1988; Kohn etal., 1990) and 
stimulate tumour cell growth (Cavanaugh &Nicolson, 1989). In conclusion, 
both host tissue and tumour cell properties are important in dictating the 
patterns of tumour metastasis.
1.3.2. Angiogenesis and Intravasation
The development of a blood supply within a solid tumour mass is critical 
for its survival. Tumour cells can release factors from the ECM which 
stimulate endothelial cell growth and direct their migration towards the
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tumour mass (Shing etal., 1984; Vlodavsky etal., 1982, 1988; Blood & 
Zetter, 1990; Mahadevan & Hart, 1990). These factors include the 
heparin-binding growth factors and endothelial cell growth factors. The 
capillary networks within tumours are defective compared to those from 
normal tissues (Blood & Zetter, 1990; Bouck, 1990). These defects include 
abnormal capillary endothelial cell morphology and subendothelial matrix 
and increased permeability, which may result in leaky vascular capillary 
networks. Defective capillaries may not be as an efficient barrier to 
invasion and therefore allow tumour cells to gain easier access to the 
general circulation. The abnormal microvasculature may be the 
consequence of the tumour cell-induced alterations in the matrix or 
caused by the factors they secrete or release from the matrix.
Tumour cells within vascularized tumours are found as cuffs of cells 
around new microvessels (Blood & Zetter, 1990; Bouck, 1990). Those 
malignant cells that penetrate the endothelial barrier may be transported 
to distant tissues, or proliferate at the site of penetration and directly 
shed cells into the blood system for dissemination. Removal of the 
primary tumour results only in removal of the initial source of malignant 
cells, and since most tumours are detectable only at an advanced stage of 
development, metastasis will have most probably occurred if the 
phenotype has been generated. Cells which have metastasized and formed 
secondary lesions also possess the potential to become the source of new 
metastatic cells.
1.3.3. Extravasation and Cell Killing
Once in the circulatory or lymphatic systems, tumour cells must overcome 
a new series of problems. Most tumour cells lodge in the first organ 
capillary bed they encounter and it is estimated that only 0.1% of
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circulating tumour cells succeed in forming a successful metastases 
(Poste & Fidler, 1980). Cell lodgement in a capillary bed can either be a 
specific or passive process. Specific lodgement involves adhesion to 
endothelial cells or subendothelial BM and most probably involves specific 
cell surface receptors on both the tumour and endothelial cell. Tumour 
cells within the circulatory system interact with blood components and 
other circulating cells, both normal and neoplastic, a process which may 
influence the cells' fate.
Most disseminated malignant cells are destroyed within the circulation, 
apparently by two distinct mechanisms of cell killing. The host immune 
system is acknowledged as being responsible for some of this killing 
(Fidler & Bucana 1977; Fidler & Kripke 1980). Macrophages, neutrophils, 
and natural killer cells constitute the non-specific immune surveillance 
mechanisms. Specific immunity is mediated by activated 
antigen-dependent cytotoxic T-lymphocytes and antibodies against tumour 
antigens. The rapid destruction of all circulating tumour cells cannot be 
accounted for by the immune system alone. Passive mechanisms also play 
a prominent role in tumour cell killing. Tumour cells encounter mechanical 
forces, including turbulence and impaction as they are transported rapidly 
within the general circulation. These forces probably account for the high 
death rate of circulating tumour cells. Other factors may include the 
reduced deformability of tumour cells compared with that of blood cells, 
and this would affect the tumour cells' ability to survive the high shear 
forces present within the microcirculation (Weiss etal., 1989). The 
survival of circulating tumour cells may thus be related to an increase in 
tumour cell deformability or their ability to form emboli with other 
tumour cells (Nicolson 1982a; Weiss et al., 1989) or with other tumour 
cells or with circulating blood cells (Gasic etal., 1986).
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Embolus formation is advantageous for the tumour cell and may endow it 
with a distinct selective metastatic advantage (Fidler & Bucana 1977; 
Fidler & Kripke 1980; Gasic 1984). Embolus formation increases the 
probability of tumour cell lodgement in blood capillaries through physical 
entrapment (Nicolson, 1988a, Blood & Zetter, 1990), and is a potential 
means of masking the tumour cell from the hostile environment of the 
vasculature. Tumour cells may also utilize the biological properties of the 
other cells within the embolus to adhere to the capillary endothelium and 
initiate extravasation (Weiss etal., 1989; Blood & Zetter, 1990).
The arrest of tumour cells in a capillary may physically disrupt the 
endothelial cell layer or cause its partial retraction exposing the 
underlying endothelial BM (Lapis etal., 1988). Traversal of this matrix is 
the rate limiting step in extravasation. Tumour cells can adhere to the BM 
matrix and to the basolateral surface of the retracted endothelial cells. 
Once tumour cells have adhered, the endothelium re-extends over them. 
Endothelia derived from different origins responds differently to tumour 
cell attachment; arteriole endothelium does not retract but outgrows and 
encompasses attached tumour cells. As tumour cells proliferate they 
occlude the arteriole lumen and extravasate only when the original 
endothelium is mechanically disrupted (Lapis etal., 1988).
Invasion of the endothelial BM completes the process of metastasis. Local 
dissolution of the matrix occurs just below the tumour cell after 8-24 
hours followed by extension of tumour cell pseudopodia into this region 
(Poste & Fidler, 1980). Within 24-48 hours the tumour cell has fully 
extravasated and is in a position to initiate a secondary tumour by firstly 
proliferating around the capillary bed before migrating through the
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perivascular interstitial matrix and into the organ parenchyma.
Metastasis is therefore a selective, sequential process. The probability of 
metastasis is never 100% and only a very small percentage of malignant 
cells survive to form metastases. Stochastic events influence the 
outcome (e.g. cell arrest in organs which will not support metastases or 
destruction in the circulation). Metastasis requires that tumour cells 
complete all of the individual processes that comprise the metastatic 
cascade. It is not sufficient for tumour cells to excel at any particular 
aspect(s) of the process, since failure to complete any of the other phases 
of the process inevitably results in tumour cell death.
1.4.1. The Extracellular Matrix
The extracellular matrix (ECM) is a complex 3-dimensional meshwork of 
collagen and elastin embedded in a viscoelastic ground substance of 
glycoproteins, glycosaminoglycans, and proteoglycans. The ECM represents 
a supportive scaffold that compartmentalizes tissues and acts as a 
mechanical barrier to invasion. It determines tissue architecture, 
mediates cell attachment, influences morphogenesis, differentiation and 
mitogenesis, and serves as a macromolecular filter. The ECM is believed to 
exert its influence through interactions with specific cell surface 
receptors. In neoplasia these interactions between cell and matrix may be 
altered and this in turn may influence cell behaviour. Different ECMs exist 
which are composed of tissue-specific collagens and glycoproteins, 
secreted and assembled by the constituent cells of the tissue, and which 
are responsible for the different structural and physical properties of the 
tissue (Junker & Heine, 1987; Campbell & Terranova, 1988; McDonald,
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1988; Hay, 1989; Timpl, 1989).
1.4.2. The Basement Membrane
The basement membrane (BM) is a highly specialised ECM that further 
compartmentalizes tissues and is central to both the progression of 
invasive tumours and haematogenous dissemination (Kramer etal., 1982; 
Liotta etal.t 1977,1980,1982; Vlodavsky etal., 1982; Barsky etal.,
1983; Martinez-Hernandez & Amenta, 1983; Furcht etal., 1986). The BM 
prevents the movement of cells between different tissue compartments, 
and acts as a molecular sieve in regulating the movement of 
macromolecules and ions (Kanwar etal., 1981). It is primarily composed 
of BM-specific collagen IV, laminin-nidogen, and heparan sulphate 
proteoglycans (HSPG) (Leblond & Inoue, 1989; Timpl, 1989). Electron 
microscopy visualizes the BM as a 20-200nm thick region comprised of 
two discrete zones; a lamina densa (electron dense) and a lamina lucida 
(electron lucid). The BM is anchored to connective tissue (CT) via the pars 
fibroreticularis, a network of collagen VII microfibrils that extend from 
the lamina densa into the adjacent CT where they terminate in BM-like 
anchoring plaques interconnected by collagen VII microfibrils.
The cells that remain in close contact with the BM are normally 
responsible for its synthesis and deposition. Cell interactions with the BM 
are regulated by specific cellular receptors which bind defined BM 
components (Hynes, 1987; Lotz etal., 1990), and the close contact 
between the BM and the cells responsible for its synthesis may represent 
a form of autoregulation. BM structural integrity is maintained through 
covalent cross-links and non-covalent interactions between the 
constituent proteins and proteoglycans resulting in a highly insoluble 
structure (Kleinman etal., 1983; Martin etal., 1984; Leblond & Inoue,
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1989; Timpl, 1989).
1.5.1. Details of Project
The B16 murine melanoma is a standard model for metastasis studies. It 
has been maintained in culture since it was first isolated in 1954, and 
from this cell line many variants have arisen which differ in metastatic 
abilities and organ preference. The variants described in this series of 
experiments were derived from a poorly metastatic B16F1 melanoma as 
described by Fidler (1973a), and preferentially colonizes the lungs of 
syngeneic C57BL mice after intravenous inoculation. From this cell line, 
variants were derived using cell cloning techniques and serial lung 
colonization selection methods. From these cell lines the 
glycosaminoglycans (GAGs), and in some instances proteoglycans (PGs), 
were partially characterized in order to determine whether qualitative or 
quantitative differences existed between different cell lines, and 
furthermore, whether they correlated with metastatic potential. The 
charge density of the various GAGs was of particular interest since this 
could influence various cell properties including cell adhesion and ligand 
binding.
Due to the location of the proteoglycans and GAGs at the cell surface, and 
their potential to interact with other cell and matrix structures, the 
effects of agents which altered GAG polymer modifications were used to 
investigate whether alterations in GAG biosynthesis influenced other 
cellular characteristics, in particular cell-cell and cell-matrix 
interactions, and more importantly, metastatic potential. Metastatic cells 
often exhibit a higher affinity for the adhesive glycoproteins and 
collagens of the ECM, and an ability to synthesize or utilise matrix 
degrading enzymes; the B16 melanomas were therefore assayed for these
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properties.
The evidence concerning the relationship between cell GAGs and 
metastatic potential is often conflicting. Different cell types exhibit 
widely differing GAG profiles and thus no clear picture has been 
established. It was intended that by characterizing some of the properties 
of the GAGs synthesized by a series of related B16 melanomas that we 
might identify and gain an insight into those properties which may be 
critical for or advantageous to the metastatic phenotype.
2.1.1. Cell adhesion and the extracellular matrix
Cell adhesion to the extracellular matrix (ECM) and other cells is a necessary 
and critical step for several biological functions. Many normal cell functions 
including cell spreading, growth and division, migration, proteolysis, 
differentiation, and morphogenesis rely upon adhesive interactions during 
their progression. Many of these events are paralleled in the processes of 
tumour cell invasion and metastasis and specific steps within the 
metastatic cascade can be identified where cell adhesions are involved. 
Consequently, tumour cell adhesive interactions with the ECM and other cells 
are critical to the successful completion of metastasis.
The ECM provides functional and positional information which mediates, 
regulates, and co-ordinates cell function and behaviour. This requires 
intimate contact between cells and the matrix, which is mediated via 
distinct, functional cell surface receptors for matrix proteins. Responses are 
therefore governed by the cells' ability or inability to adhere to the 
constituents of the matrix. The ECM is generated by the secretion of 
glycoproteins, proteoglycans and glycosaminoglycans (GAG) which are 
assembled locally into organized networks by cells. The composition and 
organization of the ECM differ between tissues; connective tissue fibroblasts 
and muscle cells are surrounded by their matrix whereas epithelial cells are 
in contact with the matrix at one cell surface only.
Tumour cell metastasis involves multiple cell-cell and cell-matrix adhesion 
events, initiating at the detachment of cells from the primary tumour and 
terminating upon the formation of metastatic foci in secondary organs. 
Throughout the metastatic process, tumour cells must also evade the host 
immune system. Many of these multiple cell-cell and cell-matrix 
interactions that occur may represent transient phases which facilitate
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other processes deemed necessary for metastasis. For example, matrix 
dissolution requires the initial attachment of a cell to a matrix component, 
while tumour cell emboli formation via cell-cell interactions is believed to 
afford protection and improve tumour cell survival in the haematogenous 
phase of metastasis.
Several antimetastatic therapies have concentrated on trying to block the 
adhesive interactions formed by tumour cells and some success has been 
recorded. Intact cell surface bound ECM components can influence artificial 
metastasis (Terranova etal. 1984), and antibodies and peptides which block 
in vitro cell adhesion can completely inhibit experimental metastasis 
(Humphries etal. 1986b, Iwamoto etal. 1987, Vollmers & Birchmeier, 1983a, 
1983b). Such results emphasize the importance of cell adhesion and its 
possible correlation with metastatic potential.
The level of cell-matrix and cell-cell adhesion has been demonstrated to 
have both positive and negative correlations with the metastatic potential of 
various tumour cell lines. Organ-derived ECMs enhance the attachment of 
murine neuroblastoma cells compared to controls (Hutchinson etal., 1989) 
with enhanced attachment correlating with increased metastatic potential in 
vivo. Conversely, cells selected in vivo for increased metastatic potential 
exhibited an enhanced attachment to organ-derived matrices and target organ 
endothelia (Nicolson, 1982b). This correlation is not universal however.
Zoller and Matzko (1989) reported that a reduction in the adherence of 
fibrosarcoma cells did not alter their metastatic potential, whereas Benke et 
al. (1988) described a murine lymphoma adhesion variant with similar in 
vitro metastatic potential as its parental, non-adherent cell line but differed 
in its in vivo growth and dissemination characteristics.
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Cell adhesion to target organ endothelium and its underlying basement 
membrane are amongst the earliest adhesion events in the experimental 
metastasis model. Tumour cells can exhibit adhesion preferences to these 
structures with cells being able to distinguish between capillary and 
lymphatic endothelial cells and subendothelial matrices from different 
sources and can correlate with metastatic potential (Lichtner etal., 1989; 
Bevacqua etal., 1990). Alby & Auerbach (1984) reported that tumour cells 
exhibited higher adhesion to endothelial cells of similar histologic 
derivation, and Nicolson and Winkelhake (1975) demonstrated that B16 
murine melanoma cells exhibit the same heterotypic aggregation preference 
with partially purified target organ cells as they do in organ colonization in 
vivo.
In some instances, altered tumour cell adhesion is concomitant with the 
expression of antigens not present on the surface of normal cells and 
tissues (Vollmers & Birchmeier. 1983a, 1983b). Since monoclonal antibodies 
directed against these antigens have no effect upon the attachment of normal 
or differentiated cells, it would appear that under certain circumstances 
tumour-associated antigens may contribute to the altered adhesive response.
The ECM exerts profound effects upon cell phenotype. ECM synthesized by 
differentiated colon carcinoma cells induces poorly differentiated, highly 
metastatic carcinoma cells to acquire a more benign phenotype (Boyd etal.,
1988). The matrix and its components can modulate cell shape and 
morphology with subsequent changes in gene expression. In the presence of 
plasma fibronectin, chondrocytes have a polygonal morphology but develop an 
elongated, fibroblastic morphology in response to cellular fibronectin
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(reviewed by Watt, 1986). The influence of ECM on cell shape is therefore 
dependent not only upon its composition and organization, but also the origin 
of the cell.
A common approach in the examination of cell-matrix interactions is to 
study the response of cells to individual ECM components. In this study, 
having isolated B16 melanoma cell variants of differing metastatic 
potentials, their abilities to attach to defined ECM components of stromal 
and BM localization was investigated. The proteins of major interest were 
fibronectin (reviewed by Humphries etal., 1989) and laminin (reviewed by 
Hunt, 1989, Campbell & Terranova, 1988) whose biological functions and 
importance, especially in metastasis, are well documented. Adhesion to the 
major structural components of ECMs, interstitial collagens I/Ill and BM 
collagen IV was also investigated.
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2.1.2. Cell adhesion and tumour cell metastasis 
ECMs exert their biological influences through their constituent proteins, 
many of which are multifunctional. Matrix proteins can induce a more 
normal phenotype in transformed cells (Fairbairn etal.,  1985; Boyd etal., 
1988; Luikart et al., 1990), the synthesis of proteolytic enzymes 
(Turpeenniemi-Hujanen et al., 1986; Teale et al., 1988), differentiation 
(Boucaut etal., 1984; Bronner-Fraser, 1986; Foster et al., 1987; Flay,
1989) and the synthesis of differentiation-associated proteins (Bissell et 
al., 1987; Bloom & Wicha, 1988), in addition to influencing cell growth 
(Couchman etal., 1982; Bitterman etal., 1983). These cell responses are 
governed by the ability to adhere to constituents of the ECM via cell 
surface integrin and non-integrin receptors (Hynes, 1987; Juliano, 1987).
The adhesive proteins of the ECM actively contribute to the pathogenesis 
of diseases characterized by aberrant adhesion such as cancer. The 
acquisition of a metastatic phenotype probably involves alterations in the 
cell's adhesive properties, as observed during neoplastic transformation 
(Junker & Heine, 1987; Benke et al., 1988). Metastasis involves a series of 
co-ordinate cell processes many of which depend upon cell adhesion, and 
agents which interfere with cell adhesion can also block tumour cell 
metastasis (Vollmers and Birchmeier, 1983a, 1983b, Vollmers etal.,
1984; Humphries etal., 1988b; McCarthy etal., 1988).
The ECM can exert profound effects upon cell behaviour. Many tumour cell
lines demonstrate reproducible alterations in their adhesive interactions
with other cells, matrices, and their individual components (Nicolson,
1988a; Noel etal., 1988; Weiss etal., 1989). In this study, the adhesive
responses exhibited by B16 melanoma cells to individual matrix proteins,
endothelial cell-derived BM, and to cell monolayers were determined in an
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attempt to relate differences with changes in metastatic potential.
2.2.1. Laminin
Laminin, initially isolated and characterized by Timplef a/., (1979) from 
the Engelbrecht-Holm-Swarm (EHS) sarcoma, is a large, multifunctional 
component of many eukaryotic tissues and is the major adhesive 
glycoprotein of the basement membrane (BM). Laminin is synthesized by 
epithelial and endothelial cells, muscle cells and by some types of 
fibroblasts. The biological properties of laminin include direct effects on 
cell adhesion and morphology, growth and differentiation, and the 
migration of normal and neoplastic cells (Kleinman et al., 1985; Hunt,
1989), in addition to a role in tumour cell-immune effector cell 
interactions (Huard etal., 1985, 1986).
2.2.2. The structure of laminin
The multifunctional nature of laminin is a property related to its large 
size and multidomain structure (reviewed by Martin & Timpl, 1987)lt has 
a Mr 850-1000KD and is composed of three polypeptide chains (Timpl et
al., 1979): one 440KD A-chain and two B-chains, B1 and B2, with Mr 220KD
and 230KD respectively. The human laminin polypeptides are encoded on 
different chromosomes; the A-chain on chromosome 18, the B1-chain on 
chromosome 7, and the B2-chain on chromosome 1 (Pikkarainen etal., 
1987; Mattei etal., 1988; Timpl, 1989). The B-chains are complexed with 
the A-chain via disulphide bonds. A fourth tissue specific component, the 
M-chain (230-240KD), has been isolated from placenta but has not been 
identified in all tissues (Dixit, 1985), and may be responsible for the 
distinct antigenic sites observed in laminins derived from the BMs of 
different tissues (Wewer etal., 1986).
The B1 -chain of laminin contains 7 distinct domains (Sasaki etal., 1987) 
and these include a-helical, globular and cysteine-rich repeats with 
homology to epidermal growth factor (EGF). The B2-chain has homologous 
domains. The A-, B1- and B2-chains are connected by disulphide bonds to 
form a cross-like structure of one long and three short arms (fig.2a). The 
short arms extend 37nm from the centre of the cruciform structure and 
the long arm 77nm. Two globular domains are present in each of the short 
arms, but the long arm contains a single globular domain formed 
exclusively from the carboxy-terminal of the A-chain (Engel etal., 1981). 
Laminin can self-assemble and polymerize in vitro in a concentration- and 
Ca2+-dependent manner (Yurchenco etal., 1985; Charonis etal., 1986). 
Native laminin binds to collagen IV and its procollagen (Charonis etal.,
1985; Rao etal., 1985), HSPG and heparin (Sakashita etal., 1980; Laurie et 
al., 1986), nidogen (Dziadek etal., 1985; Paulsson etal., 1987a; Mann et 
al., 1989), and possesses at least two different binding sites for cellular 
laminin receptors (Goodman etal., 1987; Kleinman etal., 1989).
Fig.2a: The Structure of Laminin (reproduced from Sasaki etal., 1987)
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Native laminin is heavily N-glycosylated (approx. 12% of its mass) after 
post-translational assembly of the AB1B2 complex (Chung et al., 1979; 
Morita et al., 1985a). At least 43 potential N-linkage sites have been 
described in the A-chain, with a further 13 in the B1-chain and 14 in the 
B2 chains (Sasaki et al., 1987, 1988). The glycosylation appears to be 
important for function since agents which interfere with this process 
result in an abnormally slow rate of laminin secretion (Morita etal.,
1985b). Additionally, at least one B16 melanoma cell spreading 
mechanism requires the interaction between the terminal GlcNAc of 
laminin oligosaccharide chains and cell surface B-galactosyltransferase 
(Runyan etal., 1988; Bouzon etal., 1990).
2.2.3. Functional domains of laminin
Biologically functional fragments can be generated from laminin by 
limited proteolysis, and this has permitted the identification and 
characterization of its functional domains (fig.2b). In the central region of 
the cruciform are two cell-binding domains located in domain III of the 
B1-chain (Graf etal., 1987; Kleinman etal., 1989). The binding domain for 
nidogen is also localized to this region (Paulsson et al., 1987a, Timpl,
1989). The long arm of laminin is also reported to support cell adhesion 
(Goodman etal., 1987), and collagen IV-binding is mediated through the 
globular domains on the short arms (Rao et al., 1982b, Terranova etal., 
1983).
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Fig.2b: The functional domains of laminin (reproduced from Liotta, 1986)
Molecule or
fragment Structural features Biological functions
Short arms, 35 nm Promotes cell attach-
Long arms, 76 nm ment, spreading.
Rich in a-o-mannopyr- migration, growth
anosyl residues morphogenesis,
1 and metastases
Whole laminin
Short arm R Globular ends rich in a- Globular ends bind to
domain , ,  [ t l d-galactosyl end type IV collagen
1 groups and sulfa tides
Arms may be com* Promotes cel attach*
posed of more than ment and spreading
one type of chain
Rod-shaped I Disulfide-bonded Contains laminin re-
intersection ~"t— "knot* ceptor-binding do-
of short arms Relatively protease re- main
sislant Inhibits cell attach-
Contains mannose-ter- ment and metas-
minated oligosaccha* tases
ride units
Long arm i May contain a*helix Binds heparin sulfate
I structure proteoglycan
e Protease labile Promotes neurite out­
growth
The long arm globular domain contains a heparin- and possibly a collagen 
IV-binding domain (Charonis et al., 1986), and the terminal region of the 
long arm also promotes neurite outgrowth (Edgar et al., 1984; Engvall et 
al., 1986). The inner rod-like segments from the short arms, which contain 
the cell-binding domains, consist of cysteine-rich EGF-like repeats that 
possess growth factor activity (Panayotou et al., 1989). The presence of 
these multiple cell-binding sites within the laminin molecule suggests 
that multiple adhesion systems may be employed by cells in order to 
attach to laminin.
Proteolytic fragments of laminin can mimic the functional properties of
the intact molecule. Fragments which contain both the cell-binding and
collagen IV-binding domains stimulate experimental pulmonary
metastasis by murine tumour cells, and this stimulation is dependent upon
the collagen IV-binding domains. Fragments containing only the
cell-binding domains inhibit experimental metastasis and cell attachment
to BM in vitro (Barsky et al., 1984; Furcht et al., 1986; McCarthy e ta l ,
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1988). These results indicate the importance of BM laminin and its 
interaction with collagen IV in experimental metastasis.
2.2.4. Laminin as an attachment factor
A diverse range of cell types uses laminin as an adhesive substrate, and 
laminin-binding can influence the rate and level of cell attachment to 
other matrix proteins including BM collagen IV. Intact laminin has been 
demonstrated to augment experimental metastasic potential (Terranova et 
al., 1982, 1984), and in some instances a tumour cell's capacity to utilize 
laminin as an attachment factor for collagen IV is related to its 
metastatic potential. This correlation is however not universal (Giavazzi 
etal., 1982; Terranova et al., 1982; Varani et al., 1987; Ormerod etal., 
1988; Hunt & Sherbet, 1989).
The use of cell surface laminin as an attachment factor for collagen IV is 
relevant to the haematogenous phase in metastasis (Liotta, 1986). Tumour 
cells may either bind directly to the BM via laminin or use cell surface 
bound laminin to interact with BM collagen IV. Cell surface laminin has 
significant consequences for a cell's metastatic potential, since 
non-metastatic cells which do not express cell surface laminin can 
acquire an increased metastatic potential through preincubation with 
soluble laminin prior to inoculation (Malinoff etal., 1984).
The distinctive patterns of dissemination exhibited by many tumour types
and the location and survival of metastases appears to be mediated by
environmental factors and components of the cell surface of both tumour
cells and their target organs (Nicolson, 1982a, 1988a; Fidler, 1989).
Differences in the organ colonizing specificity may be related to specific
cell adhesion preferences and differing distributions of adhesion proteins
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in target organs. Laminin stimulates metastatic tumour cells to adhere 
and spread, in addition to stimulating cell motility (Junker & Heine, 1987; 
Fridman e ta l ., 1990). Such adhesion preferences may reflect 
organ-colonizing preferences: Lewis lung carcinoma cells which 
preferentially adhere to laminin preferentially colonize liver tissue 
whereas their lung-colonizing counterparts adhere preferentially to 
fibronectin (Chung etal., 1988).
2.2.5. Laminin and cell motility
Laminin can influence cell motility, a necessary event for invasion and 
metastasis (Fligiel etal., 1986). B16 mouse melanoma cells respond to 
chemotactic and haptotactic gradients of laminin in vitro (McCarthy & 
Furcht, 1984), and such mechanisms are believed to facilitate and direct 
tumour cell migration towards regions of matrix dissolution and invasion 
in vivo.
Motility and the synthesis and secretion of laminin appear to be linked in 
some tumour systems. Laminin stimulates the motility of B16 melanoma 
variants apparently through the interaction of laminin with the cell 
surface (Fligiel et a i,  1986). Increased cell motility may be a consequence 
of laminin synthesis since the levels of intrinsic motility correspond 
positively with the level of laminin production.
Adhesion to laminin is mediated through specific receptors and antibodies 
directed against theses receptor inhibit a wide range of processes 
including laminin-induced migration (Wewer etal., 1987a), attachment to 
laminin and experimental metastasis.
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2.2.6. The laminin receptor
Several cell adhesion mechanism are employed by cells in order to attach 
to laminin. The 67-70KD non-integrin cell surface laminin receptor has 
been identified on a wide range of normal and transformed cell types 
(Terranova etal., 1983) and has a high affinity for its substrate 
[dissociation constant <2nM (von der Mark & Kuhl, 1985)]. Additional 
evidence indicates that integrin receptors also mediate attachment to 
laminin (Kramer etal., 1989; Clyman etal., 1990; Lotz etal., 1990; 
Sonnenberg etal., 1990). The identification of several distinct 
laminin-binding proteins may suggest that distinct biological functions 
may be mediated through the different receptor systems. Some of these 
laminin receptors possess receptor activity for other matrix proteins: the 
avian CSAT antigen binds both laminin and fibronectin (Knudsen etal., 
1985; Horwitz et a!., 1985). Other laminin-binding systems include the 
sulphated glycolipids (sulphatides) from erythrocytes (Roberts e ta i ,
1985; 1986).
Laminin receptor expression and distribution can be related to cell
phenotype. Several malignant epithelial tumours stain more intensely for
the receptor and have a more diffuse cell surface receptor distribution
than normal tissues ordysplastic lesions (Hand etal., 1985), a patterning
which may facilitate migration. BM disruption is often associated with
malignant progression (Barsky etal., 1983; Wewer etal., 1987b). Under
normal circumstances, laminin receptors are fully saturated through their
contact with the BM. However at regions of matrix disruption, receptors
may become available and facilitate further interactions between invading
tumour cells and the BM. The over-expression of the 67-70KD laminin
receptor is a common characteristic in neoplasia (Hand etal., 1985) and
may exert some genetic control over the metastatic phenotype and account
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for the enhanced cellular response to laminin. Conversely, a reduction in 
laminin receptors levels appears to impose a less invasive and less 
metastatic tumour phenotype.
2.2.7. Laminin and immunosurveillence
Successful metastasis requires that tumour cells evade the host immune 
system, and in particular the lymphocytic natural killer (NK) and natural 
cytotoxic (NC) cells (Hanna & Fidler, 1980; Hanna, 1985). Laminin affords 
tumour cells protection from immune effector cell-mediated cell killing 
by inhibiting their recognition by both NK-cells and NC-cells (Malinoff et 
al., 1984; Hiserodt etal., 1985a). This appears to be dependent upon the 
expression of tumour cell laminin receptors. Laminin-like molecules 
expressed on the surface of NK-cells may mediate their interaction with 
tumour cells (Hiserodt et al., 1985b), and saturation of tumour cell 
laminin receptors would seem to protect against this recognition.
In contrast, laminin also appears to promote tumour cell recognition and 
killing by host macrophages which express both cell surface laminin and 
its receptor (Wicha & Huard, 1983; Huard etal., 1985, 1986). The 
expression of cell surface laminin receptors may promote the recognition 
of and attachment to tumour cells which express cell surface laminin 
(Huard etal., 1985). ThislLaminin-mediated tumouricidal activity is not 
universal: although laminin promotes the killing of human melanoma cells 
it does not promote the killing of carcinoma cells by monocytes and 
macrophages (Perri etal., 1985). Other factors are evidently required for 
successful immunological recognition and killing.
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2.2.8. Laminin and invasion
The interactions between the epithelium and BM maintains an intact 
covering for body surfaces, and subsequent cytoskeletal reorganization 
maintains cell polarity and optimal epithelial cell functioning. The 
absence of a BM or disruptions in its integrity are often observed in 
invasive or metastatic lesions (Barsky etal., 1983; Charpin etal., 1986).
For some tumours the loss of BM laminin correlates with an increase in 
malignant potential (Meyer etal., 1985; d'Ardenne etal., 1986). Although 
BM loss is suggestive of invasion and malignancy it is not an absolute 
indicator. Rather, the relevence of alterations in BM composition and 
integrity are dependent upon tumour cell type: both non-invasive, 
malignant in situ carcinomas and locally invasive non-metastatic basal 
cell carcinomas possess an intact BM (Barsky etal., 1983).
2.2.9. Laminin and cell phenotype
Cell shape can modulate cell phenotype (Raz & Ben Ze'ev, 1983; Ben Ze’ev, 
1985), and laminin modulates both cell-cell and cell-matrix interactions. 
MCF-7 carcinoma cells exhibit increased cell-cell and decreased 
cell-matrix interactions when cultured on laminin substrates (Noel etal., 
1988). The laminin receptor influences cell shape through its interaction 
with cytoskeletal actin and the clustering of laminin receptors results in 
the reorganization of the cytoskeleton (Wicha, 1984; Cody & Wicha, 1986). 
Cytoskeletal changes influence gene expression (Bloom & Wicha, 1988) and 
attachment to laminin may induce the synthesis of proteins advantageous 
for metastasis: the interaction between laminin and its receptor induces 
the secretion of BM-degrading type IV collagenase in both human and 
murine cells (Turpeenniemi-Hujanen etal., 1986).
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2.3.1. Fibronectin
The ubiquitous adhesive glycoprotein fibronectin is a prominent 
component of blood and the ECM and is associated with the BM. Fibronectin 
is synthesized in vitro by a variety of cells and is often incorporated into 
their pericellular matrix. It has a prominent role in tissue remodelling, 
cell migration, wound healing, and in embryonic development. Like laminin, 
fibronectin is a multifunctional protein, with implications for the 
pathogenesis of cancer (reviewed by Flumphries etal., 1989).
2.3.2. Fibronectin structure
Fibronectin is dimeric, comprised of similar but non-identical subunits 
that are disulphide bond-linked close to their C-termini. The subunits (Mr
250-280KD) contain multiple but distinct globular, protease-resistant 
domains (Fig.3a) responsible for its multifunctional nature. These domains 
are arranged in tandem along each subunit and are connected by 
protease-sensitive polypeptide sequences (Alexander etal., 1978; Colonna 
et al., 1978). Fibronectin polymerizes into large disulphide-linked 
aggregates on the cell surface. The two fibronectin subunits differ in the 
presence or absence of an alternatively spliced IIICS domain that contains 
a cell-type specific cell-binding sequence (fig.3b). Each fibronectin 
subunit contains individual cell-, collagen-, and DNA-binding domains 
(fig.3a) in addition to two fibrin- and heparin-binding domains located at 
both the C- and N-terminals (Humphries et al., 1989).
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Fig.3a: The functional domains of fibronectin
FIBRIN GELATIN
HEPARIN COLLAGEN DNA CELL HEPARIN FIBRIN
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Fibronectin consists of two similar subunits, which differ in the presence 
or absence of the IIICS region, linked by two disulphide bridges close to 
their C-termini. The diagram depicts the positioning of the functional 
dom ains of the molecule (reproduced from Humphries etal., 1989).
Fig.3b: The cell-binding domains of fibronectin
CELL I CELL II
* GRGDS CS1 REDV
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The Cell I region, denoting the central cell-binding domain, contains the 
cell attachm ent peptide, GRGDS, and the accessory domain (*) necessary 
for optimal activity. Cell II, the alternatively spliced I ICS region, contains 
the cell-type specific cell-binding domains CS1 and CS5 which contains 
the REDV peptide.
34
Fibronectin contains N-linked oligosaccharide chains which appear to 
function against proteolysis (Olden etal., 1979) and modulate the 
biological functions of the molecule (Jones etal., 1986). The loss of 
these carbohydrate chains increases its interaction with gelatin and 
enhances the attachment and spreading of fibroblasts. The complexing of 
fibronectin with collagen and proteoglycans is important in the formation 
of the ECM (Ruoslahti & Engvall, 1980; Hynes, 1985; Ruoslahti & 
Pierschbacher, 1986). Fibronectin can be used by cells as an attachment 
factor for other matrix proteins and its interactions with collagen and 
fibrin are thought to be important for cell migration through blood clots 
and connective tissues.
2.3.3. Functional domains of fibronectin 
The structure and functional domains of fibronectin have been 
characterized via a combination of limited proteolysis and affinity 
chromatography. The cell adhesion activity of fibronectin has been 
restricted to a pentapeptide sequence, GRGDS, that resides within a 
hydrophobic region of the central cell-binding domain (fig.3b)
(Pierschbacher & Ruoslahti, 1984a, 1987; Yamada & Kennedy, 1984,1985). 
GRGDS peptides promote fibroblast adhesion and inhibit attachment to 
intact fibronectin (Akiyama & Yamada, 1985a). The GRGDS-motif interacts 
with the cell surface fibronectin receptor and the activity of the peptide 
is dependent upon the maintenance of the central RGD sequence with minor 
changes abolishing its activity (Pierschbacher & Ruoslahti, 1984a, 1984b, 
1987; Hayman etal., 1985; Yamada & Kennedy, 1985). A second active 
sequence within this domain is required for optimal activity of the GRGDS 
signal (Obara et al., 1987; 1988).
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2.4.4. Fibronectin and cell attachment
GRGDS-peptides exhibit a potent inhibitory effect on a variety of 
biological processes in vivo (Yamada & Kennedy, 1984). During embryonic 
development fibronectin stimulates migratory events including nural 
crest migration, gastrulation, and some aspects of immunological 
development, and injection of GRGDS-peptides can block these processes 
(Boucaut etal., 1984; Naidet et al., 1987; Savagner etal., 1986).
Fibronectin is also involved in intermolecular interactions with other 
matrix constituents, including collagen (Ruoslahti & Engvall, 1980; Nagata 
etal., 1985) and proteoglycans (Laterra et al., 1983; Lark & Culp, 1984).
The IIICS region exhibits a cell-type specific cell-binding activity, 
whereas the RGD dependent cell-binding activity appears to be specific 
for fibroblasts. The IIICS region contains two hydrophilic domains (CS1 
and CS5) that mediate adhesion with CS1 being the most active. The 
adhesion promoting activity of CS5 has been attributed to the peptide 
REDV. The IIICS region is specific for various cell types including murine 
melanoma cells and peripheral neurons (Humphries etal., 1986a, 1987, 
1988a). It is suggested that changes in the splicing of the IIICs region may 
be important in the regulation of cell adhesion in vivo. The adhesion 
promoting activities of CS1 and CS5 are additive and may function 
separately or in tandem to mediate cell interactions with fibronectin.
2.3.5. Fibronectin and motility
Fibronectin is both chemotactic and haptotactic for many cell types
(McCarthy & Furcht, 1984) and such responses can be blocked by antibodies
directed against fibronectin or its receptor. Fibronectin and high
molecular weight GRGDS-containing fragments stimulate cell motility
(Ali & Hynes, 1978; Postlethwaite etal., 1981; Seppa etal., 1981; Rovasio
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etal., 1983) suggesting that the cell-binding domain is involved in 
motility responses.
2.3.6. Fibronectin and metastasis
The loss of cell surface fibronectin is a common occurrence for tumour 
cells cultured in vitro (Hayman etal., 1982), and its addition can restore 
cellular characteristics associated with a more mature phenotype (Boyd 
etal., 1988; Noel etal., 1988). Fibronectin will also induce cellular 
characteristics advantageous for metastatic spread including cell 
proliferation and motility (Couchman etal., 1982; Bitterman etal., 1983).
The experimental metastasis of murine melanoma cells can be inhibited by 
GRGDS-peptides (Humphries etal., 1986b) even though such cells attach to 
fibronectin through the IIICS region (Humphries et al., 1986a, 1987). It 
would appear that although all cell types do not attach to fibronectin in a 
GRGDS-dependent manner, GRGDS-dependent adhesion systems are a 
principal feature of experimental metastasis. The ability of GRGDS-based 
peptides to inhibit artificial metastasis closely parallels their 
anti-adhesive activities in vitro (Humphries et al., 1988b), and the 
anti-metastatic activity, at least, appears to be dependent upon the 
preservation of the RGD motif.
GRGDS-peptides inhibit the lodgement of B16 melanoma cells in the lungs 
of experimental animals and promotes their rapid loss from this organ 
(Humphries etal., 1986b, 1988b). In addition the GRGDS-peptides prolong 
the survival time of animals inoculated with tumour cells. These 
observations suggest that fibronectin is involved in the early phases of 
cell lodgement and extravasation.
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GRGDS may influence other important aspects of metastasis. Embolus 
formation increases the probability of metastasis formation (Fidler,
1973b; Liotta etal., 1976). GRGDS inhibits fibronectin-induced platelet 
aggregation and subsequently might interfere with the interactions 
between tumour cells and the constituents of blood in the early stages of 
organ colonization. GRGDS retains its anti-metastatic activity in animals 
deficient in platelets or NK-cells (Humphries et al., 1988b), suggesting 
that these blood components are of little significant importance in 
GRGDS-mediated inhibition of experimental metastasis. Inhibition of 
tumour cell arrest and promotion of cell loss suggests that GRGDS 
interferes with the adhesive interactions that occur between tumour cells 
and the target endothelium or exposed matrices (Humphries etal.,  1986b), 
or with the subsequent migratory and chemotactic events after 
extravasation.
2.3.7. The fibronectin receptor
Attachment to and motile responses to fibronectin substrates is mediated 
through multiple fibronectin receptor species, and antibodies directed 
against these receptor inhibit such responses (Greve & Gottlieb, 1982; 
Decker etal., 1984).
The fibronectin receptor is a member of the integrin family of matrix 
receptors (Buck & Horwitz, 1987; Juliano, 1987), and is a heterodimer 
comprised of a large ligand-specific a-subunit (140-21OKD) 
non-covalently linked to a smaller 6-subunit (115-135KD). The receptor 
recognizes and binds to the central cell-binding domain of fibronectin and 
is sensitive to GRGDS-peptides. The second cell-type specific cell-binding 
region, IIICS, is also recognized by an integrin (Mould etal., 1990). In
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addition to mediating cell adhesion and subsequent adhesion-dependent 
responses, the fibronectin receptor provides a means of linking the ECM to 
the cell cytoskeleton through its ability to interact with actin 
microfilaments (Hynes & Yamada, 1982; Burridge etal., 1988). Several 
different integrin species have been demonstrated to bind to fibronectin, 
possibly indicate that this promiscuity may reflect or mediate functional 
heterogeneity in response to fibronectin. The cellular modulation of the 
integrin expression and promiscuity, and the affinity of the integrin for 
its ligand(s) and second messenger systems used to convey the 
integrin-ligand interaction would permit multiple and varied (and possibly 
graded) responses to be evoked.
2.3.8. Fibronectin and cell migration
Differences in the distribution and expression of the fibronectin receptor 
have been observed in different cell populations. Elevated levels of 
receptor with a diffuse cell surface distribution are often associated 
with migrating cells, whereas stationary cells express lower levels of 
receptor found in prominent linear arrays that co-distribute with 
extracellular fibronectin and intracellular a-actinin (Chen etal., 1986; 
Duband etal., 1986). Since migration on fibronectin substrates requires 
the interaction between fibronectin and its receptor, the diffuse receptor 
distribution and lack of stable cell-substratum contacts on motile cells 
suggest that highly motile cells exhibit weak and transient interactions 
with fibronectin that would facilitate movement. The number and cellular 
distribution of these receptors may be important in assessing the ability 
of cells to migrate and invade. In addition, cytoskeletal reorganization is 
a consequence of the interaction between fibronectin and its receptor 
(Woods etal., 1986) and has the potential to effect cell behaviour.
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Higher levels of fibronectin receptor are expressed by both motile normal 
and neoplastic cells than by their non-motile counterparts (Chen etal., 
1986; Duband etal., 1986; Krotoski etal., 1986; Saga etal., 1988), and 
this may contribute to the invasive ability of these cells. The cell-binding 
motif GRGDS is not unique for fibronectins. It is present in other matrix 
proteins including vitronectin, von Willebrand factor, thrombospondin, 
laminin, and collagens. Since RGD-peptides can interfere with cell 
attachment to other adhesion proteins (Humphries et al., 1986b), it 
suggests that such peptides interfere with the potential interactions 
between other RGDX-dependent receptors and their respective ligands. It 
may be therefore that GRGDS represents a common adhesion signal in a 
series of adhesive proteins rather than being exclusive for fibronectin.
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2.4.1. Collagen
The collagens constitute the major structural and mechanical components 
of connective tissues and are a major physical constraint on cell 
movement. These proteins are classified as a single class of structural 
proteins on the basis of common properties, and in common with other 
matrix proteins, they possess the ability to modulate cell phenotype. 
Subsequently, cell activities which interfere with the physical properties 
and integrity of collagen matrices may contribute to the process of 
metastasis.
2.4.2. Structure of interstitial collagens
All collagens are composed of three a-polypeptides which associate to 
form a polymer containing a distinct triple a-helical region which, in 
many instances, is responsible for the functional properties of the 
molecule. Collagens are synthesized as procollagens that, in addition to 
the triple-helical segments, contain globular domains (10-150KD), many 
of which are removed during processing and matrix formation. Specific 
newly synthesized procollagens (e.g. types l-lll, V, VII, and XI) also 
undergo processing to remove portions of a-helix and/or globular domains 
prior to their incorporation into the ECM (reviewed by Burgeson, 1988). 
Twelve collagen types have already been identified and are encoded on 
multiple genes. Within various collagens there also exist small, 
protease-susceptible, non-triple-helical regions which coincide with 
regions of increased helical flexibility.
Collagen molecules self-assemble in vivo and in vitro into microfibrils 
and fibrils of variable diameters and length. Several collagens form 
banded fibres which differ between tissues in length, diameter, and 
orientation, parameters that partly determine the physical properties of
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tissues. The characteristic banding patterns are reflective of the 
molecular arrangement of collagen molecules within the fibrils. Most 
banded collagen fibres contain more than one collagen type (Fleischmajer 
etal., 1988; Keene etal., 1987), e.g. fibrils of human tendon collagen 
contain both collagens I and III (Keene etal., 1987). Collagen fibril 
copolymers have been demonstrated in human skin, aorta, and amnion, 
whereas other distinct extracellular networks such as BM contain unique 
collagens.
2.4.3. The structure of the interstitial collagens I and III 
Collagen I is the main constituent of skin, bone, tendon, and blood vessels 
and is synthesized by a variety of cells, including fibroblasts, osteoblasts 
and smooth muscle cells. Both collagens I and III are similar in structure, 
being rod-like with a molecular weight of 280KD and with a length and 
diameter of approximately 295nm and 1.4nm respectively. Each a-chain of 
collagens I and III contains two functionally and structurally distinct 
regions; a central triple-helical domain and globular domains at both the 
carboxy- (C-) and amino- (N-) terminals (Fietzek & Kuhn, 1976). The 
C-terminal region globular domains of collagens I and III are similar and 
contain interchain disulphide bonds necessary for proper helix formation. 
The triple-helical region controls the formation and stabilization of the 
triple-helix and is responsible for the fibril self-assembly.
Collagen I is composed of two genetically distinct a-chains, a1 (I) and 
a 2(l) most commonly polymerized as a hetropolymer, a 1 (I)2a2(l), but the
homopolymer, [cx1 (l)]3 , has also been detected. Collagens II and III are
homopolymers of a1 (11)3 and a 1 (111)3 respectively. The structure of the
4 2
triple-helical domain of collagen is based upon a repeated tripeptide 
motif, Gly-X-Y, which is essential for helix formation. The assembly of 
collagen fibrils is dependent upon the non-uniform distribution of polar 
and hydrophobic amino acid residues into separate polar and hydrophobic 
clusters along the peptide chains of the a-helix, and the characteristic 
cross-striated patterning of collagen reflects the distribution of the 
polar residues (von der Mark etal., 1970; Fietzek & Kuhn, 1976; Kuhn & 
Glanville, 1980).
Fibrillogenesis occurs by a process of self-assembly in the extracellular 
space and is influenced by other ECM components: collagens I and III 
contain GAG-binding sites (Koda & Bernfield, 1984), and decorin, the small 
proteoglycan from tendon, has been demonstrated to influence the 
formation of collagen I and collagen III fibres (Vogel etal., 1984).
Collagen microfibrils are generated by the aggregation of four collagen 
monomers in a quarter-staggered array, producing a characteristic 67nm 
periodicity representative of the banded collagens. The 67nm overlap of 
collagen molecules in each microfibril permits the best interaction 
between the polar and hydrophobic domains of neighbouring molecules 
(Hofmann etal., 1978; Piez & Trus, 1978). The parallel alignment of 
collagen microfibrils generates collagen fibrils (10-100nm) which also 
show 67nm periodicity in cross-striations.
The level of collagen fibril organization is refelctive of tissue type and 
structural properties. In skin, parrallel, mechanically stable networks of 
collagen I fibrils exist, but in bone fibrils are organized into more 
irregularly packed 3-dimensional networks. The ability to form different
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macromolecular structures indicates that this level of fibril organization 
is regulated by mechanisms other than only amino acid sequence, and 
interactions with other connective tissue components may be involved in 
this process. The ratio of collagen I to collagen III appears to influence 
the biomechanical properties of tissues; collagen I appears to contribute 
to mechanical stability and collagen III to the elasticity and flexibility of 
connective tissues. Alterations in these ratios has pathological 
consequences in various connective tissue diseases including Marfan's 
syndrome (Krieg & Muller, 1977) and Ehlers-Danlos syndrome type IV (Pope 
etal., 1975).
2.4.4. Basement membrane collagen IV
The BM is a thin, specialized ECM that surrounds epithelial tissues, 
nerves, adipocytes, and muscle, and contains a common set of components: 
type IV collagen, laminin/nidogen and HSPG. It is the first ECM to appear 
during embryogenesis and is believed to create a barrier to control 
embryonic cell segregation and differentiation. In the adult, the BM serves 
as a molecular filter in capillaries and glomeruli and as a scaffolding to 
maintain normal tissue form during regeneration and growth.
The BM is composed of a dense network of fine cords (Inoue etal., 1983). 
Highly cross-linked collagen IV provides the basic scaffolding for this 
dense network upon which the other BM components are assembled. The 
collagen IV network exists as open, planar or condensed polygonal 
structures (Yurchenco et al., 1986) which form by the end-to-end and 
lateral alignment of collagen IV monomers (fig.4).
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Fig.4: Models of collagen IV intermolecular association
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Collagen IV monomers (upper left) may associate end-to-end at their 
C-terminal globular domain to form dimers or at their N-terminal 7S 
domain to form tetramers via a parallel/anti-parallel association of the 
7S domains. Tetramers are capable of lateral associations, with such 
associations being usually limited to short segments of the associating 
molecules. Utilization of these three means of intermolecular 
associations generates the observed collagen networks described 
(reproduced from LeBlond & lnoue,1989).
2.4.5. Structure of collagen IV
Collagen IV does not form banded collagen fibres. The collagen IV monomer 
is a heteropolymer, a1 (IV)2a2 (IV), with Mr 540KD (Mayne & Zettergren,
1980; Trueb etal., 1982) and is organized into a 390nm long triple-helical 
rod terminating at the C-terminal in the globular domain, NC1, and at the 
N-terminal in a 30nm long triple-helical domain, 7S. Each of these 
structures is involved in oligomerization (Timpl etal., 1981). The NC1 
domain contains minor amounts of two other components, M2 and M3, 
which appear to correspond to analogous segments of two other collagen
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polypeptides, a3(IV) and a4(IV). The M2 component contains the 
Goodpasture epitope, a cryptic epitope for some human autoantibodies. In 
human collagen IV the a1 (IV) and a2(IV) chains respectively contain 21 
and 23 interruptions in their Gly-X-Y triplets which in most cases match 
each other in position along the peptides, and give rise to a total of 25 
imperfections distributed along the length of the triple-helix (Babel & 
Glanville, 1984; Brazel etal ., 1987,1988; Killen etal., 1987). These 
interruptions are believed to be of functional importance by increasing the 
flexibility of the collagen IV helix (Hofmann etal., 1984). Disulphide 
linked intra- and inter-molecular links occur along the length of the 
triple-helix and 7S domain. Intramolecular cross-links are mainly formed 
in the more central region close to the site of action for type IV 
collagenase. The a2(IV) chain contains a disulphide-bonded loop of 22 
amino acids not present in the a1 (IV) chains.
The 7S and NC1 domains of the collagen IV molecule are both critical for 
its polymerization (Timpl etal., 1981). The interactions between NC1 
domains generate dimers, and 7S domains tetramers (fig.4), which are 
rapidly stabilized in situ by covalent cross-links (reviewed by Leblond & 
Inoue, 1989, Timpl, 1989), and inhibition of the cross-linking enzyme, 
lysyl oxidase, by lathyritic agents, e.g. B-APN, increases the solubility of 
collagen IV (Kleinman etal., 1983).
The folding of the triple-helix appears to start from the C-terminal and
therefore NC1 domains may be involved in the selection and alignment of
newly synthesized a1 (IV) and a2(IV) chains. Interactions between 7S
domains produce dimers which can interact with similar dimers in an
anti-parallel/parallel manner to generate tetramers. Collagen fibrils are
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stabilized by lysine-derived intermolecular cross-links which generate 
the very high tensile strength necessary for it to function as a major 
structural element in connective tissues (reviewed by Ricard-Blum &
Ville, 1988).
2.4.6. Collagen IV networks
Collagen IV in situ is assembled with other BM proteins into highly 
insoluble supramolecular aggregates, and partially extracted BM is a 
complex, 3-dimensional network of highly branched filaments. Dimers and 
tetramers formed by NC1 and 7S domains have the potential to generate 
open but unlimited network (Timpl etal., 1981; Tsilibary & Charonis,
1986). The triple-helix contains several NC1 recognition sites,and lateral 
associations can occur along the major portion of the triple-helix. A 
maximum of four collagen IV molecules can intersect the triple-helix 
through their NC1 domains at a distance of 100-200nm to generate 
irregular polygonal networks. Isolated NC1 disturb network formation by 
binding to the triple-helix at a regular distance of 100nm (Tsilibary & 
Charonis, 1986).
Type IV collagen is incorporated directly into the BM without enzymatic 
processing to a less soluble form as observed with other collagen types. In 
addition to providing the large, supportive structures for the BM and its 
components, two cell-binding domains have been identified in addition to 
binding domains for laminin and HSPG.
2.4.7. Collagen IV and cell adhesion
Laminin is recognized as being the major cell adhesive component of the 
BM but a comparable role has been indicated for collagen IV. Cell
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attachment requires an intact triple-helix and two potential cell-binding 
sites have been suggested at the C- and N-terminals (reviewed by Timpl,
1989). The triple-helix also contains many RGD sequences (Brazel etal., 
1987,1988) but their involvement in cell adhesion is unconfirmed, 
although such sequences in gelatin can be utilized by integrins.
In addition to promoting tumour cell adhesion and spreading, collagen IV 
also stimulates cell growth (Junker & Heine, 1987). However many cell 
types utilize other matrix proteins in order to bind to collagen IV. Cells 
which when presorbed with laminin exhibit an increased binding to 
collagen IV in vitro and increased organ colonization in vivo, whereas 
other cell types exhibit an increase in binding to collagen IV in the 
presence of fibronectin (Hunt & Sherbet, 1989).
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3.1.1. Glycosaminoglycans and proteoglycans
Proteoglycans and glycosaminoglycans are constituents of the ECM and the 
cell surface and have important implications in a wide range of cellular 
and physiological processes ranging from cell-cell and cell-matrix 
interactions, growth and motility to matrix organization and stabilization.
The importance of normal proteoglycan biosynthesis and functioning is 
further emphasized since few naturally occurring mutations affecting 
proteoglycan biosynthesis have been recorded.
3.1.2 . Structure of proteoglycans
Proteoglycans are composed of a protein core with one or more covalently 
attached glycosaminoglycan (GAG) chains. This somewhat loose 
biochemical classification groups together a wide range of molecules 
which differ in both functions and properties. The GAG chains are linear, 
polyanionic polysaccharides composed of repeating disaccharide subunits. 
These are negatively charged at physiological pH due to the presence of 
sulphate- and carboxyl-groups within the disaccharide subunits (reviewed 
by Gallagher etal., 1986; Ruoslahti, 1988a).
Four glycosaminoglycan species have been identified: .1. dermatan 
sulphate (DS), chondroitin-4-sulphate (C4S), and chondroitin-6-sulphate 
(C6S), .2 . heparin and heparan sulphate, .3. keratan sulphate (KS) and .4. 
hyaluronic acid (HA). GAG species differ in the composition of their 
constituent dissacharides which are composed of alternating uronic acid 
and N-acetylated amino-sugar moieties (fig.5). Chondroitin sulphate 
proteoglycans (CSPG) are constituents of both the ECM and the cell surface 
although they tend to be distributed primarily in connective tissues. The 
heparan sulphate proteoglycans (HSPG) are most commonly found as 
constituents of the cell surface and the basement membrane. The only
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non-sulphated GAG species, hyaluronic acid, is a major component of the 
ECM and is found as a free GAG not associated with core protein.
Fig.5. The structure and distribution of glycosaminoglycans
(reproduced from Molecular Biology of the Cell. Alberts, B., 
Bray, D., Lewis, J.f Raff, M., Roberts, K., and Watson, J. D. 
Garland Publishing, Inc. New York, 1989)
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Proteoglycan display considerable chemical and functional heterogeneity. 
GAGs are linked to core proteins through the neutral trisaccharide 
sequence Xylosyl-Galactosyl-Galactose (Xyl-Gal-Gal) which functions as a 
primer for the biosynthesis of the GAG chains. Synthesis is initiated by 
the covalent linkage of xylose to a core protein serine residue which then 
act as an acceptor for the successive transfer of a further two galactose 
units. Subsequent polymer formation involves the transfer of alternating 
residues of uronic acid and amino-sugar onto the non-reducing end of the 
growing GAG chain.
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Proteoglycan biosynthesis is readily modulated in vitro. B-D-xylosides 
substitute for Xyl-Gal-Gal primers and disrupt proteoglycan biosynthesis 
(Galligani etal., 1975, Robinson etal., 1975). The presence of 
B-D-xylosides within cell cultures increases the number of available 
primers and results in an increase in the amount of total GAG synthesized 
with a concomitant decrease in the molecular size of the GAG chains 
(Schwartz etal., 1974; Schwartz, 1979). Inhibition of protein synthesis 
which reduces the number of available core proteins results in an increase 
in the molecular size of the GAG chains synthesized (Kimura etal., 1981).
The mechanisms that govern chain length are however not fully understood 
but it is evident that the availability of Xyl-Gal-Gal primer is critical.
Following GAG chain elongation, chemical heterogeneity is introduced into 
newly polymerized chains via a series of polymer modifications which 
confer biochemical heterogeneity. Many of the biological properties of 
GAGs are related to their charge density and a major determinant of this 
is the degree of polymer sulphation. The level of polymer sulphation varies 
between and within each GAG species (fig.5). In general, chondroitin 
sulphates (CS-GAG) usually possess only one sulphate group per repeating 
disaccharide but "oversulphated" (e.g. DS-GAG) and "undersulphated" 
CS-GAG do occur (Razin etal., 1982; Ito etal., 1982; Kolset etal., 1983). 
Heparan sulphates (HS-GAG) and heparin tend to be more sulphated than 
CS-GAG. Heparin and HS-GAG undergo similar polymer modifications that 
are often extensive and highly characteristic: N-acetylglucosamine 
(GlcNAc) can be O-sulphated on C3 and deacetylated on C2. The subsequent 
N-sulphation of C2 is exclusive to heparin and HS-GAG and generates a 
highly sulphated disaccharide. In some instances the positions and levels 
of sulphation are identified with particular biological functions; the
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O-sulphation of glucosamine (GlcN) at C3 appears to be essential for a 
pentasaccharide sequence from heparin and HS-GAG with affinity for the 
protease inhibitor anti-thrombin III (Atha etal., 1984; Pejler etal.,
1987). The factors that control the processes of polymer modification are 
unknown, but the extent of sulphation may be dependent upon the substrate 
specificity of the particular sulphotransferases involved in the reactions 
(Nakanishi et al.f 1981). In heparin biosynthesis, the enzyme responsible 
for N-deacetylation may have a role in regulating the overall degree of 
sulphation (Riesenfeld etal., 1982). With the possible exception of 
N-sulphation, polymer modifications are incomplete; all potential sites 
will not undergo modification thereby contributing to the structural 
heterogeneity of GAG chains.
Heparins are believed to be synthesized exclusively by mast cells but 
other cell types synthesize heparin-like molecules (Marcum etal., 1986). 
Heparin is synthesized as a unique proteoglycan consisting of more than 
ten 100KD polysaccharide chains attached to a core protein that is 
predominantly composed of glycine and serine residues (Hook etal., 1984). 
Heparan sulphate proteoglycan (HSPG) has a ubiquitous distribution and is 
present in the BM and as a component of the cell surface. It contains the 
same structural units as those found in heparin but is generally less 
sulphated.
Proteoglycans are associated with the plasma membrane via several 
mechanisms. They have been identified as integral membrane proteins 
intercalated into the membrane via hydrophobic core protein domains. 
Peripherally-associated proteoglycans interact with other plasma 
membrane constituents through the core protein or GAG chains via
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salt-labile interactions (Fransson, 1987). Peripheral proteoglycans may be 
derived from intercalated proteoglycans via proteolytic processing of the 
core protein. Thirdly, proteoglycans can be covalently linked to plasma 
membrane inositol-phospholipids (Fransson, 1987).
3.1.3. Biological functions of proteoglycans
Extracellular proteoglycans and GAG interact with ECM proteins to not 
only generate the matrix, but also to function in its stablization and 
organization. The majority of proteoglycans and GAG in the ECM probably 
do not interact directly with cells, but those in close proximity may 
interact with the cell surface. Consequently cell surface proteoglycans 
have the potential to interact with components of the ECM and therefore 
act as receptors for various ECM molecules (Maciag etal., 1984; Gordon et 
al., 1987; Saunders & Bernfield, 1987), thereby contributing to the 
ECM-dependent regulation of cellular function.
Proteoglycans are potential candidates in connecting the ECM to the 
cytoskeleton (reviewed by Rapraeger etal., 1987). Murine mammary 
epithelial cell HSPG has been shown to interact with polymerized actin 
microfilaments (Rapraeger etal., 1986), and actin and HSPG co-distribute 
in rat fibroblast cultures with the HSPG being enriched within focal 
adhesions (Woods etal., 1984).
The biological functions of many proteoglycans have yet to be identified. A 
fibroblast HSPG species is identical to or structurally related to the 
transferrin receptor (Fransson etal., 1984; Coster etal., 1986). The 
receptor for TGF-B1 has been identified as a HSPG (Segarini & Seyedin, 
1988) and the TGF-B type III receptor (betaglycan) a CS/HSPG copolymer
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(Esko, 1991). The haematopoietic and epithelial cell adhesion molecule 
CD44, a putative metastasis molecule, is a chondroitin sulphate 
proteoglycan (CSPG). When overexpressed by non-metastasizing pancreatic 
adenocarcinoma cells, this molecule confers full metastatic behaviour 
(Gunthert etal., 1991). CD44 has also been demonstrated to play a role in 
collagen l-mediated melanoma cell motility and invasion (Faassen etal., 
1992), and to bind the heparin-binding domain of fibronectin (Jalkanen & 
Jalkanen, 1992). Many of those proteoglycans whose functions have been 
identified and characterized are reviewed by Esko (1991) and Birchmeier 
etal., 1991).
3.1.4. Proteoglycans and cell growth
Specific heparan sulphate species are capable of modulating cell growth, 
and certain growth factors, including EGF, bFGF and aFGF are known to be 
sequestered by heparin-like molecules (Harper & Reisfeld, 1983; Maciag et 
a!., 1984; Gordon etal., 1987; Levine etal., 1989). Other species influence 
cell growth more directly with growth control being linked to the 
synthesis of specific HSPG species. Endothelial cell-derived HSPG is a 
potent inhibitor of smooth muscle cell proliferation (Castellot etal.,
1982, Benitz etal., 1990) and is antigenically similar to basement 
membrane HSPG (Benitz etal., 1990). A cell surface HSPG synthesized and 
released by confluent hepatocytes synthesize inhibits cell proliferation 
when internalized (Ishihara etal., 1987). Fedarko & Conrad (1986) 
demonstrated that the growth inhibitory activity of a nuclear fraction 
HS-GAG was related to its enrichment in a unique chemical structure. High 
concentrations of exogenous heparan sulphate are also growth inhibitory 
for fibroblasts (Winterbourne & Salisbury, 1981), and normal hepatocyte 
heparan sulphates restore hepatoma density-dependent growth inhibition
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(Kawakami & Terayama, 1981). In contrast, exogenous heparan sulphate or 
heparin promotes endothelial cell proliferation and their long-term 
culture (Hook etal., 1984).
Evidence strongly suggests a role for GAG and proteoglycans in growth 
regulation, but they do not appear to be essential for cell division, at 
least for all cell lines, since cells deficient in GAG do not exhibit 
abnormal growth patterns in vitro (Esko, 1991), although this observation 
may be an artefact of in vitro culture.
3.1.5. Proteoglycans and the extracellular matrix 
The polyanionic nature of GAGs conceivably permits their interaction with 
molecules which are positively charged at physiological pH. Accumulated 
evidence therefore implicates a major role for cell surface proteoglycans 
in both cell adhesion processes and as receptors for circulating and 
immobilized molecules. These activities are not primarily the domain of 
the GAG side-chains. Cartilage CSPG binds to HA through a specific core 
protein domain (Ruoslahti, 1988a), but other matrix proteins possess 
positively charged heparin-binding domains. HA-binding proteins, 
including CD44, have been detected on both normal and transformed cells. 
These may play a role in endocytosis (Hook etal., 1984), but more 
importantly, they may help create and maintain highly hydrated, HA-rich, 
microenvironments that facilitate cell movement and differentiation.
The interactions between GAG and matrix proteins are believed to have 
functional importance in the structural organization and biological 
activity of the ECM. HS-GAG may promote matrix stabilization and be 
indirectly involved in the maintenance of cell differentiation and growth
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control through sequestrating and localizing growth factors (Spooncer et 
at., 1983; Gospodarowicz etal., 1987), or by maintaining gap junctional 
cell communication (Spray etal., 1987). Cell motility is also influenced by 
GAG. Heparin and HS-GAG stimulate tumour cell invasion of artificial 
matrices (Robertson etal., 1989), and CD44-like molecules are 
implicated in K1735 murine melanoma motility and invasion responses to 
collagen I (Faassen etal., 1992).
In addition to integrin-like functions, proteoglycan-matrix protein 
interactions modulate the physiology and integrity of connective tissues. 
The orderly arrangement of proteoglycans along the length of collagen 
fibres modulates fibre diameter and subsequently strength (Vogel etal., 
1984; Rapraeger etal., 1987), and additionally, GAG-collagen interactions 
contribute to the interactions between collagen and fibronectin (Ruoslahti 
& Engvall, 1980).
Fibronectin and laminin have an affinity for sulphated polysaccharides 
and, in vivo, HSPG is in close association with these proteins. HSPG 
augments the affinity of fibronectin for its cell surface receptor and 
co-distributes with actin and fibronectin during cell spreading (Woods et 
a!., 1984). HSPG is also critical for the reorganization of actin 
microfilaments into stress fibres and the subsequent formation of focal 
adhesions (LeBaron etal., 1988). It is possible that proteoglycans 
constitute initial mediators of cell adhesion responses and modulate the 
strength of interaction between integrins and their ligand. By virtue of 
their ability to occupy a large volume of space relative to their size, and 
since their chemical interactions are primarily charge based, they may 
initiate cell adhesion by acting as an initial weak link between cell and
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adhesive substrate, thereby permitting the appropriate integrin receptors 
time to fully interact.
3.1.6 . Glycosaminoglycans and cell transformation 
The relevance of the reported qualitative and quantitative changes in GAG 
bosynthesis upon malignant transformation of cells is somewhat unclear. 
Several investigators have reported that upon malignant transformation,
GAG biosynthesis shifts from the production of sulphated GAG species to 
that of HA (Kimata etal., 1983; Bouziges etal., 1990), a modification that 
has important implications for cell locomotion and matrix properties. Cell 
dfferentiation however is often associated with increased proteoglycan 
bosynthesis (Baldwin etal., 1989). Other investigators have reported the 
synthesis of undersulphated HS-GAG upon cell transformation (David & van 
den Berghe, 1983; Robinson etal., 1984), an observation that has also been 
reported for cell lines selected for high tumourigenicity (Winterbourne &
Mora, 1981). These structural alterations have the potential to modify the 
interactions between GAG and other pericellular molecules. Virally 
transformed cells that synthesize undersulphated HS-GAG fail to 
assemble a pericellular matrix even though they synthesize and secrete 
fibronectin, laminin and procollagen (Hook etal., 1984), and cells 
chemically-induced to synthesize undersulphated CSPG (Walters etal.,
1988) or HSPG (Brauer etal., 1988; Keller etal., 1989) also fail to 
assemble a matrix. These reports suggest that GAG-matrix interactions 
may be mediated via discrete saccharide sequences. This is further 
supported by the observation that chemically modified heparins and 
urdersulphated HS- and CS-GAG compete less effectively in cell adhesion 
assays.
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Undersulphated HS-GAG has a lower affinity for fibronectin (Robinson et 
a!., 1984), and consequently, GAG alterations are often associated with 
changes in the cell adhesive apparatus and properties of cells (Couchman 
e/a/., 1988; Keller etal., 1988; LeBaron etal., 1988). The adhesion and 
spreading of fibroblasts and endothelial cells appears to involve a 
HSPG-dependent mechanism, but neither HSPG or CSPG is necessary for 
maintaining the adhesion (Laterra etal., 1983; Gill etal., 1986). The 
degree of HS-GAG sulphation, however, does not appear to influence the 
processes of cell adhesion and spreading (Brauer etal., 1988).
A role for proteoglycans in tumorigenesis was suggested by Esko (1991) 
who, with co-workers, observed that GAG-deficient CHO cells were 
non-tumorigenic; mutants expressing reduced amounts of the wild-type 
levels of proteoglycan (>10%) were tumorigenic. Subsequently, HS-GAG 
was shown to be necessary and sufficient for tumour formation since only 
mutants that synthesized HS-GAG were tumorigenic whereas mutants that 
exclusively synthesized CS-GAG were not.
In this study the B16 melanoma cell lines were analysed for qualitative 
and/or quantitative differences in GAG synthesis which might be related 
to metastatic potential, and encompassed both the heterogeneous and 
highly clonal cell populations.
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3.2.1.Tumour cell-mediated ECM proteolysis
As previously discussed, many investigators have observed that the ECM of 
malignant cells is more sparse and disorganized. This often a consequence 
of the defective synthesis of matrix components (Barsky etal., 1983;
Meyer etal., 1985; Charpin etal., 1986; d'Ardenne etal., 1986), the 
synthesis of components with altered properties (Hook etal., 1984; Brauer 
etal., 1988; Walters etal., 1988), and/or enhanced cellular proteolytic 
activity (reviewed by Moscatelli & Rifkin, 1988; Tryggvason etal., 1987). 
Several cell- and matrix-associated proteinases are capable of degrading 
ECM components with a resultant loss in its mechanical and structural 
integrity. This cell-mediated destruction or remodelling of the matrix and 
subsequent invasion into the zone of matrix modification is integral to the 
process of tumour cell invasion and metastasis (Liotta, 1986).
Matrix remodelling and matrix invasion are normal physiological 
processes. Within the ECM are latent proteinases are utilized by both 
normal and malignant cells during such processes. Malignant cells can 
directly initiate matrix destruction through the secretion of specific 
matrix-degrading enzymes (Chen & Chen, 1987), and the production of 
tumour cell-derived proteinases can correlate with metastatic potential: 
these include lysosomal hydrolases such as cathepsins (Sloane etal.,
1981; Rozhin etal., 1990), collagenases (Liotta etal., 1980,1982; Reich 
etal., 1988b), and plasminogen activator (PA) (reviewed by Saksela &
Rifkin, 1988). Other neoplastic cells also initiate matrix proteolysis 
indirectly through stimulating adjacent normal cells to secrete the 
necessary proteinases (Biswas & Nugent, 1987; Prescott etal., 1989).
3.2.2. Proteolysis and cell migration
Matrix proteolysis liberate factors which are are both chemokinetic and
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chemotactic for cells. This includes not only proteolytic fragments 
derived from matrix proteins but also matrix-associated proteinases.
The release of degradation products during the process of invasion may 
direct tumour cell migration towards regions of matrix dissolution by 
both chemotactic and haptotactic mechanisms. Degradation products 
derived from the major ECM structural proteins, collagen I and collagen 
IV, have been demonstrated to be chemotactic and chemokinetic for 
hepatoma cells (Nabeshima etal., 1986). Similarly, the degradation 
products from elastin, in particular the hexapeptide VGVAPG which is 
recognized by a class of high affinity cell surface receptors (Blood etal.,
1988), are also chemotactic, and the chemotactic and haptotactic 
properties of fibronectin and laminin and their degradation products are 
well documented (McCarthy & Furcht, 1984).
3.2.3. Basement membrane degradation
The BM is a principle regulatory barrier to tumour cell metastasis. The 
role of enzymes able to degrade this structure have received much 
attention in studies of cell invasion and metastasis.
a) Collagenase IV
The metalloproteinases (MMP) family includes the collagenases which 
degrade the major structural component of the ECM. The MMP family is 
enzymatically active at neutral pH, has tightly bound Zn2+, and requires 
Ca2+ for activity (reviewed by Khokha & Denhardt, 1989; Emonard & 
Grimaud, 1990). Interstitial collagenase (MMP-1) degrades native 
collagens I, II, and III, cleaving the triple helix at a point located 1/4 of 
the distance from the C-terminus. In contrast, collagenase IV (MMP-2)
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degrades native collagen IV at a specific point 1/4 of the distance from 
the N-terminus, and will degrade denatured fibrillar collagens (I, II, III).
The resultant loss of collagen tertiary structure that arises from the 
actions of collagenases permits other proteinases to participate in 
further collagen degradation.
Collagenase IV appears to be highly important in the invasion of the BM. 
Tumour cell-derived enzymes appear to be responsible for the degradation 
of both BM collagen IV and HSPG. Tumour cell invasion of reconstituted BM 
gels correlates with a highly metastatic phenotype and can be used to 
select for such cell phenotypes (Tullberg etal., 1989). Elevated serum 
levels of collagenase IV activity have been associated with metastatic 
disease in humans (Hashimoto etal., 1988). Collagenase IV is associated 
with the cell surface (Nakajima etal., 1989) and the level of enzyme 
activity correlates with the metastatic potential of several tumour types 
(Garbisa etal., 1988; Reich etal., 1988b), but is not always indicative 
(Garbisa etal., 1988).
Natural and synthetic inhibitors of collagenase IV which depress tumour 
cell invasion through reconstituted BM can also reduce the incidence of 
lung tumours in mice injected with metastatic murine melanoma cells 
(Reich etal., 1988a). Antibodies directed against collagenase IV (Hoyhtya 
etal., 1990) and PA (Reich etal., 1988a) also inhibit tumour cell invasion 
in vitro. Retinoic acid has been observed to inhibit tumour cell-mediated 
subendothelial matrix and collagen IV degradation and the invasion of 
reconstituted BM (Nakajima etal., 1989; Emonard & Grimaud, 1990). The in 
vivo and in vitro anti-tumour activity of retinoic acid may therefore be a 
consequence, at least in part, of its inhibitory effect on the levels of
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collagenase IV.
b) Heparanase
HSPG is believed to be important to the structural integrity of the BM 
through its potential to bind to and link several other BM proteins 
(reviewed by Gallagher etal., 1986), and its loss or degradation may 
result in a loss of this integrity. Heparanase activity correlates with 
metastatic potential for both murine B16 melanomas and fibrosarcomas 
(Nakajima etal., 1983; Ricoveri & Cappalletti, 1986), and the ability of 
both normal and malignant blood-borne cells to extravasate also 
correlates positively with their ability to degrade subendothelial BM HSPG 
via cell-derived heparanase (Savion etal., 1987; Vlodavsky etal., 1988).
HS-GAG can be degraded by lysosomal heparanases (Ricoveri & Cappalletti, 
1986) and by plasma membrane-associated heparanase (Gallagher etal.,
1988). The cell surface heparanase is active at physiological pH (Gallagher 
etal., 1988) and is ideally situated to directly interact with HSPG. This 
heparanase may be responsible for modulating cellular interactions 
mediated via HSPG or release biologically active HS-GAG fragments from 
the cell periphery, e.g. fragments with growth regulatory activity (Fedarko 
& Conrad, 1986) or with anticoagulant activity (Marcum etal., 1986). The 
lysosomal heparanases have an acidic pH optimum and may become 
involved in matrix degradation when acidic conditions, often associated 
with metastatic progression (Young etal., 1988; Hill, 1990; Young & Hill,
1990), subsequently arise within tumours.
Heparanase has multiple potential effects upon the nature of the ECM: not 
only has heparanase the potential to disrupt BM integrity, but it can
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modulate the degradative activities of other matrix- and cell-associated 
proteinases and the availability and activity of growth factors for both 
normal and malignant cells thereby influencing invasive growth 
phenomena including angiogenesis.
c) Other proteinases
Plasmin and collagenases are both prominent in the processes of invasion 
and metastasis, and specific inhibitors of these proteinases are able to 
block these processes (Reich e ta l ,  1988a, 1988b; Nakajima e ta l ,  1989; 
Hoyhtya etal., 1990). Plasmin and its latent proenzyme form plasminogen, 
are bound to both the cell surface and to the ECM where it is immobilized 
and protected from inactivation. Activated plasmin degrades most matrix 
components but also activates other latent proteinases including the 
procollagenases (Salo et al,  1982; Emonard & Grimaud, 1990; Reich et 
al,  1988b). The resultant amplification or cascade of proteolytic activity 
functions to increase the efficiency of ECM destruction.
Proteinases are associated with the cell surface of both malignant and 
normal cells. Urokinase-type plasminogen activator (u-PA) may be of 
particular importance in the localized destruction of the ECM. u-PA and its 
related proteinase, tissue-type PA (t-PA), generate activated plasmin 
from plasminogen, and high affinity u-PA receptors have been identified 
on the surface of normal and malignant cells (reviewed by Saksela &
Rifkin, 1988; Laiho & Keski-Oja. 1989). The u-PA receptor-ligand complex 
is enzymatically active and able to degrade matrix components. u-PA is 
distributed beneath cells at cell-cell and cell-substratum contact sites 
(Pollanen eta l ,  1988) and the receptor-ligand complexes are localized to 
the leading front of migrating monocytes (Estreicher e ta l ,  1990). The
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direct catalytic action of u-PA on ECM components and the presence of 
ECM destruction at regions of cell-matrix contact (Fairbairn etal., 1985) 
suggest that the u-PA receptor may be functionally important in both 
localizing, and concentrating, the proteolytic activity of u-PA to regions 
of cell contact and to the invasive front of migrating cells.
Matrix destruction is not singularly a function of tumour cell-derived 
proteinases. In situ, tumour cell-normal cell interactions can alter both 
the composition and structure of the matrix and the levels of 
matrix-degrading enzymes. Such indirect effects may be responsible for 
the ECM alterations associated with tumour cell invasion. The plasma 
membrane protein, tumour cell collagenase stimulatory factor (TCSF), is 
present on certain neoplastic epithelial cells including B16 melanomas. 
This protein is responsible for the stimulation of collagenase synthesis 
and secretion by some normal fibroblast cell lines in response to intimate 
contact with the tumour cells (Biswas & Nugent, 1987; Prescott etal.,
1989).
Since tissues and their matrices are heterogeneous in nature and 
composition, it unlikely that any one enzyme is capable of removing all 
connective tissue barriers. Subsequently several classes of proteinases 
are implicated in tumour invasion (Tryggvason etal., 1987). The specific 
conditions under which each is active make it unlikely that they function 
simultaneously in the same microenviroment. The physiological conditions 
within tumours vary through time, requiring cellular adaptative responses. 
The existence of multiple degradative mechanisms may permit cells to 
remodel their enviroment or maintain normal proteinase-dependent 
functions irrespective of changes in physiological conditions.
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3.2.4. Proteolysis and cell growth
Proteolytic activity is readily modulated by growth factors (reviewed by 
Gospodarowicz etal., 1987; Laiho & Keski-Oja, 1989), possibly released 
from the ECM upon its degradation, and by the presence of pericellular and 
extracellular proteinase inhibitors (reviewed by Tryggvason etal., 1987; 
Saksela & Rifkin, 1988; Khokha & Denhardt, 1989, Rozhin etal., 1990). The 
matrix-degrading activity of cells is balanced by the presence and local 
concentration of cell-associated and matrix-associated inhibitors. These 
include tissue inhibitor of metalloproteinases (TIMP) and plasminogen 
activator inhibitors (PAI) and the levels of these inhibitors are often 
modulated in a similar fashion by the factors which modulate proteinase 
activity.
Several growth factors bind to highly sulphated GAG (Gospodarowicz et 
al., 1987; Roberts etal., 1988), and degradation of ECM heparan sulphate 
releases growth factors stored within the matrix. GAG-binding growth 
factors include the angiogens, acidic- (aFGF) and basic fibroblast growth 
factor (bFGF). aFGF and bFGF are potent endothelial cell mitogens 
(Gospodarowicz etal., 1987; Vlodavsky etal., 1988) and bFGF is also an 
important mitogen for B16 melanoma cells. Normal and malignant cells, 
heparin, HS-GAG and heparanase rapidly liberate FGFs from the ECM. The 
binding of HS-GAG and heparin to FGFs stabilizes the angiogen's tertiary 
structure and protects it from inactivation (reviewed by Gospodarowicz 
etal., 1987; Gordon etal., 1989; Mueller etal., 1989; Sommer & Rifkin,
1989).
3.2.5. The influence of the ECM
The production and secretion of proteolytic enzymes by both normal and
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malignant cells is modulated by the ECM (Emonard etal., 1990). Contact 
with BM laminin apparently initiates tumour cell invasion by stimulating 
the production of collagenase IV (Turpeenniemi-Hujanen etal., 1986; 
Emonard etal., 1990). The synthesis of collagenase IV is also stimulated 
by purified laminin and BM matrigel; BM matrigel and collagen I also 
stimulate interstitial collagenase activity in normal and malignant 
trophoblasts (Emonard etal., 1990). Degradative activity is influenced by 
the composition and assembly of the ECM; matrigel, but not soluble 
laminin, stimulates interstitial collagenase activity. Somatic cell hybrid 
studies suggest that collagenase IV activity and the effect of laminin on 
its secretion may be genetically linked to the metastatic phenotype 
(Turpeenniemi-Hujanen etal., 1985). Plasmin activation is also influenced 
by the matrix; the secretion of u-PA and its rate of proteolytic conversion 
to a more active form is influenced by highly sulphated GAG, in particular 
heparin (Falcone, 1989; Watahiki etal., 1989).
Heparanase activity (Nakajima etal., 1983; Ricoveri & Cappelletti, 1986) 
and collagenase IV activity (Poste & Fidler, 1980) have been observed to 
correlate with the metastatic potential of various B16 melanoma cell 
lines. In order to determine whether this relationship existed for the B16 
melanoma variants developed in this study, and to further characterize 
these cell lines, cells were assayed for their collagenase and heparanase 
activities through their ability to liberate ^H-proline (collagenase) and 
35S0 4  (heparanase) from metabolically-labelled CPAE subendothelial 
matrices.
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SECTION 5. MATERIALS AND METHODS
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4.1.1. Materials and methods:
All reagents and chemicals used were of analytical grade.
Cell Culture: The B16 melanoma cells were maintained in complete 
medium, comprising Eagle’s Minimal Essential Medium (MEM) containing 
10% foetal calf serum (FCS) or newborn calf serum (NCS), 2mM 
L-glutamine, 100IU/ml penicillin and 100jig/ml streptomycin, (Life 
Technologies). Cell culture medium was routinely changed on day 3 and 
cells passaged on day 4. In order to minimise any potential phenotypic 
drift within the B16 melanoma cell populations experiments were 
conducted with cells which had not exceeded passage five. Calf pulmonary 
arterial endothelial cells (CPAE) were maintained in Dulbecco's Minimal 
Essential Medium (DMEM) (Life Technologies) containing 10% FCS and the 
aforementioned concentrations of antibiotics and L-glutamine. All cells 
were maintained at 37°C in a humidified atmosphere of 5% CO2 in air.
B16 melanoma cells were seeded in 80cm2 and 25cm2 culture flasks 
(Nunc) at cell densities which produced 5.0-6.0x10® cells and 1.5-2.0x10® 
cells/flask, respectively, after four days culture.
For cell growth curves B16 cells were plated at very low density in 35mm 
petri dishes and grown for up to 6 days. Each day cells from triplicate 
dishes were detached with 0.05% trypsin/0.02% EDTA and the cells 
counted electronically in a Coulter counter.
Cell treatments: B16 melanoma cell cultures were treated with a series 
of chemical agents which influenced GAG and PG biosynthesis.
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1. Sodium chlorate: 1M sodium chlorate was prepared in PBS pH7.2, and 
sterilized by filtration. For experiments, cells were cultured in 
sulphate-depleted complete medium for 4 days, supplemented daily with 
50mM sodium chlorate. Sodium chlorate is an inhibitor of 
phosphoadenosylphosphosulphate (PAPS) biosynthesis. PAPS is the 
sulphate donor in GAG biosynthesis and its inhibition causes a reduction in 
GAG charge density.
2 . Heparin: A stock solution of 1 mg/ml heparin in PBS was filter 
sterilized and 20pg/ml of heparin added daily to cell cultures.
3. N.N-Dimethvlformamide (DMFT B16 melanoma cells were grown in 
complete medium containing 0.5% DMF (v/v) for 4 days. The medium was 
replaced routinely on day 3 and on day 2 for GAG studies.
4. 5-Hexvl-2-DeoxvUridine (HUdR/KL103T HUdR/KL103 was a kind gift 
from Dr. Josef Timar, (Semmelweis Medical University, Budapest). 
HUdR/KL103 was dissolved in Eagle's MEM or PBS at 50°C  for 10mins to a 
maximum of 5mg/ml, filter sterilized and stored at -20°C . Cell cultures 
received 50pg HUdR/KL103 per ml of complete medium on a daily basis, 
and 75pg HUdR/KL103 per ml of medium on day 3 prior to the harvesting
of cells on day 4.
5. p-nitrophenvl-B-D-xvlopvranoside (B-D-xvloside); B-D-xyloside was
prepared as a stock solution of 80mg/ml in dimethyl sulphoxide (DMSO).
Under experimental conditions, B16 cells were maintained in complete
medium containing 0.5mM B-D-xyloside for 4 days with fresh medium
being added on day 3. For controls, cells were maintained in complete
medium containing an equal volume of DMSO only.
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B16 Murine Melanomas: All B16 melanoma cells were derived from B16F1 
melanoma cells kindly provided by Dr.lan R. Hart (ICRF, London). The B16F1 
melanoma is a poorly metastatic cell line propagated from the parent B16 
melanoma. B16F1 cells were used to generate cell populations with a 
greater lung colonization potential using the experimental metastasis 
method described by Fidler (1973a). B16F1 melanoma cells were injected 
into the tail vein of 6 week old syngeneic C57BL mice and after 18-21 
days the mice were sacrificed, their lungs removed, and tumours excised 
for growth in culture. After 3 and 5 such passages through the lungs, the 
melanoma cells were designated B16F1 M3 and B16F1M5 respectively.
Production of B16 melanoma cell clones: B16 clones were derived from 
the B16F1M3 melanoma by limiting dilution. 1 OOjlxI of B16F1M3 melanoma 
cell suspension (5 cells/ml) was plated into each well of a 96-well 
culture plate. Each well was checked daily, and those containing only one 
cell per well marked as being monoclonal. Once grown to confluence, the 
clones were trypsinised and transferred to 25cm^ culture flasks for 
expansion. Stocks of cells were frozen down in liquid nitrogen. The 
metastatic potential of each clone was assayed by the artificial 
metastasis/lung colony formation model.
Tumour Spheroids: 2% Agar (Life Technologies) was melted and maintained 
at 43°C . The agar was diluted to 0.5% with preheated complete medium 
and 2-3ml added to 35mm petri-dishes. The agar was allowed to set and 
equilibrate with complete medium at 37°C for 2 hours. Dishes were 
seeded with 8x10^ cells and incubated without agitation for 24 or 96 
hours for aggregation and growth studies respectively.
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Enaelbrecht-Holm-Swarm Sarcoma (EHST The EHS sarcoma is a basement 
membrane-rich murine tumour and was propagated in DBA mice by the 
subcutaneous implantion of minced tumour tissue (Orkin etal., 1977). The 
tissue was harvested when the tumour mass was 2-4cm in diameter.
Experimental Metastasis/Luna Colonization Model: B16 melanoma cells 
were grown for four days in culture flasks until confluent. Cells were 
detached with trypsin/EDTA and washed three times with sterile 0.9%
NaCI. The cell suspension was adjusted to 5x10^ cells/ml and 200pl of 
suspension injected into C57BL/6 mice via the tail vein. After 18-21 
days, the mice were sacrificed and their lungs excised and washed in PBS 
before being fixed in formyl saline. The number of visible lung tumours 
were then counted to provide a measure of metastatic potential.
Production of subendothelial matrix: (Vlodavsky etal., 1982). 4x10^ CPAE 
cells were grown to confluence in 35mm petri dishes in 1.5ml of culture 
medium (DMEM, containing 10%FCS, 2mM L-glutamine, 100IU/ml penicillin, 
100pg/ml streptomycin, and supplemented with 5% (w/v) dextran [average 
M.W. 40kD]). Filter sterilized ascorbic acid in PBS was added daily to a 
final concentration of 50pg/ml. Cells were cultured for 10-12 days with 
medium being replaced on days 3 and 7. To harvest the endothelial ECMs, 
cell layers were washed once with sterile PBS, and then treated for up to 
10mins with sterile 0.5% Triton X-100 in PBS (v/v) at room temperature 
to dissolve the cell layer and leave the underlying matrix intact. The 
remaining nuclei and cytoskeletons were removed by a brief exposure 
(2-3mins) to sterile 25mM NH4OH, followed by 4 washes with PBS. The 
matrix-coated dishes could be stored in PBS for several weeks at 4°C.
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Radiolabellina of subendothelial matrix: (Vlodavsky etal., 1982). 4x104 
CPAE cells were grown to confluence in 35mm petri dishes under the 
aforementioned cell culture conditions. To radiolabel subendothelial 
matrix collagens, the culture medium was replaced on day 3 with 1 ml 
proline-depleted medium containing 5% (w/v) dextran, 10% FCS, 100IU/ml 
penicillin, 100pg/ml streptomycin, 2mM L-glutamine and 5jiCi/ml 
3H-proline. Ascorbic acid continued to be added on a daily basis until the 
matrices were harvested. On day 7 an additional 1ml proline-depleted 
medium containing 5pCi/ml 3H-proline was added to the dishes. On day 
12, the radiolabelled matrix was prepared as described previously. For 
radiolabelling matrices with 35SC>4 , the radiolabelling procedure for
3H-proline was slightly modified. The radiolabelling medium was 
sulphate-depleted DMEM (Life Technologies) containing 5% (w/v) dextran, 
10% FCS, 100IU/ml penicillin, 100pg/ml streptomycin, 2mM L-glutamine, 
and up to 30pCi/ml 35SC>4 , and the aforementioned radiolabelling and 
harvesting procedures were followed.
If dishes containing radiolabelled matrix were to be used immediately 
they were first preincubated for at least 3 hours to liberate any free 
radiolabel still present. If not, dishes were stored in PBS at 4°C.
Subendothelial matrix degradation assav: Petri-dishes containing 
radiolabelled subendothelial matrices were seeded with 1.5-2.0x103 
cells in complete medium and incubated for 2 hours. Non-adherent cells 
and contaminating serum were removed by gentle washing with sterile 
PBS. The numbers of adherent cells in control and treated cultures were 
similar and exceeded 90%. Attached cells were incubated in 1ml 
serum-free MEM containing 100IU/ml penicillin, 100pg/ml streptomycin,
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and 2mM L-glutamine for 48 hours at 37°C after which the medium was 
removed, centrifuged, and two aliquots taken for scintillation counting. 
Results were expressed as disintegrations per minute (dpm)/number of 
cells seeded.
Uronic Acid Determination: In the generation of an ion-exchange 
chromatographic profile of non-radiolabelled GAGs, the uronic acid 
content of column fractions was determined using the method of 
Blumenkrantz & Asboe-Hansen (1973). 200jil samples of eluted GAG were 
set in crushed ice to which 1.2ml of 12.5mM sodium tetraborate in 
concentrated H2SO4 was added and thoroughly mixed. The samples were
then heated to 100°C for 5 minutes and the samples then cooled on ice. 
20jil of 0.15% m-hydroxydiphenyl in 0.5% NaOH was added and mixed, and 
the absorbance measured at 520nm. A standard plot of absorbance at 
520nm versus uronic acid concentration was generated by dissolving a 
range of glucuronic acid (GlcU) standards (0-20jig) in 0 .2ml of buffer, and 
treating accordingly with tetraborate.
Protein Estimation: Protein concentrations were determined using the 
method of Bradford (1976). 10Optl of test solution was mixed with 5ml of 
filtered Bradford reagent [0.1% (w/v) Coomassie Brilliant Blue G250, 4.5%  
EtOH (v/v), 10% phosphoric acid], and the absorbance at 595nm measured. 
A standard curve was generated using a bovine serum albumin (10-1 OOpig).
Basement Membrane and Extracellular Matrix Components: Basement 
membrane proteins (laminin/nidogen and type IV collagen) were extracted 
from the EHS sarcoma, type I/III collagens from rat tail tendon, and 
fibronectin from human plasma.
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Fibronectin: Plasma fibronectin was prepared using a modification of the 
method of Miekka etal. (1982). 3.8% tri-sodium citrate-treated human 
plasma containing 5.0mM benzamidinium chloride was centrifuged at room 
temperature (10,000g, 30min). The supernatant was applied to a 
Gelatin-Sepharose affinity column (70mmx25mm) equilibrated with 0.1 M 
NaCI, 50mM 6-amino-hexanoic acid, 3.0mM sodium azide, 50mM tris/HCI, 
pH7.4, after an initial separation via a Sepharose 4B gel filtration 
pre-column (40-70mm). Non-specifically bound protein was eluted with 
100ml of 1M NaCI, 5.0mM benzamidinium chloride, 50mM 
6-amino-hexanoic acid, 3.0mM sodium azide, 50mM tris/HCI pH7.4, 
followed by 50ml 50mM tris/HCI, 1 .OmM EDTA, pH7.4. The Sepharose 4B 
pre-column was then removed and the bound fibronectin eluted with 3M 
urea, 50mM tris/HCI, 1.0mM EDTA, pH7.4, and the eluted material 
monitored at 280nm. All steps were performed at room temperature. 
Fibronectin prepared in this manner contains only minor impurities. The 
maximum expected yield was 14-16mg fibronectin per 100ml plasma. The 
fibronectin could be stored at -20°C in the 3M urea solution. Prior to use, 
aliquots of the fibronectin stock were dialysed against 0.15M NaCI, 50mM 
tris/HCI, pH7.4 and the concentration determined using the Bradford assay.
Laminin-Nidoaen Complex: The complex was prepared according to the
method of Paulsson etal. (1987a). Frozen EHS tissue was homogenized in
0.15M NaCI, 50mM tris/HCI, pH7.4, containing 0.5mM N-ethylmaleimide
(N-EM), and 0.5mM phenylmethylsulphonylfluoride (PMSF) as protease
inhibitors. The homogenate was centrifuged (8000rpm for 20mins in a
Beckman centrifuge) and the pellet re-homogenized in the same buffer
including 10mM EDTA. The homogenate was stirred for 1 hour at 4oC,
centrifuged at 8000rpm for 20mins, and the supernatant collected and
stored at -20°C . Aliquots of the supernatant were separated on a Biogel
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A5M (BioRad) gel filtration column (26mm x 900mm) equilibrated in 0.15M 
NaCI, 50mM tris/HCI, pH7.4, 0.5mM N-EM, and 0.5mM PMSF. The elution of 
proteins was monitored at 280nm. The laminin-nidogen complex which 
eluted at the void volume (V0) was pooled and concentrated by
ultra-filtration through an Amicon PM10 membrane to approximately 
1 mg/ml and stored at -20°C.
Type I/Ill Collagen: Collagen was prepared according to the method of 
Schor (1980). 1g of rat tail tendon was sterilized in EtOH and dissolved in 
250ml of pre-cooled 0.5M acetic acid by stirring for 48 hours at 4°C . The 
solution was centrifuged (10,000g, for 30mins at 4°C) and the pellet 
discarded. An equal volume of pre-cooled 20% NaCI (w/v) was added to the 
supernatant and stirred overnight at 4°C. The collagen-rich, salt-insoluble 
material was recovered by centrifugation (10,000g, for 30mins at 4°C) 
and resuspended in 200ml of pre-cooled 0.25M acetic acid before being 
dialysed against 3-4 changes of pre-cooled 0.1% acetic acid, and was 
sterilized by centrifugation (20,000g, for 6 hours at 4°C). The collagen 
concentration was determined by weighing a freeze-dried aliquot of the 
solution.
Type IV Collagen: DBA mice subcutaneously implanted with EHS sarcoma 
tissue were fed with 0.3% B-aminoproprionitrile fumarate (B-APN) in 
their drinking water. B-APN is a lathyritic agent that inhibits the 
cross-linkage of collagen IV monomers. The extraction of collagen IV was 
performed using the method of Kleinman etal. (1983, 1986). After 
excision, 200-400g of EHS sarcoma tissue was washed in ice cold 3.4M 
NaCI, 50mM tris/HCI, pH7.4, 2mM N-EM, 8mM EDTA. The tissue was 
homogenized in ice cold 0.5M NaCI, 50mM tris/HCI, pH7.4, 2mM N-EM, 8mM
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EDTA, and extracted twice by centrifugation (10,000g) with the same 
buffer at 4°C. This removed the cellular proteins and laminin-nidogen 
complex. The residue was extracted at 4°C  with pre-cooled 2M guanidine 
HCI, 50mM tris/HCI, pH7.4, 2mM N-EM, 8mM EDTA, 0.1 mM PMSF, followed 
by the same buffer containing 2mM dithiothreitol (DTT). This second 
extract, containing most of the solubilized collagen IV, was dialyzed 
against 10 litres of pre-cooled 1.7M NaCI, 50mM tris/HCI, pH7.4, 2mM DTT, 
1mM EDTA, 0.1 mM PMSF until a precipitate was formed. The precipitate 
was collected by centrifugation (12,000g, for 1 hour at 4°C), dissolved in 
pre-cooled 2M guanidine/HCI, 50mM tris/HCI, pH7.4, 2mM DTT, 1mM EDTA, 
0.1 mM PMSF, and dialysed against pre-cooled 4M urea, 0.25M NaCI, 50mM 
tris/HCI, pH8 .6 , 2mM DTT, 1mM EDTA, 0.1 mM PMSF. The dialysed collagen 
IV was mixed with DEAE-cellulose equilibrated with the same buffer and 
the unbound material collected and dialyzed against the 2M guanidine/HCI 
buffer. This was then centrifuged at 60,000g for 90mins at 4°C  to remove 
aggregates. The supernatant, reported to contain approximately 80%  
dimeric collagen IV, was dialysed against 2M urea, 50mM tris/HCI, pH7.4, 
2mM DTT, 5mM glycine, 1 mM EDTA, 0.1 mM PMSF. After a second round of 
ultracentrifugation, the collagen IV can be further purified on Sephacryl 
S-1000 (5mmx95mm) equilibrated in the same buffer. Collagen IV was 
stored at -20°C in 2M guanidine HCI buffer.
Adhesion Assav: 35mm petri dishes were coated with ECM components at
40pg/dish, (an optimum standard concentration used in cell adhesion
assays in this laboratory) and treated with 10mg/ml bovine serum
albumin (BSA) in PBS to block any unoccupied adhesive sites. Fibronectin
and laminin were prepared in 0.15M NaCI, 50mM Tris/HCI pH 7.4, and
collagens I and IV in 0.1% acetic acid for coating petri dishes. CPAE and
B16 melanoma cells were grown to confluence in 35mm dishes for
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cell-cell adhesion assays. B16 melanoma cells cultures which had been 
grown for four days to near confluency were detached with trypsin/EDTA, 
washed, and their cell densities adjusted to 2.0x10^-2.5x10^ cells/1.5ml 
in serum-free MEM. Cells were then plated at the above density onto the 
substrates and incubated at 37°C  for set time periods. Non-adherent cells 
were washed off and the remaining cells detached with trypsin/EDTA and 
two aliquots taken for electronic cell counting in a Coulter counter. The 
percentage cell attachment was expressed as the [number of cells 
adherent at time x / number of cells added per dish at time 0 (or 
alternatively, the number of cells adhered to culture plastic after 2 
hours)] x100.
For assays of adhesion to cell monolayers and subendothelial matrices,
B16 melanoma cells were labelled with 10OpCi of 51 Cr /80cm^ flask 
overnight. The same assay procedure was followed for the ECM and BM 
substrates, except that after the washing off of non-adherent cells, the 
remaining cells were solubilized with 0.1 M NaOH. Two aliquots were taken 
for counting in a Wilj gamma-counter. The percentage attachment was 
expressed as [dpm at time x / dpm cells seeded] x100. For all experiments, 
triplicate dishes were used per cell line per time point and all 
experiments were performed in triplicate.
Measurement of cell spreading in vitro: B16 melanoma cells grown on 
tissue culture plastic were photographed at a magnification of X125. The 
outlines of cells were carefully cut from photographs and weighed, and 
cell spread area was then expressed in milligrammes.
Melanin and Tyrosinase Assays: A modified procedure was used from those
reported by Lotan and Lotan (1980) and Halaban etal. (1983). Duplicate
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cultures of melanoma cells were grown in 60mm petri dishes for 4 days 
until confluent. The cell layers were washed with ice cold PBS, pH 7.2 and 
scraped in 1 ml of the PBS. From this both the melanin and tyrosinase 
assays were performed. A 100pl aliquot was used for the tyrosinase 
assay, 2x100pl aliquots for cell counts and the remaining 700jj.I for the 
melanin determination.
For the tyrosinase assay, the cells were gently pelleted and then 
resuspended and lysed in 0 .2ml of PBS pH7.2 containing 1.0% Nonidet P-40. 
The solution was then centrifuged at 16,000g for 5 mins and the 
supernatant transferred to clean eppendorf tubes containing 0 .2ml of PBS 
containing 2x10'4M L-DOPA, 4x10"4 M L-tyrosine and 2.0|iCi L-[3,5-3H] 
tyrosine, and incubated at 37°C for one hour. The reaction was stopped by 
the addition of 0.5ml of cold trichloroacetic acid (TCA) and centrifuged.
The supernatant was transferred to 1.5ml eppendorf tubes containing 
100mg of activated charcoal, mixed and centrifuged. 0.5ml samples were 
taken from each tube and mixed with 5ml of Ecoscint scintillation 
cocktail prior to being counted in a Packard Tri-Carb 300C scintillation 
counter. Tyrosinase activity was measured as the release of 3H-radiolabel 
(as 3H2 0 ) per 1.0x103 cells.
For the melanin assay the cell suspension was initially subjected to two 
cycles of freeze/thawing. Perchloric acid was added to a final 
concentration of 0.5M and the suspension kept on ice for 10 mins before 
being centrifuged at 16,000g for 5 mins. The pellets were extracted twice 
with 0.5M perchloric acid, twice with a cold 3:1 v/v mixture of EtOH:ether, 
followed by a final extraction with ether and then air dried. Pellets were
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then dissolved by boiling in 1.0ml 0.85M KOH for 10 mins. The insoluble 
material was pelleted and the absorbance of the supernatant read at 
400nm. Absorbances were compared with those obtained for preprepared 
melanin standards and results expressed as jag of melanin/103 cells. All 
experiments were performed in triplicate.
Radiolabellina of Glvcosaminoalvcans (GAG1: For qualitative GAG analyses 
different B16 melanoma cells, grown in 80cm2 flasks for 4 days until 
confluent, were radiolabelled for the final 48 hours with either 5pCi 
3H-GlcN or 2pCi 14C-GlcN (ICN-Flow Radiochemicals) per ml of medium. 
On day 4 the medium was removed and the cell layer washed twice with 
Ca2+- and Mg2+-free PBS and pooled with the medium. This was 
designated the medium GAG fraction. The cell layer was detached with 
trypsin/EDTA and the cells resuspended in complete medium. The cells 
were pelleted by centrifugation and the medium removed. The cell pellet 
was washed twice with Ca2+- and Mg2+-free PBS, centrifuged and the 
washings pooled with the medium. This was designated the 
trypsin-releasable GAG fraction. The cell pellet was then resuspended in 
Ca2+- and Mg2+-free PBS and designated the cell-associated GAG fraction.
0.5mg of both chondroitin sulphate and heparin (Sigma) was added as 
carrier GAG to all fractions. The fractions were boiled for 5 mins and 
prepared for Pronase digestion. Identical GAG fractions from different 
cell lines which were differentially labelled with either 3H- o r 14C-GlcN 
could be pooled for direct comparison of their GAG properties.
For quantitative GAG analyses, the previous procedure was followed
except that triplicate 80cm2 flasks were dual labelled with 20jaCi 33S 04
and 5jaCi 3H-GlcN per ml of medium and all fractions kept separate. After
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48 hours incubation the cells were switched to sulphate-depleted 
complete medium for radiolabelling.
Pronase Digestion: GAG fractions dialysed against 50mM tris/HCI pH7.6, 
were digested for 24 hours with 0.5mg Pronase (Sigma) in 50mM tris/HCI 
pH7.6, per ml of sample at 50°C, with a further addition after 6 hours 
incubation. Samples were then boiled and dialysed against column buffer 
in preparation for DEAE-ion exchange chromatography.
Ion Exchange Chromatography (1EC): GAGs were initially separated on 
DEAE-cellulose (Whatman Biosystems Ltd) ion exchange columns 
(80mmx10mm) using a linear 0.05M-0.7M NaCI gradient in 10mM tris/HCI, 
pH7.6. DEAE is cationic, with molecular structure -CH2-N+(CH3)3
Fractions were collected as 2.5ml volumes and an aliquot taken from 
every second fraction for scintillation counting on a Packard Tri-Carb 
300C. Radioactive peaks corresponding to the sulphated GAGs were pooled, 
split into equal sized fractions, and prepared for either nitrous acid 
deamination at low pH or chondroitinase ABC (Sigma) digestion to 
generate, respectively, intact chondroitin sulphates (CS) or heparan 
sulphates (HS) only. These were then dialysed against column buffer for 
further qualitative determination on DEAE-cellulose. In quantitative GAG 
analyses, the relative proportions of individual GAG species were 
estimated by gel filtration chromatography on Sephadex G-50 columns 
(Pharmacia/LKB Biotechnology) following sequential degradation of void 
volume material with chondroitinase ABC and nitrous acid.
For qualitative analyses, Mono-Q-Sepharose (Pharmacia/LKB) was used to 
provide a measure of the degree of GAG sulphation. Mono-Q-Sepharose is a
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highly polycationic ion exchange resin and within the range of pH2.0-4.0 
the binding of GAGs to the resin is due to charged sulphate groups 
(Couchman eta l., 1988). GAG was eluted from the Mono-Q-Sepharose 
column (90mm x 15mm) with a linear gradient of 0.2M-1.8M NaCI in 50mM 
tris/HCI, pH2.0, or alternatively, in 50mM sodium acetate, pH4.0, 
containing 0 .1%(v/v) Triton X-100 (Sigma). Fractions were collected as 
2.5ml samples and an aliquot taken from every second fraction for 
scintillation counting.
Gel Filtration Chromatography: Freeze-dried GAG was rehydrated in 0.2ml 
0 .5M NaCI for gel filtration chromatography on Sephadex G-50 columns 
(600mmx5mm) equilibrated in the same buffer. 700jliI samples were 
collected and 10Optl samples analysed for their radioactive content. For 
quantatative GAG analyses, samples treated with either chondroitinase 
ABC or nitrous acid were separated on Sephadex G-50 columns into two 
peaks; the void volume (V0) represented intact GAG, and the included
volume (Vj), which elutes near to the total volume (Vj), degraded GAG.
These peaks permit the levels of heparan sulphate and chondroitin 
sulphates to be calculated.
Proteoalvcan analysis: B16 melanoma cells were radiolabelled for 
qualitative analysis as previously described and their proteoglycans 
isolated and analysed by the method described by Couchman etal. (1988). 
The medium fraction consisted of the culture medium plus three washes 
with PBS at 37°C. The cell layer was solubilized overnight at 4 °C  in 10ml 
of 4M urea, 1.0% (v/v) Triton X-100, 25mM tris/HCI pH7.5, plus the 
following protease inhibitors; 0.2mM PMSF, 10mM N-EM, 50mM 
aminocaproic acid (ACA), 20mM EDTA, and 5mM benzamidinium chloride.
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The two proteoglycan pools, medium and cell-lysate, were diluted 1:5 
with 4M urea, 0.2M NaCI, 50mM tris/HCI, pH8.0, plus protease inhibitors, 
and applied to a 30mmx10mm column of DEAE-cellulose equilibrated in 
the same buffer with 0.1% Triton X-100. The ion-exchange column was 
washed with 10 column volumes of equilibration buffer followed by 5 
column volumes of 4M urea, 50mM sodium acetate, pH4.0, 0 .2mM NaCI, 0.1%  
Triton X-100, plus protease inhibitors. Radiolabelled GAGs and PGs were 
eluted in 10x1 ml fractions of 4M urea, 50mM sodium acetate, p H 4 .0 ,1.5M 
NaCI, 0.1% Triton X-100, plus protease inhibitors. Under these conditions 
no unincorporated radiolabel co-purified with the macromolecules.
The molecular size of the PGs and GAGs was estimated by Sephadex CL-4B 
gel filtration using 900mmx15mm columns equilibrated with 0.1% (w/v)
SDS, 50mm tris/HCI pH8.0, 0.35M NaCI, 0 .2g/L sodium azide and protease 
inhibitors. Radiolabelled macromolecules were eluted at 6ml/hour and 
collected as 1.5ml fractions. An aliquot was taken from each fraction for 
scintillation counting.
Heparan sulphate PG (HSPG) and GAG (HS-GAG) was isolated by digesting 
contaminating chondroitin sulphates (CS) with 0 .1U/ml chondroitinase 
ABC in 50mM tris/acetate, pH8.0, 30mM sodium acetate, 0.1% Triton 
X-100, 0.1 mg/ml BSA, 0.2mM PMSF, 5mM N-EM, and 10mM EDTA overnight 
at 37°C . Chondroitin sulphates were isolated by deamination of heparan 
sulphates with nitrous acid at low pH.
Preparation of Heparan and Chondroitin Sulphates: GAG fractions
separated by DEAE-cellulose IEC were dialysed against distilled water,
split into two equal samples and freeze dried. Chondroitin sulphates were
digested with chondroitinase ABC (0.25units in 0.05M Tris-acetate buffer,
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pH8.0, containing 0.15M NaCI and 0.1% (w/v) BSA overnight a t37°C  
(Oldberg etal., 1977). Heparan sulphates were degraded by deaminative 
cleavage at low pH (Shively and Conrad, 1976): 50pl of 3.6M acetic acid 
and 0.48M sodium nitrite were added to the sample to generate nitrous 
acid, and incubated for 90mins at room temperature. The reaction was 
terminated by neutralization with 2M sodium carbonate.
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Results:
4.2.1. Production of metastatic cell lines
From a poorly metastatic B16 murine melanoma cell line, B16F1, a series 
of cell lines was derived that differed in their metastatic potential, 
growth rates, and morphology. Metastatic potential (capacity) was 
assessed as a measure of a cell line's ability to colonize the lungs of 
syngeneic C57BL mice following bolus administration via tail vein 
injection into experimental animals. The moderately metastatic cell lines 
B16F1 M3 and B16F1M5 (Table.1) were generated from B16F1 cells via this 
artificial metastasis system described by Fidler (1973a). B16F1M3 and 
B16F1M5 cells were developed from the lung colonies formed by B16F1 
cells that were sequentially passaged through the lungs of syngeneic 
C57BL mice three and five times respectively. B16F1M5 melanoma cells 
proved to be phenotypically unstable in vitro, and therefore most of the 
experimental work concentrated on the more stable B16F1 M3 melanoma 
cell line.
A panel of B16 melanoma cell clones were generated from the B16F1 M3 
melanoma cell line by the process of limited dilution. From this panel of 
B16F1M3-derived clones, two clones were identified which possessed 
widely contrasting metastatic capacities and were stable in vitro for the 
duration of the experiments: B16F1H5 was poorly metastatic whereas 
B16F1D2 was highly metastatic (Table 1).
The major aim of the study was to determine to what extent tumour 
cell-derived proteoglycans were involved in the latter phases of tumour 
cell metastasis as measured by an artificial metastasis model. A series 
of chemical agents reported to influence the biosynthesis and chemical
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Table.1 Luna Colonization Efficiencies
Lung colony formation after intravenous injection of B16 melanoma 
cells (1x105 cells/0 .2ml saline)
Cell Line mean (s.d) Ranae n
B16F1 (a)(b)(g) 3.0 (3.3) 0-14 31
B16F1+0.5%DMF (a) 7.7 (7.6) 0-23 14
B16F1M3(b) 38.6 (46.8) 0-158 47
B16F1 M3+0.5% DMF(b) 118.6 (67.6) 14->200 28
B16F1M3+50mM sodium chlorate 37.7 (15.4) 10-62 6
B16F1M3+50g/ml HUdR/KL103 38.5 (49.9) 0-163 13
B16F1M3+20pg/ml heparin 25.4 (14.9) 2-60 12
B16F1 M5(g) 34.7 (21.7) 6-78 6
B16F1 D2(c) 100.7 (86.3) 1-234 17
B16F1 H5(c) 1.1 (1.0) 0-3 10
B16F1D2+DMSO carrier(d) 104.1 (102.4) 17-286 15
B16F1 D2+0.5mM B-D-xyloside(d) 42.2 (32.2) 0-94 17
B16F1 M3(LT)(e) 47.8 (54.7) 10->200 12
B16F1 M3+0.5% DMF(LT)(e) 124.0 (65.9) 13->200 11
B16F1 M3(LT:C4D1)(f) 152.0 (59.3) 16->200 9
B16F1 M3(LT:D4C1)(f) 47.8 (38.2) 4-116 10
Abbreviations:
LT: long term culture (five passages total)
C4D1: four passages in complete medium followed by a final passage 
in complete medium+0.5%DMF.
D4C1: four passages in complete medium+0 .5%DMF followed by a final 
passage in complete medium only.
Significance values (Student's t-test):
(b)(c)(e)(f): 0.001 >P 
(a)(d): 0.05>P 
(g):0.01>P
characteristics of proteoglycans was assayed for their ability to 
interfere with the metastatic ability of B16 melanoma cells. The ability 
of these agents to interfere with metastatic potential may therefore be 
related to, or be a consequence of, proteoglycan modifications.
4.2.2. Lung colonization potential
B16 melanoma cells were assayed for their metastatic ability using the 
method described by Fidler (1973a) which measures the cells' ability to 
colonize a target organ, in this case the lungs of syngeneic C57BL mice 
(Table 1).
DMF, a putative reversible inducer of differentiation (Spremulli & Dexter, 
1984) was analysed for its biological effects on B16 melanoma cells. The 
induction of a more differentiated cell phenotype is usually associated 
with an inhibition of metastatic ability. Other chemical agents widely 
reported to modify proteoglycan biosynthesis were also assayed for their 
effects on lung colonization; these agents were sodium chlorate, heparin, 
B-D-xyloside, and 5-hexyl-2-deoxyuridine (HUdR/KL103). Briefly, sodium 
chlorate is an inhibitor of proteoglycan sulphation (Humphries & Silbert, 
1988) whereas heparin promotes GAG sulphation (Nader etal., 1989). 
B-D-xylosides interfere with proteoglycan biosynthesis by competing 
with proteoglycan core proteins for GAG chain synthesis (Schwartz etal., 
1974), and HUdR/KL103 is described as a specific inhibitor of GAG 
synthesis (Lapis etal., 1987). The effects of these agents on lung 
colonization is summarized in Table 1.
Heparin, sodium chlorate and HUdR/KL103 had no significant effect on the 
lung colonization potential of moderately metastatic B16F1M3 melanoma
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cells. However, the effect of 0.5% DMF and 0.5mM B-D-xyloside were both 
significant but contrasting. Pretreatment with 0.5% DMF resulted in a 
significant increase in the lung colonizing potential of both the poorly 
metastatic B16F1 cells and the moderately metastatic B16F1M3 cells 
(P<0 .001). This was in contrast to the significant reduction in lung 
colonization when highly metastatic B16F1D2 melanoma cells were 
treated with 0.5mM B-D-xyloside (P<0.05).
In order to minimise the effect of phenotypic drift that can arise through 
prolonged culture of tumour cells, long-term cultures of B16F1M3 
melanoma cells were prepared and their lung colonization potential 
determined (Table 1). B16 melanoma cells which underwent 24 days (5 
passages) of continuous culture possessed a similar lung colonization 
potential as early passage cells. Prolonged cell culture in the presence of 
0.5%DMF provided similar values for lung colonization as early passage 
cells treated with DMF. Switching cells from DMF-medium to normal 
medium after 20 days (passage 4) resulted in the reacquisition of the 
moderately metastatic phenotype (D4C1). In contrast, the addition of DMF 
to long-term cultures after 20 days induced the highly metastatic 
phenotype.
These results would indicate that at passage 5, any phenotypic drift that 
had occurred in culture was minimal, and that the cell populations were 
stable up to that point. Pretreatment with DMF did not apparently select 
for subpopulations of tumour cells with increased lung colonization 
potential since its removal resulted in the reacquisition of the original 
potential. DMF-induced changes in cell phenotype were rapid and 
reversible. In consequence, all experimental work was performed with
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cells between passages 2 and 5.
4.2.3. Cell growth
The B16 melanoma cell lines used displayed differences in their initial in 
vitro growth rates. The kinetics of cell growth in vitro were measured as 
cell doubling times. Cell viability in culture (as measured by trypan blue 
exclusion) was in excess of 92%, and pretreatment of cells with different 
GAG-altering chemical agents assayed did not affect the viability.
Poorly metastatic B16F1 cells had a cell doubling time ranging from 
approximately 23 hours on days 2-3 and decreasing to 12 hours on days 
3-4. The moderately metastatic B16F1 M3 cell line was relatively faster 
growing with cell doubling times of approximately 13-14 hours over days 
2-4 (fig.6a). B16F1M5 melanoma cells were slower growing with a 
relatively stable cell doubling time of 17 hours over days 2-4 (fig.6b). 
Variability in cell growth rates was observed in different vials of 
cryopreserved cells that were thawed for expansion in vitro. These 
variations may probably reflect differences in cell sensitivity and 
recovery from cryopreservation.
Treatment of the B16F1 M3 melanoma cells with 0.5% DMF initially reduced 
cell growth rates over the first 48 hours. On days 2-3 the cell doubling 
time was approximately 16 hours, recovering to 13 hours on days 3-4 
(fig.6a). B16F1M3 cells initially treated with 0.5% DMF and then allowed 
to recover after removal of the DMF did not significantly alter their 
growth rate during the recovery period and maintained a growth rate 
similar to that measured for their DMF-treated counterpart. DMF had very 
slight suppressive effect upon the cell doubling times of B16F1M5 cells
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Fia.6a: B16 melanoma cell growth rate in vitro (mean t  SEM: n=12)
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(fig.6b). The presence of HUdR/KL103, sodium chlorate, and heparin had no 
significant influence upon cell growth (not shown).
Low concentrations of DMF (<0.1 %) stimulated cell growth by up to 20%. At 
higher concentrations (0.3%-1.0%) a proportional but gradual reduction in 
cell numbers resulted with cell numbers being reduced to approximately
40% following 5 days incubation in 1.0% DMF (fig. 6c). DMF had no 
observable effect upon the initial rates of cell attachment and spreading 
on culture plastic since the great majority of cells were attached and 
spread within a few hours. One effect of DMF appears to be an initial 
inhibition of cell growth occuring within the first 48 hours of exposure 
(fig. 6a). After the first 48 hours the B16 melanoma cells appear to adapt 
to the presence of DMF and recover their usual growth rate.
The B16 melanoma cell clones derived from B16F1 M3 cells also exhibited 
differences in cell doubling times (fig.6d). B16F1H5 cells had a doubling 
time of approximately 14 hours on days 2-3 and 18 hours on days 3-4.
B16F1D2 melanoma cells had a more consistent cell doubling time over 
days 2-4 of 17 hours. It was observed that the in vitro culture of cells in 
the presence of 0.5mM 3-D-xyloside reduced the cell numbers by 
approximately 20% after 4 days, and is suggestive of the possible 
involvement of normal proteoglycan synthesis in the regulation of B16 
melanoma cell growth.
4.2.4. Cell morphology
The production of metastatic variants from B16F1 melanoma cells 
generated cells which differed in cell morphology and growth rates. In
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Figures 7A-7H: B16 melanoma cell morphology in vitro
(Cells photographed x125 magnification using a Leitz Diavert microscope, Wild PhotoAutomat 
MPS55 and Ilford FP4 Plus f 125 photographic film)
B16F1 (7A); B16F1M3 (7B); B16F1+0.5%DMF (7C); B16F1M3+0.5%DMF (7D); B16F1H5 
(7E); B16F1D2 (7F); DMSO-treated B16F1D2 control cells (7G); and B16F1 D2+0.5mM 
(3-D-xyloside (7H)
vitro, B16F1 cells (fig.7A) grew as poorly spread cells which formed tight 
colonies. B16F1M3 cells (fig.7B) grew as looser cell colonies and appeared 
flatter than the B16F1 cells. It was also more common to see individual 
B16F1M3 cells. Treatment of B16F1 cells with 0.5% DMF did not induce 
gross morphological alterations although the cells were more pigmented 
(fig.7C), but treatment of B16F1 M3 cells with 0.5% DMF caused gross 
morphological alterations (fig.7D). Cells became epithelioid and flattened 
with irregular cell margins. Pretreatment of B16 melanoma cells with 
HUdR/KL103, heparin or sodium chlorate had no visible effects upon cell 
morphology (not shown).
B16F1 M3-derived cell clones did not display morphological differences in 
vitro. Both the poorly metastatic B16F1H5 (fig.7E) and highly metastatic 
B16F1D2 (fig.7F) melanoma clones expressed similar morphology and cell 
spreading. The B16F1D2 cells though formed more diffuse colonies than 
B16F1H5 cells. Pretreatment of B16F1D2 cells with B-D-xyloside had no 
visible effects upon cell morphology or cell spreading in vitro (figs.7G,
7H).
4.2.5. Tumour spheroids
It was observed that DMF-treated cells were more resistant to 
detachment with trypsin/EDTA from culture dishes than untreated cells, 
and that they rapidly formed cell aggregates when in suspension. Since 
cell aggregation and embolus formation are believed to afford physical 
protection to circulating tumour cells and facilitate tumour cell arrest, 
tumour cells were grown in suspension for 24 hours to measure 
aggregation (spheroid formation) and for 72 hours to permit measurement 
of cell growth.
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Figures 7I-7P: B16 melanoma cell lines as 24 hour spheroid cultures
(Cells photographed x125 magnification using a Leitz Diavert microscope, Wild PhotoAutomat 
MPS55 and Ilford FP4 Plus f125 photographic film)
B16F1 (71); B16F1M3 (7J); B16F1+0.5%DMF (7K); B16F1M3+0.5%DMF (7L); B16F1H5 
(7M); B16F1D2 (7N); DMSO-treated B16F1D2 control cells (70); and B16F1 D2+0.5mM 
6-D-xyloside (7P)
After 24 hours B16F1 cells and DMF-treated B16F1 cells both formed 
small tumour cell aggregates of similar size, the only observable 
difference being that DMF-treated cells were more pigmented (figs.7l, 7J). 
Tumour cell spheroids formed by DMF-treated B16F1 M3 cells were no 
larger than those formed by control cells (figs.7J, 7L) except for being 
more pigmented. DMF had no obvious effect upon the size of tumour 
spheroids formed by B16F1 and B16F1M3 cells. At 72 hours DMF had no 
effect upon the growth rates of tumour spheroids. This was observed for 
all cell lines tested.
At 24 hours, B16F1D2 tumour cell spheroids appeared to be marginally 
larger than those of B16F1H5 cells (figs.7M, 7N), and 6-D-xyloside had no 
apparent effect upon spheroid formation (Figs.70, 7P). It is therefore 
difficult to assess the contribution to metastatic potential that 
differences in spheroid formation in vitro made. The cell adhesion studies 
to cell monolayers may be more representative especially if since the 24 
hour time interval used in this assay is too long for an accurate 
assessment of cell-cell interactions.
4.3.1. Induction of differentiation: Melanin and tyrosinase 
The process of melanogenesis is the most commonly used marker for 
melanoma cell differentiation. Melanin synthesis is normally associated 
with differentiated cell function, and the enzyme tyrosinase is involved in 
several critical steps of the process. The B16 melanoma cell lines and cell 
clones were relatively amelanotic at low cell densities and melanotic at 
high densities. Due to the putative effects of DMF upon cellular 
differentiation, B16F1 and B16F1 M3 cells were incubated in differing 
concentrations of DMF and their intracellular melanin and tyrosinase
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Fig.8a; Effect of DMF on tyrosinase activity (as measured bv the
3
release of * -HgO) in B16 melanoma cells fmean *  SEM: n=4)
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levels measured for comparison with controls.
B16F1 melanoma cells were greater than 2-fold more melanotic than their 
B16F1 M3 melanoma counterparts. DMF had a concentration-dependent 
effect upon melanin and tyrosinase levels with B16 melanoma cells 
exhibiting a concentration-dependent increase in melanin synthesis and 
tyrosinase activity (fig.8a). DMF stimulated tyrosinase activity with 
maximal stimulation occurring around 0.5% DMF. There was a 2-fold 
maximal stimulation over concentrations of 0.25%-1.0% DMF. The lowest 
concentration of DMF used (0.1%) produced a 50% stimulation of tyrosinase 
activity. At higher DMF concentrations there appeared to be a slight 
inhibition of tyrosinase activity from the maximal level recorded. The 
level of intracellular melanin followed a near-linear relationship with 
DMF concentration. Intracellular melanin levels were stimulated up to 
6-fold by 1.0% DMF, and 0.5%DMF a greater than 4-fold increase (fig. 8b).
Incubation of B16F1 cells with 0.5% DMF produced a 2-3 fold stimulation 
of intracellular melanin levels without significantly altering the level of 
tyrosinase activity (fig.8b). Initially, B16F1 melanoma cells possessed 
approximately double the tyrosinase activity as B16F1M3 cells. DMF did 
not alter the tyrosinase activity measured in B16F1 cells and induced a 
doubling of this activity in B16F1 M3 cells. These results might then 
indicate that the level of tyrosinase activity in B16F1 cells is maximal 
for these B16 melanomas.
Melanogenesis is influenced by pH but DMF had no affect on the pH of the 
culture medium. It would therefore appear that DMF does not mediate its 
effects upon melanogenesis through extracellular pH.
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The levels of intracellular melanin synthesized by B16F1H5 and B16F1D2 
melanoma cell clones were also measured and no difference recorded (not 
shown) although both were slightly more melanotic than B16F1 cells.
4.3.2. Cell spreading and adhesion
A positive correlation between lung colonization and cell spreading was 
observed in vitro. Increased lung colonization potential coincided with 
increased cell spreading for B16F1M3 and DMF-treated B16F1M3 cells 
(fig.9). However, this correlation did not hold with the B16 melanoma cell 
clones. This correlation was not evident when B16 melanoma cells were 
allowed to attach and spread upon ECM glycoproteins in vitro.
Heterogeneity in the in vitro cell adhesion responses to immobilized ECM 
proteins was observed with the different B16 melanoma cell lines. Cells 
were also tested for their ability to attach to pulmonary endothelial cell 
monolayers, BM-like matrices derived from pulmonary endothelial cells, 
and to melanoma cell monolayers to measure homotypic cell adhesion, A 
process comparable with spheroid formation.
The level of melanoma cell adhesion to bovine serum albumin (BSA) was 
also determined since BSA was used as the blocking agent in the in vitro 
adhesion assays to immobilized matrix proteins. All 35mm petri dishes 
were treated with 40jig of matrix protein in 1.5ml buffer. The actual 
amount of matrix protein which bound to the culture dish was not 
determined, but this concentration had proved to be sufficient for 
maximal cell adhesion in previous studies performed in this laboratory. 
Initially each of the B16 melanoma cell lines tested exhibited very poor 
attachment to BSA-coated dishes (figs.10 ,11 ,12 ). At later time points
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increased levels of adhesion were often observed (figs.10,12) that might 
indicate the initiation or employment of other cellular process to 
facilitate cell adhesion.
The melanoma cell lines were tested for their abilities to attach to rat 
tail tendon collagen. The collagen derived from this source is a complex of 
interstitial cotlagens type I and III. Initially this substrate proved to be a 
relatively poor substrate for B16 melanoma cell adhesion (figs.13 ,1 4 ,1 5 , 
16). Within the first 30 minutes incubation the levels of cell attachment 
were <10% for all cell lines tested. After 60 mins incubation maximal 
attachment was usually in the range of 10%-30%. Some cell lines 
exhibited a significant increase in cell attachment by 90 minutes, and this 
might possibly reflect either degradation of collagen or the synthesis of 
factors which facilitate attachment to collagen (figs.13,15).
Fibronectin provided a highly adhesive substrate for the attachment of all 
B16 melanoma cell lines tested (figs.17 ,1 8 ,1 9 , 20). Cell attachment to 
fibronectin substrates was rapid with high levels of attachment being 
attained (60%-90% after 90mins) for all cell lines irrespective of 
metastatic potential.
Differences in cell attachment to BM-derived proteins was more evident. 
Moderately metastatic B16F1M3 cells displayed a higher maximal adhesion 
to petri dishes coated with laminin-nidogen complex when compared with 
poorly metastatic B16F1 cells (fig.21). Pretreatment of B16F1M3 cells 
with 0.5%DMF reduced this maximal adhesion to a level that was similar 
to that attained for B16F1 cells. B16F1M5 melanoma cells, which later 
proved to be unstable, displayed similar levels of cell attachment to
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Fia.12: Cell attachment to BSA (mean ± SEM: n=61
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Fia.13: cell attachment to collagen type I (mean ± SEM: n=121
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Fig.14: cell attachment to collagen type I (mean t  SEM: n=61
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Fip.15: Cell attachment to collagen type I (mean + SEM: n=6^
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Fia.16: Cell attachment to collagen type I (mean ± SEM: n=121
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Fig.16: Cell attachment to collagen type I fmean ± SEM: n=121
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Fig.17: Cell attachment to fibronectin (mean ±  SEM; n=12)
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Fia.19: Cell attachment to fibronectin (mean ± SEM: n=61
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laminin-nidogen (fig.22) as B16F1 cells. Conversely, the B16F1H5 clone 
displayed a higher maximal adhesion to laminin-nidogen than the B16F1D2 
clone (fig.23). Pretreatment of B16F1D2 melanoma cells with 0.5mM 
B-D-xyloside did not influence cell attachment to laminin-nidogen-coated 
dishes (fig.24). The heterogeneity in the levels of cell adhesion to 
laminin-nidogen substrates in vitro by metastatic and poorly metastatic 
B16 melanoma cells suggests that no specific adhesion response to 
laminin-nidogen correlates with the metastatic potential of these cell 
lines. The ability to adhere to laminin, irrespective of efficiency, may 
only be required to initiate subsequent events which may be critical for 
the continuence or completion of the metastatic process.
In the adhesion assays, both B16F1M3 and DMF-treated cells exhibited a 
faster initial rate of attachment to BM collagen IV than poorly metastatic 
B16F1 cells (fig.25). The maximal levels of attachment were similar for 
B16F1, B16F1M3 and DMF-treated cells, although B16F1 cells had a 
slightly higher proportion of cells attached by 90 mins. B16F1M5 cells 
displayed a higher rate and maximal level of cell attachment than B16F1 
cells (fig.26). Elevated levels of initial cell attachment may be crucial 
since the process of extravasation is complete within minutes in vivo.
Once again the converse applied to B16 melanoma clones; poorly 
metastatic B16F1H5 cells had a faster initial rate of attachment to 
collagen IV than the highly metastatic B16F1D2 cells (fig.27) although the 
maximal level of attachment at 90 mins was similar for both.
B-D-xyloside treatment inhibited the attachment of B16F1D2 melanoma 
cells to BM collagen IV substrates (fig.28) suggesting that proteoglycans 
are potentially involved in this adhesion process.
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Fia.21: Cell attachment to laminin/nidoaen (mean + SEM: n=1
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Fig.21; The adhesion values for obtained B16F1 M3 cells over time points 
20-90 mins were statistically significant (0.01 >P; Student’s 
t-test) when compared with those obtained for B16F1 and 
DMF-treated cells.
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Fin.22: Cell attachment to laminin/nidoaen fmean ±  SEM: n=12)
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Fig.23: Cell attachment to laminin/nidoaen (mean ± SEM: n=61
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Fig.23; The adhesion values obtained for B16F1H5 cells over the time 
points 10-90 mins were statistically significant (0.01 >P;
Student's t-test) when compared with those obtained for B16F1D2 
cells.
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Fig.24: Cell attachment to laminin/nidoqen (mean ± SEM:
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Fig.25: Cell attachment to collagen type IV (mean + SFM- n
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Fig.25; The adhesion values for B16F1M3 and DMF-treated B16F1M3 cells 
over the first 20 mins were statistically significant (0.05>P;
Student's t-test) when compared with those obtained for B16F1 
cells.
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Fig.26: Cell attachment to collagen .type IV (mean + SEM: n=61
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Fig.26; The adhesion values obtained for B16F1M5 cells over the time 
points 30-90 mins were statistically significant (0.01 >P; 
Student's t-test) when compared with those obtained for B16F1 
cells.
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Fig.27: Cell attachment to collagen type IV (mean + SEM: n=fit
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Fig.27; The adhesion values obtained for B16F1H5 cells over the time 
points 10-30 mins were statistically significant (0.01 >P;
Student's t-test) when compared with those obtained for B16F1D2 
cells.
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Fia.28: Cell attachment to collagen type IV fmean + SFM-
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Fig.28; The adhesion values obtained for B16F1D2 cells over the time 
points 20-60 mins were statistically significant (0.01 >P; 
Student's t-test) when compared with those obtained for 
B-D-xyloside treated cells.
Pulmonary endothelial cells and their underlying BM-like matrix was 
assessed for their ability to support B16 melanoma cell attachment since 
these structures are more representative of naturally occuring substrates 
encountered by tumour cells in vivo. For those B16 melanoma cell lines 
tested, there was both a rapid rate of cell attachment to CPAE monolayers 
(figs.29, 30) and to isolated subendothelial matrices (figs.31, 32) and high 
levels of maximal cell attachment. No differences in the rate and level of 
cell attachment to these substrates could be identified between 
metastatic and and poorly metastatic B16 melanoma cell lines and clones. 
The fact that there are no discernible differences in the rate and level of 
attachment to the subendothelial matrix (figs.31, 32) questions the 
significance and relevance of cell adhesion assays to individual basement 
membrane proteins. The most important aspect may be the secondary 
events that are elicited by the interaction of cells with matrix proteins 
which can influence the metastatic process.
Once again heterogeneity in the adhesion responses of cell lines to the 
same substrate was observed (e.g. Figs.23 & 24). These differences may 
reflect changes in the cell populations through a measure of phenotypic 
drift or changes in the cell subpopulations that constitute the cell line. 
Differences in cell culture conditions may also have proved influential
A short series of homotypic cell adhesions was also performed to 
complement the spheroid studies in which B16 melanoma cell lines were 
assayed for their ability to attach to B16 melanoma monolayers. Poorly 
metastatic B16F1 melanoma cells and moderately metastatic B16F1M3 
melanoma cells had similar rates and maximal levels of cell attachment 
to their monolayers (fig.33). However, DMF treatment resulted in the
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Fia.30: Cell attachment to CPAE monolayers (mean ±  SEM: n=6)
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Fia.31: Cell attachment to CPAE subendothelial matrix
(mean + SEM: n=61
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Fiq.32: Cell attachment to CPAE subendothelial matrix
(mean ± SEM: n=fi(
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Hq.,33; Cell attachment to (homotypic) B16 melanoma monolayers
(mean ± SEM: n=6)
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Fig.33; The adhesion values obtained for DMF-treated B16f1M3 cells over 
time points 20-90 mins were statistically significant (0.05>P; 
Student's t-test) when compared with those obtained for B16F1 
and B16F1 M3 cells.
stimulation of both the rate and maximal level of attachment to 
DMF-treated monolayers. DMF-treatment may therefore partly mediate its 
augmentation of organ colonization by stimulating cell aggregation and 
embolus formation.
4.3.3. Degradation of the subendothelial matrix 
The subendothelial matrix synthesized by CPAE cells was metabolically 
labelled with 3H-proline (3H-Pro) or ^sulphate (35g) to predominantly 
radiolabel (putatively) collagen and proteoglycans respectively.
In vitro, no significant difference in the collagenolytic abilities of 
metastatic and poorly metastatic B16 melanomas could be determined. All 
B16 melanoma cell lines and clones were capable of stimulating the 
release of 3H-Pro from subendothelial matrices. Similar levels of 
3H-Pro-releasing activity were detected in B16F1, B16F1M3, and 
DMF-treated melanoma cells (fig.34a). Similarly, the B16 melanoma cell 
clones, B16F1H5 and B16F1D2, exhibited near equivalent levels of 
3H-Pro-releasing activity (fig.34b).
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Fig.34 Release of ^H-Pro from metabolically labelled CPAE
subendothelial matrices
a) Release of ^H-Pro from radiolabelled matrices by B16F1, B16F1M3 and 
B16F1M 3+0.5% DMF cells (mean ±  SEM; n=3)
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Fig.34a-b; The P-values indicated were calculated using Student's t-test
b) Release of 3H-Pro from radiolabelled matrices by B16F1D2 and
B16F1H5 cells (mean ± SEM; n=3)
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The release of 35s from radiolabelled subendothelial matrices was 
demonstrated to show a positive correlation with metastatic potential. 
B16F1 M3 cells possessed a significantly higher level of 35S-releasing 
activity than B16F1 cells (P<0.01); pretreatment with 0.5% DMF did not 
influence the 35s-releasing activity of B16F1M3 cells (fig.35a). 
Similarly, this positive correlation was also detected in the B16 
melanoma clones: a significantly higher level of 35s-releasing activity 
(P<0.01) was associated with B16F1D2 cells when compared with 
B16F1H5 cells (fig.35b).
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Fig.35 Release of from metabolically labelled CPAE
subendothelial matrices
a) Release of 35S from radiolabelled matrices by B16F1, B16F1 M3 and 
B16F1 M3+0.5%DMF cells (mean ± SEM; n=3)
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Fig.35a-b; The P-values indicated were calculated using Student's t-test
b) Release of 35S from radiolabelled matrices by B16F1D2 and 
B16F1H5 cells (mean ± SEM; n=3)
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4.4.1. Proteoglycan Analyses
Ion-exchange chromatography (I EC) and gel permeation chromatography 
(GPC) were employed to study the qualitative and quantitative differences 
In GAG and proteoglycan biosynthesis that existed between the B16 
melanoma cell lines used in this study. In certain experiments, three GAG 
fractions were isolated and analysed: the medium (MEDIUM) fraction, the 
trypsin-releasable (TRYPSIN) fraction and the cell-associated (CELL) 
fraction. The medium fraction contained GAG released into the culture 
medium; the trypsin fraction the GAG present on the cell surface as 
proteoglycan or released by trypsin/EDTA; the cell fraction comprised 
internalized GAG and proteoglycan, trypsin-insensitive proteoglycans, and 
newly synthesized proteoglycan not yet expressed on the cell surface. The 
initial I EC separation generated a characteristic elution profile containing 
two distinct regions (fig.36a). The first major peaks contained small GAG 
fragments, glycopeptides and poorly charged molecules and the minor 
second peak contained the sulphated GAG of interest.
Constituent GAG species were separated by digestion with chondroitinase 
ABC or nitrous acid at low pH to generate HS-GAG or CS-GAG species alone 
respectively. These intact GAG species were separated from degraded GAG 
via Sephadex G50 GPC (fig.36b, fig.36c). This procedure does not however 
distinguish between HS/CSPG copolymers.
Two fractions, medium-associated and cell-lysate, were generated for 
proteoglycan analysis. The medium-associated fraction again comprised 
culture medium proteoglycan and GAG, and the cell-lysate fraction the 
cell surface and intracellular proteoglycans and GAG.
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Fig,36a; Ion Exchange Chromatography 
Initial DEAE-Cellulose Separation
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Fig.36b: Sephadex G5Q GPC  
Chondroitinase ABC digestion elution.profile
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Fig.36c: Sephadex G5Q GPC  
Nitrous acid deamination elution profile
3H-incorporation (dpm) — °~ 35S-incorporation (dpm)
riooo150001
12000- “ 800
9 0 0 0 - -6 0 0
6 0 0 0 “ “ 400
O —0
200
2 51 5 201 3 0
Fraction number
’S-incorporation 
(dpm
)
H
-in
co
rp
or
at
io
n 
(d
pm
)
Fig.36d: Sephadex G5Q GPC  
Nitrous acid deamination of HS-GAG elution profile
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4.4.2. Qualitative differences in GAG synthesis 
The GAG synthesized by B16 melanoma cells of differing metastatic 
potentials were compared, and the effects of chemical modifiers of GAG 
biosynthesis assessed via I EC.
a) B16F1 versus B16F1M3 melanoma cells
The CS-GAG and HS-GAG synthesized by poorly metastatic B16F1 and 
moderately metastatic B16F1M3 melanoma cells possessed similar 
chemical properties. DEAE-Cellulose IEC failed to identify any significant 
qualitative differences in the charge densities of either the CS-GAG 
(fig.37) or the HS-GAG (fig.38) from the medium fraction, although 
comparison of the elution profiles appeared to indicate that the HS-GAG 
elution later.
Similar observations were noted for the trypsin-releasable GAG fractions.
B16F1 and B16F1 M3 melanoma cells synthesized CS-GAG species with 
similar charge density, although there was a wider spread of charge 
densities for B16F1 CS-GAG (fig.39). The HS-GAG synthesized by these 
melanomas were also of a similar charge density (fig.40).
No qualitative difference in the charge densities of the cell-associated 
CS-GAG (fig.41) and HS-GAG (fig.42) synthesized by B16F1 and B16F1M3 
cells could be identified by DEAE-Cellulose IEC. The cell-associated GAG 
fractions however eluted closer to the end of the salt gradient, indicating 
the probability of a higher charge density.
HS-GAG and CS-GAG from the medium and trypsin-releasable fractions 
were further analysed on Mono-Q-Sepharose at low pH to measure the
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Fig.38; DEAE-Cellulose IEC
Medium fraction HS-GAG
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Fig.39; DEAE-Cellulose IEC 
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Fig.40; DEAE-Cellulose IEC
Trypsin fraction HS-GAG
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Fig.41; DEAE-Cellulose IEC
Cell Fraction CS-GAG
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Fig.42; DEAE-Cellulose IEC
Cell fraction HS-GAG
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degree of polymer sulphation. Mono-Q-Sepharose IEC suggested that in 
both the medium (fig.43) and trypsin-releasable fractions (fig.44),
B16F1 M3 melanoma cells synthesized CS-GAG with a lower degree of 
polymer sulphation than B16F1 melanoma cells. No difference in the 
degree of HS-GAG polymer sulphation was detected by Mono-Q-Sepharose 
IEC for the trypsin-releasable fractions (fig.45), although B16F1 cells 
appeared to synthesize a slightly more sulphated medium fraction HS-GAG 
(fig .46).
b) B16F1 M3 ± 0.5%DMF
Incubation of B16F1M3 melanoma cells with 0.5% DMF resulted in profound 
changes in GAG biosynthesis. DMF induced the synthesis of B16F1M3 
CS-GAG with a reduced charge density in both the medium (fig.47) and 
trypsin-releasable fractions (fig.48), with the reduction in charge density 
being more pronounced in the trypsin-releasable fraction. The CS-GAG 
present in the cell-associated fraction synthesized by DMF-treated cells 
also exhibited a large reduction in charge density (fig.49).
In contrast, DMF-treatment appeared to have the opposite effect upon the 
charge density of the medium fraction HS-GAG (fig.50), resulting in an 
increase in charge density as measured via DEAE-Cellulose IEC. DMF though 
appeared to have no obvious effect upon the charge density of the HS-GAG 
present in the trypsin-releasable fraction (fig.51). DMF-treated cells also 
exhibited a reduction in the charge density of the HS-GAG from the 
cell-associated fraction (fig.52).
The DMF-induced alterations in GAG biosynthesis were associated with 
changes in the degree of polymer sulphation as detected via Mono-Q-
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Fig.44; Mono Q Sepharose IEC
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Fig.45; Mono Q Sepharose IEC
Trypsin fraction HS-GAG
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Fig.46; Mono Q Sepharose IEC
Medium fraction HS-GAG
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Fig.47; DEAE-Cellulose IEC
Medium fraction CS-GAG
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Fig .48; DEAE-Cellulose IEC 
Trypsin fraction CS-GAG
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Fig.49; DEAE-Cellulose IEC
Cell fraction CS-GAG
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Fig.50; DEAE-Cellulose IEC
Medium fraction HS-GAG
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Fig.51; DEAE-Cellulose IEC
Trypsin fraction HS-GAG
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Fig.52; DEAE-Cellulose IEC
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Sepharose IEC analysis. When compared to those from control cultures, the 
medium and trypsin-releasable fractions from DMF-treated B16F1M3 
melanoma cells contained undersulphated CS-GAG (fig.53 & fig.54 
respectively) and oversulphated HS-GAG (fig.55 & fig.56 respectively), 
including the trypsin-releasable HS-GAG which showed no difference in 
charge desity as measured via DEAE-Cellulose IEC.
c) B16F1 versus B16F1M5
Preliminary DEAE-Cellulose IEC studies with B16F1 and B16F1M5 cells 
failed to demonstrate a qualitative difference in the charge density 
properties of the medium (fig.57) and trypsin-releasable (fig.58) HS-GAG 
fractions synthesized. As a consequence of the instability of the B16F1M5 
phenotype, no further GAG analyses were performed with this cell line.
d) B16F1H5 versus B16F1D2
Poorly metastatic B16F1H5 and highly metastatic B16F1D2 melanoma 
cells were found to synthesize medium and trypsin-releasable CS-GAG 
with similar charge density properties (fig.59 & fig.60 respectively).
Similarly, the trypsin-releasable HS-GAG synthesized by both clones also 
possessed similar charge density properties (fig.61), whereas B16F1H5 
cells produced a more highly charged medium fraction HS-GAG than 
B16F1D2 cells (fig.62).
Mono-Q-Sepharose IEC failed to demonstrate a difference in the degree of 
polymer sulphation of the medium CS-GAG fraction (fig.63) or the 
trypsin-releasable HS-GAG fraction (fig.64), supporting the observations 
obtained using DEAE-Cellulose IEC (fig.59 & fig.61). Mono-Q-Sepharose IEC 
also failed to demonstrate a significant difference in the degree of
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Fig.53; Mono Q Sepharose IEC
Medium fraction CS-GAG
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Fig.54; Mono Q Sepharose IEC
Trypsin fraction CS-GAG
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Fig.55; Mono Q Sepharose IEC
Medium fraction HS-GAG
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Fig.56; Mono Q Sepharose IEC
Trypsin fraction HS-GAG
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Fig.57; DEAE-Cellulose IEC
Mediun fraction HS-GAG
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Fig.58; DEAE-Cellulose IEC
Trypsin fraction HS-GAG
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Fig.59; DEAE-Cellulose IEC 
Medium fraction CS-GAG
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Fig.60; DEAE-Cellulose IEC
Trypsin fraction CS-GAG
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Fig.61; DEAE-Cellulose IEC
Trypsin fraction HS-GAG
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Fig.62; DEAE-Cellulose IEC
Medium fraction HS-GAG
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polymer sulphation of the trypsin-releasable CS-GAG (fig.65), suggesting 
that the increase in charge density of B16F1D2 trypsin-releasable CS-GAG 
(fig.60) is not related to an increase in the degree of polymer sulphation. 
Mono-Q-Sepharose also indicated that although B16F1H5 cells synthesized 
a predominantly more sulphated medium HS-GAG than B16F1D2 cells, 
B16F1D2 cells synthesized HS-GAG with a wider range of sulphation 
levels (fig.66).
e) B16F1M3 ± 50mM sodium chlorate
Sodium chlorate inhibits GAG sulphation by competing with GAG for the 
sulphate donor phosphoadenosylphosphosulphate (PAPS) (Burnell & Roy, 
1978; Baeuerle & Huttner, 1986). The presence of 50mM sodium chlorate in 
culture induced B16F1 M3 cells to synthesize both medium fraction and 
trypsin-releasable fraction HS-GAG with reduced charge density (fig.67 & 
fig.68 respectively). The trypsin-releasable fraction demonstrated the 
most pronounced reduction in charge density. In agreement with other 
reports, sodium chlorate also induced a largely reduced charge density in 
CS-GAG (fig.69).
f) B16F1 M3 ± 20fag/ml heparin
Preincubation of cells with heparin has been reported to alter the degree 
of HS-GAG polymer sulphation (Nader etal., 1989). The qualitative effect 
of heparin on B16F1 M3 melanoma cell GAG synthesis was therefore 
analysed using Mono-Q-Sepharose IEC. It was observed that heparin did not 
affect the degree of CS-GAG polymer sulphation in the medium and 
trypsin-releasable fractions nor the trypsin-releasable HS-GAG fraction. 
However heparin was observed to induce the synthesis of oversulphated 
medium fraction HS-GAG (fig.70).
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Fig.63; Mono Q Sepharose IEC
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Fig.64; Mono*Q-Sepharose IEC
Trypsin fraction HS-GAG
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Fig.65; Mono-Q-Sepharose IEC
Trypsin fraction CS-GAG
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Fig.66; Mono*Q-Sepharose IEC
Medium fraction HS-GAG
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Fig.67; DEAE-Cellulose IEC
Medium fraction HS-GAG
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Fig.68; DEAE-Cellulose IEC
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Fig.69; DEAE-Cellulose IEC
Medium fraction CS-GAG
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Fig.70; Mono Q Sepharose IEC
Medium fraction HS-GAG
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The previous IEC analyses of B16F1M3 GAG fractions have suggested that 
the cell surface contains more highly charged HS-GAG species than those 
present in the culture medium. Heparin is able to displace endogenous GAG 
from the cell surface (Kaji & Sakuragawa, 1990), and therefore control 
cells were briefly exposed to heparin prior to the harvesting of the cell 
fractions in order to assess whether heparin displaced "oversulphated" 
HS-GAG from the cell surface. Subsequently it was observed that no 
difference in the degree of polymer sulphation could be detected in either 
the CS-GAG or HS-GAG from the medium or trypsin-releasable fractions, 
and both the medium and trypsin-releasable HS-GAG had similar levels of 
sulphation (not shown). This suggests that heparin therefore stimulates 
B16F1M3 cells to synthesize medium fraction HS-GAG with an increased 
degree of polymer sulphation.
g) B16F1D2 ± 0.5mM 13-D-xyloside treatment 
The GAG derived from the medium-associated and cell-lysate fractions 
derived from the proteoglycan from control and 13-D-xyloside treated 
B16F1D2 cells were analysed via IEC. 13-D-xyloside was observed to 
influence GAG synthesis; the CS-GAG associated with the cell surface of 
B-D-xyloside-treated cells (fig.71) and the medium-associated HS-GAG 
(fig.72) had a lower charge density than those of control cells, though this 
reduction was less pronounced for the HS-GAG. In contrast, pretreatment 
with 3-D-xyloside-treatment had no effect on the charge density 
measured for either the medium-associated CS-GAG (fig.73) or the cell 
surface HS-GAG (fig.74).
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Fig.71; DEAE-Cellulose IEC
Cell lysate fraction CS-GAG
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Fig.72; DEAE-Celiulose IEC
Medium fraction HS-GAG
3 H-GicN incorporation (dpm) -  °~ 1 4C-GlcN incorporation (dpm)
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Fig.73; DEAE-Cellulose IEC
Medium fraction CS-GAG
■® ^H-GlcN incorporation (dpm) — °~ 14C-GlcN incorporation (dpm)
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Fig.74; DEAE-Cellulose IEC
Cell lysate fraction HS-GAG
3 H-GlcN incorporation (dpm) — 1 4C-GlcN incorporation (dpm)
240360
2 0 0300
160240
1 2 0180
801 20
4060
o-V
60 8 0 1004020
Fraction number
B16F1D2-i-8-D-xyloside 
C-GlcN 
incorporation 
(dpm
)
4.4.3. Qualitative differences in proteoglycan synthesis 
Qualitative Sepharose CL4B GPC was performed on the proteoglycans and 
GAG synthesized by the B16 melanoma cell clones, B16F1H5 and B16F1D2. 
Furthermore, due to the significant effect of B-D-xyloside on lung 
colonization and the mode of action of this agent, the proteoglycans from 
B-D-xyloside-treated cells were also analysed in this manner.
Two distinct proteoglycan fractions were isolated and analysed; the 
medium-associated and cell-lysate fractions. A measure of proteoglycan 
and GAG size (Kav) was determined from their point of elution from the 
GPC column where the peak was highest:
Kav = (Ve-V0)/(Vt-V0)
V0: void volume
V :^ total included volume
Ve: volume in which molecule of interest elutes
For a 90cm Sepharose CL4B GPC column the V0 volume was typically 25ml 
and the volume 75ml.
a) B16F1H5 vs B16F1D2
Sepharose CL4B GPC analysis of the medium-associated proteoglycan 
fraction demonstrated that both cell lines possessed similar elution 
profiles (fig.75). The elution profile for each cell line comprised two 
major regions. For B16F1D2 cells the first region contained two separate 
peaks with Kav of approximately (~) 0.32 and 0.45. The smaller second
region contained a peak with an Kav „ 0.59 which was also observed for
B16F1H5 cells. The first region of B16F1H5 cells contained a peak
105
with a Kav ,*0.42 at its highest point and a third distinct peak (Kav ,*0.85) 
eluting close to the total included volume (Vt). The resultant loss of most
of the first region in both the medium-associated (fig.77 & fig.78) and 
cell-lysate (fig.79 & fig.80) fractions upon pronase digestion indicated 
that the first peak represented the proteoglycan fraction and the second 
peak free GAG.
The cell-lysate proteoglycan fraction elution profiles were comprised of 
two regions that differed markedly between the two cell lines (fig.76).
The first peak (Kav ,*0.39) was the predominant form in B16F1D2 cells
with the second peak (Kav ,*0.75) being the minor form. This pattern was
reversed for the B16F1H5 cells where the first peak (Kav ,*0.49) was less
distinct and the second peak (Kav .*0.72) was the major form.
Overall, the medium-associated fractions from B16F1H5 and B16F1D2 
melanoma cells contained proteoglycans and GAG of similar size, but the 
B16F1D2 cells possessed a larger cell-lysate fraction proteoglycan pool. 
These fractions were subsequently digested with chondroitinase ABC or 
nitrous acid to leave intact HSPG or CSPG fractions respectively. The GPC 
elution point for GAG chains was determined by digesting proteoglycans 
with pronase.
B16F1D2 cells synthesized larger cell-lysate HSPG (fig.81; Kav ,*0.50) 
than that synthesized by B16F1H5 cells (Kav ,*0.57). Additionally, the 
cell-lysate fraction from both cell lines contained free HS-GAG chains 
identifiable as a distinct second peak (Kav ,*0.78). Similarly, the
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Fig.75; Sepharose CL4B GPC
Medium fraction PG/GAG
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Fig.76; Sepharose CL4B GPC
Cell lysate fraction PG/GAG
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Fig.77; Sepharose CL4B GPC
Medium fraction CSPG/GAG/Pronase
■*—  3 H-GlcN incorporation (dpm) — — - 4C-GlcN incorporation (dpm)
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Fig.78;Sepharose CL4B GPC
Medium fraction HSPG/GAG/Pronase
3 14H-GlcN incorporation (dpm) C-GlcN incorporation (dpm)
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Fig.79; Sepharose CL4B GPC
Cell lysate fraction CSPG/GAG/Pronase
3H-GlcN incorporation (dpm) — — 1 4C*GlcN incorporation (dpm)
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Fig.80; Sepharose CL.4B GPC 
Cell lysate fraction HSPG/GAG/Pronase
*—  3H-GIcN incorporation (dpm) — -  -  14c-GIcN incorporation (dpm)
r  800
r 700
800- r 600
r500600-
r 400
4 0 0 i F-300
r 200
2 0 0 -
r  1 00
6050403020
Fraction number
Bt6FtH5 
C-G/cN 
incorporation 
(cfpm
)
Fig.81; Sepharose CL4B GPC
Cell lysate fraction HSPG/GAG
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Fig.82; Sepharose CL4B GPC
Cell lysate fraction CSPG/GAG
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Fig.83; Sepharose CL4B GPC
Medium fraction HSPG/GAG
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Fig.84; Sepharose CL4B GPC 
Medium fraction CSPG/GAG
H-GicN incorporation (dpm) 14C-GlcN incorporation (dpm)
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cell-lysate fraction CSPG (fig.82) from B16F1D2 cells was apparently 
larger (Kav „0.50) than that of B16F1H5 cells (Kav ^0.54). Interestingly,
these peaks were not completely lost upon pronase digestion (fig.79). The 
cell-lysate fraction (fig.82) also contained distinct free CS-GAG peaks 
and for B16F1H5 cells, an additional third peak eluting close to V t.
HSPG was not present in the medium-associated fraction of either cell 
line. Rather, a peak that appeared to correspond to free HS-GAG chains 
(fig.83) and which did not alter significantly upon pronase digestion 
(fig.78) was present. The region corresponding to the medium-associated 
CSPG revealed that there was no significant difference in the size of the 
CSPG synthesized by either cell line (fig.84). A similar observation was 
noted for the CS-GAG in this fraction although the radioactivity eluting 
close to Vt was marginally smaller for B16F1H5 cells (fig.84). Pronase
digestion did not eliminate all of the radioactivity associated with either 
the medium-associated or cell-lysate CSPG peaks (fig.77 & fig.79), 
suggesting that either these peaks represent very high molecular weight 
CS-GAG or pronase resistant CSPG since both were sensitive to digestion 
with chondroitinase ABC (fig.78 & fig.80).
The medium-associated pronase-resistant chondroitin sulphate species 
synthesized by B16F1H5 melanoma cells and eluting in the proteoglycan 
region (fig.77), had an apparently smaller molecular weight (Kav „0.54)
than that synthesized by B16F1D2 cells (Kav „0.46). A similar difference
was also observed in the cell-lysate chondroitin fraction (fig.79); the 
large chondroitin sulphate species synthesized by B16F1H5 cells was 
apparently smaller (Kav „0.57) than that synthesized by B16F1D2 cells
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(Kav „0.50). There were no significant differences in the siizes of the free
CS-GAG chains (fig.77 & fig.79) and HS-GAG chains (fig.78 & fig.80) 
synthesized by both cell lines.
In brief, B16F1D2 melanoma cells appeared to synthesize larger 
cell-lysate CSPG and HSPG species than B16F1H5 cells. Neither cell line 
synthesized a medium fraction HSPG. Free GAG chains were present in both 
the medium-associated and cell-lysate fractions which also contained a 
pronase-resistant, chondroitinase ABC-sensitive peak eluting in the 
proteoglycan region of the Sepharose CL4B GPC column. The ratios of 
proteoglycan to GAG also differed; in the cell-lysate fraction B16F1D2 
cells synthesized proteoglycan as the predominant GAG form whereas free 
GAG chain was the predominant form for B16F1H5 cells. The medium 
fraction ratio of proteoglycan to GAG were similar except that B16F1H5 
cells possessed a distinct third peak that eluted close to Vt .
b) B16F1D2 ± 0.5mM B-D-xyloside
Sepharose CL4B GPC proteoglycan analysis of the medium-associated 
fraction revealed the presence of two distinct peaks in control cells, 
whereas cells treated with 8-D-xyloside possessed only the second of the 
two peaks (fig.85). Pronase digestion resulted in the virtual elimination of 
this first peak in control cells (fig.87) indicating that this corresponded 
to proteoglycans (Kav J145). The second peak was pronase-resistant and
corresponded to free GAG chains (Kav JD.70). 8-D-xyloside treatment
therefore resulted in the elimination of the proteoglycan peak from the 
medium-associated fraction of B16F1D2 cells. The medium-associated 
fraction also contained a pronase-resistant peak (fig.87) with an elution
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point (Kav JD.5) similar to that observed in the medium-associated and 
cell-lysate chondroitins in fig.77 and fig.79.
There were no significant differences in the GPC elution profile obtained 
for the cell-lysate fraction from control and G-D-xyloside treated cells.
Both elution profiles contained two distinct peaks corresponding to 
proteoglycan (Kav „0.57) and GAG (Kav JD.72) fractions (fig.86). Pronase
digestion resulted in a shift in this proteoglycan peak (fig.88). The results 
indicate that B16F1D2 melanoma cells cultured in the presence of 
G-D-xyloside maintain a similar cell surface proteoglycan profile as that 
observed for control cells. Indirect comparison of the cell-lysate 
proteoglycan profiles for B16F1D2 cells in fig.76 and fig.86 reveal 
differences in the two constituent peaks elution profiles, which may 
reflect the presence of DMSO in the culture medium of the control and 
G-D-xyloside-treated cells.
CSPG was the only proteoglycan present in the medium of the B16F1D2 
cells (fig.89). The medium-associated fraction from both control and 
G-D-xyloside-treated cells also contained free CS-GAG and HS-GAG chains 
(fig.89 & fig.90 respectively). Sepharose CL4B GPC analysis again failed to 
detect the presence of HSPG in the medium-associated heparan sulphate 
fraction of control cells (fig.90). Free HS-GAG chains were also present in 
the cell-lysate fraction of both the control and G-D-xyloside-treated 
cells (fig.92).
The cell-associated fraction from control and treated cells contained both 
CSPG (fig.91), HSPG (fig.92), and free CS-GAG and HS-GAG. The cell-lysate
CSPG and HSPG were of similar size (Kav „0.57) as were the GAG species
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Fig.85; Sepharose CL4B GPC
Medium fraction PG/GAG
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Fig.86; Sepharose CL4B GPC
Cell lysate fraction PG/GAG
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Fig.88; sepharose CL4B GPC
Cell lysate fraction PG/GAG/Pronase
3H-GIcN incorporation (dpm) — 1 4C-GlcN incorporation (dpm)
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Fig.89; Sepharose CL4B GPC
Medium fraction CSPG/GAG
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Fig.90; Sepharose CL4B GPC
Medium fraction HSPG/GAG
3H-GlcN incorporation (dpm) ~  — 1 4C-GlcN incorporation (dpm)
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Fig.91; Sepharose CL4B GPC
Cell lysate fraction CSPG/GAG
^H-GlcN incorporation (dpm) — 1 4C-GlcN incorporation (dpm)
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Fig.92; sepharose CL4B GPC
Cell lysate fraction HSPG/GAG
3H-GIcN incorporation (dpm) — *" 1 4C-GlcN incorporation (dpm)
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synthesized (KJD.75). Interestingly, G-D-xyloside-treated cells possessed
a similar cell-lysate proteoglycan elution profile as that observed for 
control cells for both chondroitins and heparans (fig.91 and fig.92).
4.4.4. Quantitative differences in GAG synthesis 
Quantitative changes in GAG synthesis may influence the structure and 
function of the pericellular matrix. Consequently quantitative differences 
in the GAG synthesized by the B16 melanomas were subjected to analysis. 
Metabolic labelling of cell medium, trypsin-releasable and cell-associated 
GAG with ^H-GlcN was used to estimate the relative proportions of 
HS-GAG and CS-GAG synthesized, and the total amounts in each fraction. 
Metabolic labelling with permitted the estimation of the ^ H /^ S  
ratio and the degree of N-sulphation of HS-GAG. The n value used for 
statistical analysis refers to the number of fractions analysed.
a) B16F1 vs B16F1 M3 ± 0.5%DMF
The relative proportions of CS-GAG and HS-GAG in the medium and 
trypsin-releasable fractions of B16F1, B16F1 M3 and DMF-treated 
melanoma cells were measured using Sephadex G50 GPC separation of 
3H-GlcN-labelled GAG species. GAG fractions were degraded with 
chondroitinase ABC and separated by GPC into intact and degraded 
fractions thereby permitting calculation of the relevant proportions of 
radioactivity in each peak (fig.36b). Intact GAG eluted close to V0 as a
distinct peak and degraded GAG close to Vt. The V0 volume contained the 
HS-GAG and was confirmed by nitrous acid deamination at low pH (fig.36d) 
resulting in a peak shift towards Vt. Because of the non-uniform 
distribution of N-sulphate groups along the HS-GAG chains, deamination of
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HS-GAG generates a series of degradation products with a range of 
differing molecular weights which do not all elute near to Vt.
The relative proportions of HS-GAG and CS-GAG in the medium fractions 
of the melanoma cell lines, B16F1, B16F1M3, and DMF-treated B16F1M3 
cells did not differ significantly (Table.2), although significant 
differences were detected in the trypsin-releasable GAG fractions: B16F1 
and B16F1M3 cells possessed significantly different proportions of 
HS-GAG and CS-GAG (0.01 >P). Incubation of B16F1M3 cells in the presence 
of DMF significantly altered the proportions of HS-GAG and CS-GAG to 
values comparable for those obtained for B16F1 cells. DMF induced a 
significant increase in the level of HS-GAG and a concomitant decrease in 
that of CS-GAG (0.05>P).
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Table.2 % Glvcosaminoqlvcan composition (m eantSEM : n=3)
MEDIUM TRYPSIN
CS-GAG HS-GAG CS-GAG HS-GAG
B16F1 35.1+4.3 64.9±4.3 40.3±1.1a 59.7±1.1b
B16F1M3 44.5+3.5 55.5±3.5 70.8±4.2ac 29.2±4.2bd
B16F1M3+DMF 50.8±4.4 49.2+4.4 42.6±4.9c 57.4±4.9d
Significance values (Student's t-test):
(a)(b): 0.01>P
(c)(d): 0.05>P
Table.2: %_CQmpQsition of GAG in each cuJture fraction-isolated.
(mean ± SEM.: p=31
c
oV3 £=
O  O03 ~ca
03
=3O
-Co0303
oCL
V—
ooc
2_o
O
— X 
c  o o  o >>40
tOOCl
E
oo
O
<O
•o03
3
to0303
E
toOS
1 00
8 0
6 0
4 0
20
0
S ign ificance  values (Student's t-test):
C ) ( t )  P<0-01  
( • ) (0 )  P < 0 .0 5
H i
.. • • «««v<ss<fi
>&'&<<<<■
□□
MEDIUM CS-GAG 
MEDIUM HS-GAG 
TRYPSIN CS-GAG 
TRYPSIN HS-GAG
B16F1 B16F1 M3 B 16F 1M 3 + DM F
CELL LINE
1 1 2
The total quantity of radioactivity associated with the medium GAG 
fraction was similar for both B16F1 and B16F1M3 melanoma cells 
(Table.3a and Table.3b). The incubation of B16F1M3 cells in 0.5%DMF 
stimulated the level of ^H-GlcN incorporated into medium GAG by 
approximately 20% to 15.95x10^dpm/10^ cells, although this increase 
was not statistically significant (P>0.05). The level of radioactivity 
associated with the trypsin-releasable fraction indicated that B16F1 M3 
cells possessed 20% more cell surface GAG (3.72x10^dpm/10^ cells) than 
B16F1 cells (3.12x10^dpm/10^ cells), and 0.5%DMF stimulated this value 
by a further 60% to 5.91x105dpm/105 cells. DMF-treated B16F1M3 cells 
possessed approximately 90% more cell-surface associated GAG than 
B16F1 cells. The poorly metastatic B16F1 and moderately metastatic 
B16F1 M3 melanoma synthesized similar levels of total extracellular GAG 
(medium-associated and trypsin-releasable), and DMF induced a 30%  
stimulation of this extracellular level by B16F1 M3 cells. A pattern 
emerged relating the level of trypsin-releasable GAG to metastatic 
potential. B16F1 cells possessed the lowest level of radioactivity and 
highly metastatic DMF-treated cells the highest level. The level of 
radioactivity associated with the trypsin-releasable GAG fraction of 
moderately metastatic B16F1M3 was intermediate (Table.3b).
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Table.3a Quantity of Glvcosaminoglvcan as Measured bv
3H-GIcN Incorporation 
3H-GlcN incorporation (dpm x10 '^) per 1CP cells 
(mean±SEM; n=3)
MEDIUM TRYPSIN
CS-GAG HS-GAG CS-GAG H.S-GAG
B16F1 4.85±0.91 8.65±0.11a 1.28±0.002bc 1.84±0.13de
B16F1M3 6.40±0.57 6.71±0.64a 2.65±0.30b 1.07±0.01df
B16F1M3+DMF 7.98±1.40 7.97±0.72 2.18±0.01c 3.73±0.04ef
Significance values (Student's t-test):
(a)(b): 0.05>P
(d): 0.01>P 
(c)(e)(f): 0.001 >P
T a b le .3 a : Q u a n tity  o f GAG p re se n t in ce ll c u ltu re  fra c t io n s  (^-H -G lcN  in c o rp o ra tio n ^
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Table.3b Total Glvcosaminoglycan as Measured bv
3H-G1cN Incorporation 
3H-GIcN incorporation (dpm x10 '3) per 10^ cells 
(mean±SEM; n=3)
B16F1 
B16F1M3
B16F1M3+DMF
Significance values (Student's t-test): 
(a)(b): 0.001>P
(c): 0.05>P
MEDIUM 
13.50±0.48 
13.11 ±0.57 
15.95+1.00
TRYPSIN 
3.12±0.06ac 
3.72±0.15bc 
5.91±0.02ab
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The level of 35S04  incorporated into CS- and HS-GAG (Table.3c) were too
low to estimate the 3H/35S ratio or the degree of N-sulphation present in 
HS-GAG. The degree of 35S-incorporation is therefore can best estimated 
from the Mono-Q-Sepharose IEC results obtained for the cell lines.
Table.3c 3^ SO^ Incorporation into Glycosaminoalvcan
35S0 4 -incorporation (dpm x10"3) per 106 cells
(mean±SEM; n=3)
MEDIUM TRYPSIN
CS.-GAG HS-GAG .G.S-GAG HS-GAG
B16F1 2.26±0.12f 10.44±0.12g 0.70±0.07b 0.90±0.07eh
B16F1M3 *1.58±0.21 9.85±0.21a 0.26±0.02bc 0.58±0.02de
B16F1M3+DMF 1.64±0.15f 8.51±0.15ag 0.50±0.05c 1.32±0.05dh 
Significance values (Student's t-test):
(a)(c)(f):0.05>P
(b)(h): 0.01>P
(d)(e)(g): 0.001 >P *n=2
1 2
Table.3c; ^S u lp h a te  incorporation into Q°G 
(mean 1 §EM: a -3  except * n=2i
Significance values (Student's t-test):
( * ) ( t ) (A )  P < 0 .0 5  
(•)(H ) P<0.01
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b) B16F1H5 vs B16F1 D2
B16F1H5 and B16F1D2 melanoma cells possessed sim ilar HS:CS ratios for 
their trypsin-releasable and cell-associated fractions, but there was a 
significant increase in the level of HS-GAG in the m edium -associated 
fraction (0.01 >P), becoming nearly exclusive for B16F1D2 cells (Table.4).
B16F1D2 cells incorporated twice as much radioactivity into GAG as 
B16F1H5 cells (Table.5a, Table.5b). The cell surface of B16F1D2 cells 
contained 36% more GAG than that of B16F1H5 cells; B16F1D2 cells also 
possessed 197% more cell-associated GAG and 94% more medium fraction 
GAG (Table.5b).
Table.4 % Glycosaminoglvcan composition (mean+SEM: n=3)
B16F1H5 B16F1D2
CS-GAG HS-GAG CS-GAG HS-GAG
MEDIUM 42.7+0.3a 57.3±0.3b 14.8±5.1a 85.2±5.1b
TRYPSIN 51 .1±8.6 48.9±8.6 53.0±2.8 47.0±2.8
CELL 48.4±5.7 51.6±5.7 51.7±1.8 48.3±1.8
Significance values (Student’s t-test):
(a)(b): 0.01 >P
%_ C om p os i t ion  o( GAG in each cu ltu re  f rac t ion  iso la ted
1 0 0  -q
0 q
O O
60o z to o
OJ
-  i
c  «  
o
s  -  40
g. ?E 3
2 0
0 -
Significance values (Student's t-test): 
(*)(•) P<0.01
B16F1H5
T
CELL LINE
1 1 7
M  MEDIUM CS-GAG
□  MEDIUM HS-GAG
□  TRYPSIN CS-GAG
□  TRYPSIN HS-GAG
□  CELL CS-GAG
□  CELL HS-GAG
B16F1 D2
Table.5a
MEDIUM
TRYPSIN
CELL
Quantity of Glvcosaminoqlvcan as Measured bv 
3H-GIcN Incorporation 
3 H-GlcN incorporation (dpm x10'^) per 103 cells 
(mean±SEM; n=3)]
B16F1H5 
CS-GAG HS-GAG
B16F1D2 
CS-GAG HS-GAG
2.56±0.02 3.44±0.02a 1.72±0.59 9.89±0.59a
1,02±0.17 0.97±0.17 1.44±0.08 1.27±0.08
0.93+0.11b 0.99±0.11c 2.95±0.10b 2.75±0.10c
Significance values (Student’s t-test): 
(a)(b)(c): 0.001 >P
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(mean±SEM; n=3)]
MEDIUM 
TRYPSIN 
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Significance values (Student's t-test): 
(a)(b)(c): 0.01>P
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The CS-GAG present in the medium and trypsin fractions from B16F1H5 
and B16F1D2 cells possessed similar sulphation characteristics (fig.5c). 
The levels of incorporation of ^^S-isotope into the medium fraction (as 
assessed via the ratio; Table.5d) indicated that both the medium
fraction of both B16 melanoma clones contained CS-GAG with very similar 
levels of sulphation, and the degree of CS-GAG sulphation as measured by 
Mono-Q-Sepharose IEC (fig.63) was in close agreement with this 
observation even though B16F1H5 CS-GAG eluted over a slightly wider 
range of salt concentrations indicating a wider range of sulphation levels. 
There was no significant difference in the ^ H /^ S  ra^0 for the trypsin 
fraction CS-GAG from the melanoma clones (Table.5d). This corresponded 
with the Mono-Q-Sepharose IEC elution profile (fig.65) where the CS-GAG 
from B16F1D2 and B16F1H5 cells eluted over the same range of salt 
concentrations.
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Table.5c
MEDIUM
TRYPSIN
CELL
35S 0 /|Incorporation into Glvcosaminoalvcan
33S0 4  incorporation (dpm x10"4) per106 cells 
(mean+SEM; n=3)
B16F1H5 
CS-GAG HS-GAG 
1.13±0.55 6.03±0.55
0.55±0.08 0.98±0.08
0.38±0.05 0.58±0.05
B16-E1Q2 
■QSiSAG HS-GAG 
0.75±0.23 7.1310.23
0.3810.13 0.7310.13
0.4010.08 0.5510.08
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The ratio of 3H- to 3^S-incorporation (3H/35s) for the medium fraction 
HS-GAG also corresponded with the results obtained from Mono-Q 
Sepharose IEC. The HS-GAG from B16F1H5 eluted later than that of 
B16F1D2 cells (fig.66) and had a smaller ^H/3^S ratio (Table.5d). These 
factors indicated that B16F1H5 cells incorporated more 35S-radiolabel 
into their medium fraction HS-GAG than did B16F1D2 cells. However the 
3H/35S ratio for the trypsin-releasable HS-GAG fraction did not 
correspond to the Mono-Q-Sepharose elution profile. The ratio of 3h /35s  
suggested that B16F1H5 synthesized HS-GAG with a significantly higher 
degree of 35S-incorporation (0.05>P) but Mono-Q-Sepharose IEC failed to 
support this observation (fig.64).
Table.Sd 3h /35s  Ratio (mean+SEM: n=3)
B1.6F1HS B16F1P2
CS-GAG HS-GAG CS-GAG HS-GAG
MEDIUM 4.9210.19 2.0310.18a 5.6410.57 3.7310.16a
TRYPSIN 5.9510.51 3.23i0.25b 8.5110.91 5.11+0.17b
CELL 8.3111.17 4.9110.18 11.6013.94 9.1712.57
Significance values (Student's t-test):
(a)(b): 0.05>P
Sephadex G50 GPC of HS-GAG deaminated with nitrous acid at low pH was
used to determine the degree of N-sulphation present in these GAG chains.
IEC (fig.62 & fig.66) and the 3h /35s  ratio (Table.5d) suggested that the
HS-GAG from the medium fraction of B1F1H5 cells was more sulphated
than that of B16F1D2 cells. The ratio of N-:0-sulphate agreed with those
observations (Table.5e) even though the difference was not statistically
significant and may reflect the wider elution profile observed for
B16F1D2 HS-GAG on Mono-Q-Sepharose.
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Table.5e HS-GAG N-sulphate : O-sulphate ratio
(mean±SEM; n=3)
B16F.1P2 B16F1H5
MEDIUM 0.91±0.13 1.21±0.16
TRYPSIN 0.91 ±0.04 0.83±0.05
The trypsin-releasable fraction HS-GAG from B16F1D2 and B16F1H5 cells, 
which eluted at the same point on DEAE-Cellulose or Mono-Q-Sepharose 
(fig.61 & fig.64), had very similar levels of N-:0-sulphation. In most 
instances the levels of ^ S O ^ i n c o r p o r a t i o n  into GAG (measured as the
^ H /^ S  ratio) appeared to correspond with the elution profile obtained 
with Mono-Q-Sepharose IEC at low pH. Since discrepancies do arise, it may 
be more advisable to employ both methods to determine the degree of GAG 
sulphation.
c) B16F1D2 ± 0.5mM B-D-xyloside
B-D-xyloside induced significant alterations in the HS : CS ratios (0.01 >P) 
of both the medium and cell-associated fractions (Table.6). B-D-xyloside 
treatment had no significant effect upon the ratio of cell surface HS-GAG 
to CS-GAG but stimulated CS-GAG levels in the medium fraction, resulting 
in a near reversal of the HS : CS ratio. In addition, B-D-xyloside 
stimulated the level of cell-associated HS-GAG radioactivity.
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Table.6 ■%-GlycosamiaQqlycaa-CQmpQSitiQ.n..(mean±SEMLQ?41 
B16F1D2 Control B1.6.FtD2+B-D.^ y loside
MEDIUM
TRYPSIN
CELL
Significance v
(a)(b)(c)(d): 0
CS-GAG
34.5±7.4a
59.5±7.4
69.2±2.6c 
ues (Student's 
1>P
HS-GAG
65.5±7.4b
40.5±7.4
30.8±2.6d
:-test):
CS-GAG 
72.3±1.6a 
43.6±5.6 
51.6±3.8c
HS.-.GAG 
27.7±1.6b 
56.4±5.6 
48.4±3.8d
B-D-xyloside treatment resulted in a significant decrease in the total 
amount of GAG present on the cell surface and a significant increase of 
that present in the culture medium (Table.7a and Table.7b). B16F1D2 cells 
treated with B-D-xyloside showed a 267% increase in total medium GAG 
synthesized, and a 40% reduction in cell surface GAG, with no significant 
alteration in the level of cell-associated GAG.
These observations are in agreement with the proposed mechanism of 
action of B-D-xylosides in that B-D-xyloside stimulates GAG biosynthesis 
by inhibiting the polymerization of GAG chains onto core protein. The cell 
surface of B-D-xyloside-treated cells did not appear to contain a full 
complement of GAG when compared with control cells, suggesting that 
either the normal cell surface complement of proteoglycan, or the number 
or size of GAG chains polymerized onto proteoglycan core proteins is 
reduced. It is also conceivable that the cell surface contains naked core 
protein bare of GAG chains.
B-D-xyloside was observed to reduce the charge density of the cell-lysate
CS-GAG (fig.71) and medium HS-GAG (fig.72) of B16F1D2 cells, and have
negligible effects on the charge density of the medium fraction CS-GAG
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(fig.73) and cell-lysate HS-GAG (fig.74). These observations conflict with 
the 3H/35S ratios which suggested that B-D-xyloside treated cells 
incorporate more 35s-jsotope into their GAG than control cells (Table.7d). 
It is possible that changes in GAG charge density may reflect alterations 
in the size of the GAG chains induced by B-D-xyloside and which were not 
detectable on Sepharose CL4B. Therefore the level of sulphation may not 
be the only factor involved in the charge density properties of the GAG 
induced by B-D-xyloside. Other investigators report that B-D-xyloside 
stimulates 35S-incorporation into GAG, including increasing the degree of 
GAG sulphation (Murray et at., 1983). This therefore requires confirmation 
using Mono-Q-Sepharose IEC.
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Table.6: % Compogition of .GAG in each culture fraction isolated 
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Table.7a .Quantity of GlycQSamjnog!ygaQ^J^asJUJ£dJ?y
3H-G1cN Incorporation 
3H-G!cN incorporation (dpm x 10"3) per 103cells 
(mean±SEM; n=4)
B16F1 D2 control B16F1 D2+B-D-xyloside
C.S-GAG HS.=.GAG GSiGAG HS-GAG
MEDIUM 2.79±0.60a 5.30±0.60b 21.48±0.48a 8.23±0.48b
TRYPSIN 1.40±0.17c 0.95±0.17 0.61±0.08c 0.79±0.08
CELL 1.23±0.05d 0.55±0.05e 0.98±0.07d 0.92±0.07e
Significance values (Student’s t-test):
(a): 0.001>P
(b)(c)(d)(e): 0.05>P
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Table.7b Total GlycQsaminoglycan as Measured.by
3H-GIcN Incorooratiori 
3 H-GIcN incorporation (dpm x 10~3) per 103 cells 
(mean±SEM; n=4)
B16F1D2 control
MEDIUM 8.09±0.83a
TRYPSIN 2.35±0.04b
CELL 1 .78±0.12
Significance values (Student's t-test):
(a): 0.01>P
(b): 0.001>P
B16F1 D2+B-D-xvloside 
29.71±5.07a 
1.40±0.003b 
1.90±0.52
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Tab!e.7c 35SO/| Incorporation into Glvcosaminoalvcan
35SC>4 incorporation (dpm x 10"4) per 10® cells 
(mean+SEM; n=2)
B16F1D2 control
CS-GAG HS-GAG
MEDIUM 2.84±0.50a 6.21±0.50b
TRYPSIN 0.86±0.09 0.90+0.09c
CELL 0.99±0.03d 0.36±0.03e
Significance values (Student's t-test):
(a)(d)(e): 0.01 >P
(b)(c): 0.05>P
B16F1 D2-t-f3-D-xvloside 
CS-GAG HS-GAG
34.07±2.97a 24.48±2.97b 
0.54±0.09 1.49±0.09c
0.63±0.01d 0.90±0.01e
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Table.7d 3H/35S Ratio (meantSEM: n=2)
B16F1D2 Control B16F1 D2+6-D-xvloside 
CS-GAG HS-GAG CS-GAG HS-GAG
MEDIUM 6.16±0.59a 3.65±0.56b 3.38±0.26a 1.81±0.26b
TRYPSIN 8.06±1.56 4.04±0.74 5 .6U 0 .26  2.6510.25
CELL 6.8110.42 6.5311.18 7.9310.22 4.7811.15
Significance values (Student's t-test):
(a)(b): 0.05>P
The N-:0-sulphate ratios (Table.7e) indicate a lower level of N-sulphation 
of HS-GAG in the medium fraction from B16F1D2 control cells compared 
with B-D-xyloside treated cells. This would contribute to the reduced 
charge density observed for the HS-GAG from B-D-xyloside-treated as 
observed by DEAE-Cellulose I EC (fig.72). The finding that there was no 
significant difference in the N-:0-sulphate ratio for the cell-lysate 
HS-GAG fraction was in agreement with the observed IEC observation of 
no charge density difference for the cell-lysate HS-GAG from these cells 
(fig .74).
Table.7e HS-GAG N-sulphate : O-sulphate Ratio
(xlSEM; n=2)
B16F1D2 control B16F1 D2+B-D-xvloside
MEDIUM 1.62±0.03a 8.59±1.02a
TRYPSIN 2.70±0.37 3.21 ±0.82
Significance values (Student's t-test):
(a): 0.05>P
Once again, one consistently identifiable trait correlated with metastatic 
potential; the level of cell surface GAG measured as radioactivity. B16
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melanoma metastatic capacity appears to coincide with an increase in 
the total level of cell surface radioactivity: moderately metastatic 
B16F1M3 cells possessed approximately 20% more cell surface GAG than 
poorly metastatic B16F1 cells; highly metastatic B16F1D2 cells 
approximately 30% more than poorly metastatic B16F1H5 cells; and 
B-D-xyloside, which inhibited lung colonization, reduced the level of cell
| surface radioactivity associated with B16F1D2 cells by 40%.
it
i
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5.1.1. Discussion
The B16 murine melanoma system was developed initially as a tumour 
model for screening therapeutic agents, and has also proved to be well 
suited for studies concerning the biochemistry of tumour cell arrest and 
organ colonization (Fidler, 1973a, 1973; 1978). It is estimated that 
between 105-107 cells are shed daily from a given primary tumour (Butler 
& Gullino, 1975; Liotta etal., 1976). Consequently, the intravenous bolus 
administration of tumour cell inoculi within this range is quantitatively 
comparable to the clinical situation, even though it fails to mimic the 
true clinical situation of a slower rate of cell release, often as cell 
aggregates. The system, although not truly representative of tumour cell 
metastasis since it bypasses the initial phases of the metastatic cascade, 
permits the rapid screening of putatative anti-metastatic therapies.
Metastatic potential can be modulated through the transference of plasma 
membrane from highly to poorly metastatic cells (Poste & Fidler, 1980). 
Therefore constituents of the tumour cell surface are responsible for the 
direct mediation of the metastatic phenotype. Proteoglycans and GAG play 
a variety of roles in a number of biological processes and phenomena; 
cell-cell and cell-matrix interactions (Izzard etal., 1986; Rapraeger et 
a/., 1986,1987; Ruoslahti, 1988a), matrix stabilization (Robinson etal., 
1984; Brauer etal., 1988; Keller etal., 1988), growth (Castellot etal.,
1982; Fedarko & Conrad, 1986; Benitz etal., 1990), migration, (Funderburg 
& Markwald, 1986; Robertson etal., 1989), morphology and differentiation 
(Thompson & Spooner, 1983; Carey etal., 1987; Katoh-Semba etal., 1989; 
Luikart etal., 1990), and cell invasion and metastasis (Gunthert etal.,
1991; Faassen et a!., 1992). Since the functions of these molecules are 
becoming more widely understood, their role in, and the nature and 
relevence of their chemical properties in B16 melanoma metastasis was
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evaluated.
5.1.2. Cell adhesion
Many biological processes are initiated by and are dependent upon cell 
adhesion, and evidence relates changes in cell adhesion with alterations in 
metastatic potential. Increases in cell-matrix interactions have been 
associated with increased metastatic potential (Terranova etal., 1984; 
Chung etal., 1988; Humphries etal., 1989; Hunt, 1989; Hutchinson etal., 
1989; Tullberg etal., 1989; Fridman etal., 1990), but not all changes are 
concomitant with positive changes in metastatic potential (Nabi & Raz, 
1988; Zoller & Matzku, 1989).
The cell adhesive characteristics of the B16 melanoma cell lines used in 
this study to defined ECM proteins had no apparent correlation with 
metastatic potential, except possibly collagen IV. Several investigators 
have demonstrated a correlation between cell attachment to collagen IV 
and metastatic potential (Terranova etal., 1982,1984; Liotta, 1986; Hunt 
& Sherbet, 1989), an interaction which can be mediated via laminin 
(Fligiel etal., 1988). Some metastatic cell lines exhibited an increase in 
their rate of attachment to collagen IV when compared with poorly 
metastatic cells. This relationship was not universal for all cell lines 
tested; poorly metastatic B16F1H5 cells attached more readily, and with 
higher numbers, to collagen IV than highly metastatic B16F1D2 cells. The 
nature of these cells may reflect their originally clonal nature, and they 
may therefore constitute minor unrepresentative populations of the 
original B16F1 M3 cell line from which they were derived.
However the observation questions the relationship between increased 
levels of matrix protein-specific cell attachment and metastatic
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potential. Since increased rates and levels of attachment to collagen IV 
were only detected in metastatic B16 cell lines comprised of 
heterogeneous populations, and since it is possible to isolate and identify 
metastatic cell populations via their rapid attachment to ECM proteins, it 
would have to be determined whether the B16 cells that rapidly attached 
to collagen IV actually represented competent metastatic subpopulations.
In addition, the adhesion assay reflects only those cells capable of 
adhering during the time frame of the experiment. In vivo, the attachment 
and extravasation of metastasizing cells is a rapid process, and multiple 
mechanisms may be employed simultaneously to enact these processes.
Intravenous inoculation can generate metastatic lesions of a monoclonal 
origin (Poste et al., 1982b; Fidler & Talmadge, 1986). This observation and 
the fact that individual ECM proteins are encountered in vivo as complexes 
comprised of several different ECM proteins would lessens the importance 
of determining the adhesion profiles of heterogeneous cell populations to 
individual matrix proteins. If one assumes that metastatic tumour cells 
constitute minor subpopulations within a highly heterogeneous primary 
tumour cell population (a theory which is now under critical review) then 
the selection of metastatic cell populations via their ability to attach 
rapidly to defined ECM proteins points to an important function for these 
events in the metastatic phenotype. Therefore increased cell attachment 
to individual ECM components may contribute to a metastatic phenotype or 
be advantageous in certain phases of the process, but it is not appear to be 
indicative of metastatic potential for these tumour cell lines.
Although cell adhesion is central to the underlying processes of tumour 
cell metastasis, and anti-adhesive therapies are capable of interfering
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with the process (McCarthy etal., 1988; Saiki etal., 1990a), it is difficult 
to fully assess the significance of changes in cell adhesion as they relate 
to the tumour cells ability to complete the metastatic process.
Since metastasizing tumour cells do not encounter ECM proteins as 
individual entities but rather as heterogeneous ECM complexes in tissues, 
the results of cell attachment to barriers which are encountered during 
metastasis are in all probability more relevant. Anti-adhesive therapies 
that inhibit cell attachment to ECM proteins and the invasion of BM 
structures (Gehlsen etal., 1988) indicate that individual ECM proteins 
play an important role, but since cells simultaneously express multiple 
integrin and matrix-binding receptor species, the importance of any one 
specific receptor type in mediating attachment to a complex ECM is 
diminished. The expression and activity of multiple matrix-receptor 
systems may be additive in respect to their effect on cell attachment to 
complex ECMs, and may therefore negate any qualitative or quantitative 
differences detected in adhesion to individual matrix proteins
Metastasis requires that tumour cells lodge in an appropriate target 
organ, capable of supporting their growth, and penetrate the capillary 
endothelium and subendothelial matrix. Several studies have failed to 
detect quantitative differences in cell lodgement within target organs by 
metastatic and non- or poorly metastatic cells. Further studies revealed 
that the retention of cells within the organ is a critical factor, with 
metastatic cells being retained for longer. When the levels and rates of 
B16 cell attachment to CPAE endothelial monolayers and their underlying 
subendothelial matrix was measured, it was observed that there were no 
significant differences between cells of differing metastatic potential.
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This may be that this is a consequence of at least two factors; the 
histological source of the endothelial cells (arteriole as opposed to 
capillary), and the animal source (bovine as opposed to murine). Many cell 
lines have been observed to display selective and preferential adhesion to 
capillary endothelial cells and matrices from their preferred target organ 
(Nicolson & Winkelhake, 1975; Nicolson, 1982a, 1988a; Lichtner etal., 
1989; Bevacqua etal., 1990). In addition, the attachment of B16 cells to 
CPAE monolayers may actually be mediated via fibronectin (from culture 
serum) absorbed onto the endothelial cell surface. Furthermore, since 
melanoma cells originate within the basal epithelia, one may expect them 
to exhibit rapid and high levels of attachment to BM-like structures. The 
failure to detect quantitative differences in cell attachment to complex 
matrices supports the arguement that these cells may utilize multiple 
adhesion mechanisms in a simultaneous fashion.
Events subsequent to cell adhesion may be more important to, and more 
reflective of, metastatic potential. This would include the production or 
activation of matrix-degrading proteinases and the stimulation of cell 
migration. Other factors must also be considered such as the capacity of 
the host organ stroma to support further tumour cell growth. Many tumour 
cell lines show preferential organ colonization, and the presence of 
particular factors (Cauvanaugh & Nicolson, 1989) and conditions within 
the organ stroma are critical. In addition to cell adhesion being a major 
determinant of organ colonization the organ microenvironment is also 
intrinsically involved.
Though quantitative and qualitative differences in cell attachment to 
individual matrix proteins could be demonstrated, their significance in
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lung colonization is unclear since they had no bearing upon the levels and 
rate of attachment to complex ECMs or cell monolayers. Although cells 
may initially attach to only one, undetermined ECM protein, other systems 
may come rapidly into play. An enhanced level of attachment to an 
individual matrix protein may result in a more rapid inducement of those 
cellular processes required to complete the step of extravasation.
It is interesting to observe that heterogeneity in adhesive responses to 
ECM substrates occurred within the cell clones B16F1H5 and B16F1D2 
(figs.15, 19, 24, & 28). Within these clonal cell populations, all cells were 
not capable of attaching to the ECM substrates within the time period of 
the experiment suggesting that biological diversity in cellular responses 
had arisen. It is possible that different subpopulations, possibly with 
different metastatic potentials, had arisen during the period of cell 
expansion and culture.
Pretreatment of B16F1D2 melanoma cells with B-D-xyloside had a 
significant suppressive effect on the level of cell attachment to collagen 
IV. It is possible that the other effects attributed to B-D-xyloside (i.e. the 
reduction in total cell surface GAG and inhibition of lung-colonization) 
may be related to the inhibitory effect of B-D-xyloside on cell adhesion to 
collagen IV. Furthermore, afunction of proteoglycans may therefore be to 
mediate cell attachment to collagen IV, a process that is apparently 
critical for metastasis. Alternatively, the loss of cell surface laminin 
may be the causative means of reduced attachment to collagen IV. Since 
laminin possesses a well characterized GAG-binding domain, and cell 
surface laminin correlates with metastatic potential, the reduction in 
cell surface GAG induced by B-D-xyloside may result in a reduction in cell
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surface-bound laminin.
Tumour cell aggregation is particularly relevant to metastasis. The 
production of tumour cell aggregates in vitro failed to demonstrate any 
significant difference between B16F1, B16F1M3and DMF-treated cells 
although visual observations suggested that DMF stimulated cell-cell 
aggregation. The failure of the assay to support the visual observations 
may be primarily due to the assay's failure to accommodate for the cell 
collisions that occur between cells during the haematogeneous phase of 
tumour cell dissemination. Evidence for the visual observations was 
obtained from the cell adhesion assays to homotypic monolayers; cells 
treated with DMF adhered more rapidly and in higher numbers (up to 20%  
more) than either B16F1M3 or B16F1 cells (fig.33). This increase in the 
aggregative potential may contribute to the increase in lung colony 
formation, by both increasing the probability of cell lodgement and 
affording the cells physical protection from mechanical damage.
A correlation between cell spreading on culture plastic in vitro and 
metastatic potential was demonstrated: poorly metastatic B16F1 cells 
were significantly less well spread (P<0.01) than B16F1 M3 cells which 
were also significantly less well spread (P<0.01) than their DMF-treated 
counterparts (fig.9). This could either reflect an increase in tumour cell 
size, which in turn may contribute to an increased probability of physical 
entrapment of more metastatic cells within the pulmonary capillaries. 
Secondly, the increased spread area may indicate that metastatic tumour 
cells are more able to reorganize their cytoskeletons, a process which 
may be related to alterations in cell motility and gene expression which 
may be beneficial to or necessary for the metastatic phenotype. The
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increase in cell spread area in vitro may be related to the findings of 
Baniyash etal. (1981) who demonstrated that that an increase in the 
metastatic potential of B16 melanoma cells was related to a decrease in 
cell density (as a measure of mass and volume). The findings for the cell 
clones, B16F1H5 and B16F1D2, do not support this hypothesis since these 
cell spread area of these cell lines in vitro did not differ significantly. It 
is possible though that the clones are not truly representative of the 
metastatic and non-metastatic subpopulations within the primary tumour 
from which they are derived. Therefore the role of cell spreading and its 
relationship to cell phenotype merit further evaluation.
5.1.3. Differentiation
Tumour cell metastasis has been described as a cloning process since 
tumours can arise from single progenitor cells (Poste etal., 1982a; Fidler 
& Talmadge, 1986; Hu etal., 1987). Tumorigenesis and malignancy may 
arise through cellular dedifferentiation and the induction of a more 
differentiated cell phenotype may be concomitant with reduced malignant 
potential and improved host survival times. Haematological neoplasms are 
susceptible to polar solvents which induce both morphological and 
functional differentiation (Collins etal., 1978; Breitman & He, 1990).
B16F1 M3 melanoma cells were cultured in the presence of DMF in an 
attempt to induce a more differentiated phenotype and to observe whether 
the polar solvent influenced their metastatic potential. In some respects 
differentiation was achieved. DMF induced a dose-dependent increase in 
intracellular melanin and tyrosinase activity, commonly used markers for 
the differentiation of pigmented cells. The increases recorded for the 
levels of these markers induced by 0.5% DMF in B16F1M3 cells closely 
reflected those levels present in poorly metastatic B16F1 cells.
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However, morphological and functional differentiation was not achieved: 
DMF-treated cells became highly flattened and epithelioid and their lung 
colonizing potential was augmented (Table.1). The effects of DMF were 
also readily reversed upon removal of the agent. The results suggest that 
DMF is not a differentiation-inducing agent for B16 melanoma cells and 
that melanin and tyrosinase, in conjunction with DMF, appear to be 
inadequate markers of B16 melanoma cell differentiation. It is possible 
that DMF, while inducing characteristics associated with differentiated 
cells, also induces characteristics associated with dedifferentiation 
which might negate any positive effect that the solvent had on cell 
differentiation. Another closely related polar solvent, N-methylformamide 
(N-MF), also fails to induce the cellular differentiation of B16 melanoma 
cells (Spremulli & Dexter, 1984), and in humans DMF is metabolized to 
N-MF. It is possible therefore that the ineffectiveness of DMF is a 
consequence of its metabolism to N-MF.
DMF had little effect upon the interactions between cells and matrix 
proteins except to suppress cell attachment to laminin-nidogen. This 
suppressed level was comparable to that observed for B16F1 cells, and 
may suggest that, in this instance, lung colonization is not closely related 
to the ability of these B16 melanoma cells to attach to laminin.
DMF induced B16F1M3 cells to synthesize a cell surface HS-GAG:CS-GAG 
composition similar to that observed for B16F1 cells (Table.2). Cell 
proteoglycans have been demonstrated to interfere with cell adhesion to 
ECM components (Lewandoska etaL, 1987). Since DMF-treatment reduced 
the level of B16F1 M3 cell attachment to laminin/nidogen to that observed 
for B16F1 cells, the increase in cell surface CS-GAG induced by DMF may
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contribute to this reduction, possibly by interfering with the interaction 
between HS-GAG and the GAG-binding domain of laminin.
The increased lung colonization potential of DMF-treated cells was not 
due to the selection of highly metastatic tumour cell subpopulations from 
the B16 cell population. DMF stimulated the lung-colonization potential of 
the tumour cell population as a whole since removal of the agent resulted 
in the re-acquisition of the original level of lung-colonizing ability even 
with long-term cultures.
The mode of action of differentiation-inducing agents are multifold, 
causing changes in enzyme activities, chromatin structure, antigenicity, 
surface membrane composition, fluidity, and growth kinetics (Spremulli & 
Dexter, 1984). This study did not determine whether the increase in 
tyrosinase activity induced by DMF was quantitative or qualitative. 
Tyrosinase activity peaked with 0.5% DMF (fig.8a) and was similar to the 
level exhibited by the more melanotic B16F1 cells and their DMF-treated 
counterparts, suggesting that the activity was maximal. By virtue of its 
small molecular weight and polar nature, DMF partitions into cellular 
membranes and may modify tyrosinase activity either by directly 
influencing gene expression or membrane fluidity (Spremulli & Dexter, 
1984). The increase in tyrosinase activity is reflected in the accumulation 
of intracellular melanin (and extracellular levels). Similar increases in 
the levels of melanin and tyrosinase induced by DMF and N-MF in B16 
melanomas have also been detected by other investigators (Spremulli & 
Dexter, 1986). Since melanin levels and tyrosinase activity showed a poor 
correlation with the cellular differentiation of the B16 melanoma cells 
used in this study, their role as markers of cellular differentiation may
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only apply to the differentiation of normal, non-transformed, pigmented 
cells.
In conclusion, although DMF induced some aspects of differentiation over a 
range of concentrations, their functional potential in restoring a less 
metastatic phenotype appears to have been negated, possibly through the 
expression of other uncharacterized side-effects induced by DMF. It is 
also possible that the observed increase in metastatic potential may only 
reflect the increases in cell size, homotypic cell-cell interactions and 
alterations in GAG biosynthesis since DMF-treated cells failed to 
demonstrate any significant positive differences in their ability to 
degrade subendothelial matrix or attach to ECM proteins. Bennett etal. 
(1986) also observed that the induction of melanoma cell differentiation 
with a-MSH, using melanin and tyrosinase as markers, also induced an 
increase in metastatic potential. The differentiative effects accorded to 
polar solvents may be as a result of the direct effects of the agents on 
DNA and the factors that control its transcription, or their effects on 
cell-mediated cytotoxicity (Spremulli & Dexter, 1984).
Other reports of the influence of polar solvents, including DMSO and DMF, 
upon lung colonization have been recorded (Takenaga, 1984; Bentel etal., 
1990). Such agents stimulate the lung colonizing potential of poorly 
metastatic LLC cells and elevate both the levels of cathepsin B and 
plasminogen activator and the degradation of subendothelial matrix 
(Takenaga, 1984). Cells pretreated with polar solvents are also more 
resistant to detachment from culture plastic by trypsin, and DMSO has 
been demonstrated to induce a more organized cytoskeleton in B16 
melanoma cells (Lampugnani eta/., 1987). Cytoskeletal reorganization
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affects various cellular processes including growth and gene expression. 
The presence of proteoglycans in focal contacts and their involvement in 
the linkage of the cytoskeleton to the ECM suggests a role for cellular 
proteoglycans in the development of cell morphology and phenotype. Since 
DMF was observed to induce a more flattened cell morphology and to 
stimulate GAG biosynthesis, it could be suggested that these two events 
are linked; increased biosynthesis of cell associated GAG may indicate an 
increase in proteoglycan biosynthesis. This may be concomitant with in an 
increase in their accumulation within focal contacts resulting in an 
increase in cell-matrix stabilization and altered cell morphology. This 
hypothesis also applies to the untreated B16F1M3 cells which also display 
increases in GAG biosynthesis and more flattened cell morphology when 
compared with B16F1 cells. The altered cell morphology, if a consequence 
of increased proteoglycan biosynthesis, may induce the changes in cell 
phenotype that differentiate between these cell lines, thereby possibly 
implicating a role for proteoglycans in the regulation of gene expression.
DMF may mediate its initial growth inhibitory effects either through 
direct genetic effects or by the synthesis of growth-inhibitory molecules.
The growth of human colon carcinoma cells is reversibly supressed by 
N-MF through its inhibition of c-myc expression (Chatterjee etal., 1989), 
and the induction of a non-transformed cell phenotype with reduced 
growth rate in AKR-MCA cells by DMF may be a consequence of its 
stimulation of the synthesis of a TGF-B-like protein (Levine etal., 1987).
An increase in, or acquisition of, metastatic potential may represent a 
cellular response to the development of stress conditions (e.g. hypoxia, 
nutrient deficiencies and necrosis) within cells and tumours (Alterman et
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a/., 1989; Young etal., 1988; Hill, 1990; Young & Hill, 1990), and once the 
conditions of stress are eleviated the cells may reacquire a more normal 
phenotype. The DMF-induced increase in lung-colonizing potential may 
therefore be a consequence of, or response to, environmental or cellular 
stress(es). Whether DMF itself is a stress agent, or whether it induces the 
synthesis or accumulation of stress factors is undetermined. DMF was 
observed however to rapidly induce the synthesis of cytotoxic levels of 
extracellular melanin. The accumulation of this substance may represent a 
stress factor which induces an enhancement in metastatic potential.
Under these conditions the metastatic phenotype may represent an "escape 
response" elicited in order to improve the cells probability of survival.
5.1.4. Cell Growth
Although DMF had an initial growth inhibitory effect on B16F1M3 cell 
growth, the effect did not endure and DMF-treated cells appeared to regain 
growth rates similar to their original rates of growth. The reacquisition 
of a normal growth rate may reflect an adaptation response by the cells to 
DMF by which cells become less sensitive to its effectsF. It is also 
possible that DMF activates, in a temporal manner, the expression or 
accumulation of other factor which account for the normalizing of cell 
growth rate. This may be effected through the induction of enzymes 
capable of metabolizing DMF to a less active form or the synthesis of 
molecules which are capable of either transporting DMF out of the cell or 
inactivate it through complexing it into an inert form.
The initial DMF-induced inhibition of cell growth may possibly be related 
to the positive effects of DMF on HS-GAG sulphation. Heparin-like HS-GAG 
have been identified as regulators of cell growth (Kawakami & Terayama,
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1981; Castellot etal., 1982; Gordon etal., 1988,1989). Therefore the 
anticancer and growth inhibitory effects of polar solvents on in situ 
tumours (Spremulli & Dexter, 1984) may be related to the induction of 
similar GAG alterations. Unfortunately, the influence of cell surface or 
medium fraction HS-GAG in the regulation of B16 melanoma cell growth 
was not determined. However, if B16 melanoma-derived HS-GAG is growth 
inhibitory for other cell populations within a tumour it may provide a 
selective growth advantage by permitting the expansion of those tumour 
cell subpopulations which are resistant and which may be metastatic.
N-MF, and therefore possibly DMF, suppresses the expression of the c-myc 
proto-oncogene, by reversibly inhibiting its transcription (Chatterjee et 
al,  1989). Suppression of c-myc may be associated with the ability of 
N-MF to increase cell doubling times. Heparin and endothelial cell HS-GAG 
inhibits smooth muscle cell growth and also inhibits c-fos and c-myc 
expression (Pukac etal., 1990), possibly through the selective inhibition 
of a Protein Kinase C-dependent pathway for proto-oncogene induction. 
Although the link between the synthesis of highly sulphated HS-GAG and 
B16 melanoma cell growth is at present circumstantial, it is nonetheless 
seductive. B16F1 cells were observed to synthesize medium HS-GAG with 
a higher degree of sulphation than B16F1 M3 cells and subsequently 
possessed a slower growth rate. DMF which induced B16F1M3 cells to 
synthesize oversulphated medium HS-GAG and was accompanied by an 
initial reduction in their growth rate. Consequently, the inhibitory effect 
of DMF on cell growth may be twofold; DMF elicits its growth inhibition 
through increasing HS-GAG sulphation and inhibiting c-myc expression.
Unfortunately this potential relationship does not hold for the B16
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melanoma cell clones; B16F1H5 cells synthesize, on average, a more 
sulphated HSPG than B16F1D2 cells, but possess a faster growth rate. 
However, it is also possible that B16F1H5 cells represent a subpopulation 
of cells resistant to any growth inhibitory properties associated with 
HS-GAG. Heparin was however observed to elicit no effect on the growth 
rate of B16F1 M3 cells. This may either indicate that heparin is a selective 
growth inhibitor for some cell types, or that any growth inhibitory 
property associated with B16 melanoma HS-GAG is specific for these B16 
melanoma cells. Alternatively, the growth inhibitory properties of DMF 
may be only related to an inhibition of proto-oncogene expression.
5.1.5. Matrix dissolution
The degradation of BM collagen IV disrupts the structural integrity of this 
matrix. Whereas differences in the abilities of cells to adhere to 
individual ECM components may not reflect their capacity to attach to 
complex matrices, it may be critical and reflective of their ability to 
degrade ECM. The interaction between tumour cells and laminin is known 
to induce in some cell types the synthesis of type IV collagenase 
(Turpeenniemi-Hujanen etal., 1986; Emonard etal., 1990) and to correlate 
with metastatic potential (Turpeenniemi-Hujanen etal., 1985; Reich et 
al., 1988b; Hoyhtya etal., 1990). In this study however, the attachment of 
B16 melanoma cells to laminin-nidogen in vitro and their abilities to 
liberate ^H-proline from metabolically labelled subendothelial BM was 
inconsistent with metastatic potential, indicating that the B16 cell lines 
did not differ significantly in collagenase activity. Additionally, the 
efficiency of tumour cell attachment to laminin did not reflect 
collagenolytic activity, and might therefore suggest that laminin does not 
induce collagenase synthesis in these B16 melanoma cell lines. To what
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extent melanocytes are involved in the normal maintenance and turnover 
of the BM and its constituent proteins is not known. However since these 
results indicate an intrinsic level of collagenase activity in B16 cells this 
may reflect a normal function of melanoma cell precursors in the 
maintenance and turnover of BM collagen IV. Although the results indicate 
that collagen IV degaradation was insufficient in itself to reflect 
metastatic potential, it may be reflective of invasive potential which was 
not investigated in this study. Metastatic ability probably involves other 
co-ordinated and possibly related activities. Collagenase activity 
stimulates cell migration and metastatic cell populations may be more 
responsive to the migratory signals and factors elicited through the 
action of these enzymes.
BM HSPG is believed to assist in the maintenance of the structural 
integrity of the BM by interacting with different matrix proteins through 
their GAG-binding domains. Degradation of the GAG chains could result in 
the loss of this integrity and loosen the matrix structure, facilitating 
matrix invasion. Degradation of matrix HSPG may also liberate GAG-bound 
growth factors and enhance the activity of matrix-associated proteinases 
(Falcone, 1989; Watahiki etal., 1989). The actions of heparanases have the 
potential to elicit a wide range of biological phenomena that would be 
advantageous for invading cells. Consequently, heparanase activity has 
been demonstrated to correlate positively with the metasatic potential of 
several cell lines (Nakajima etal., 1983; Savion etal., 1987; Vlodavsky et 
al., 1988). In this study ^^S-releasing activity, suggestive of heparanase 
activity, also correlated positively with lung colonizing potential: more 
metastatic B16 melanoma cell lines and clones possessed higher levels of 
this activity than their poorly metastatic counterparts although DMF did
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not influence the level of this activity in B16F1M3 cells. Polar solvents 
modulate protease activities in a range of different cell lines (Spremulli 
& Dexter, 1984; Takenaga, 1984), but the increase in lung colonization 
attributed to DMF in this study does not appear to be a consequence of its 
modulation of heparanase activity. There may be a subsequent relationship 
between ^H-proline- and ^^S-releasing activities and metastatic 
potential. It is probable that the joint actions of collagenases and 
heparanases have deleterious effects upon the integrity of the BM matrix. 
Cells with enhanced heparanase activity may disrupt the BM more severely 
and more rapidly, thereby improving their prospects of escaping from the 
constraints imposed by the matrix.
5.1.6. Proteoglycans
Glycosaminoglycans exert strong influences on several biological 
processes intrinsic to the metastatic process. Matrix invasion is enhanced 
by both heparin and HS-GAG (Robertson etal., 1989), and can be blocked 
specifically by pretreatment of cells with heparins, HS-GAG or highly 
sulphated chitins (Saiki etal., 1990b); the inhibitory effects of these 
molecules appears to be related to their degree of polymer sulphation. 
Heparin is also capable of blocking the attachment and migration of B16 
cells to laminin-coated substrates (Saiki etal., 1990b), and heparin and 
chitin analogues inhibit heparanase and type IV collagenolytic activities. 
Cathepsin B and plasminogen activator (PA) activities can correlate with 
B16 melanoma lung-colonizing ability (Wang etal., 1980; Sloane etal., 
1981,1982) and can also be modulated by GAG. Consequently, since 
cell-derived GAG possesses the potential to modulate both cellular 
behaviour and the actions of environmental factors, the influence of local 
concentration, distribution, composition, and intrinsic properties of GAG
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merits evaluation.
From data derived from qualitative GAG studies there appeared to be no 
consistent correlation relating charge density and the degree of GAG 
sulphation to the lung colonizing potential of B16 melanoma variants.
DMF had a positive effect upon both the charge density and the degree of 
sulphation of HS-GAG synthesized by B16F1M3 cells (which was countered 
by a concomitant negative effect upon both CS-GAG charge density and 
sulphation). Similarly, cells cultured in the presence of heparin 
synthesized oversulphated medium HS-GAG, yet heparin did not influence 
lung colonization; poorly metastatic B16F1H5 cells also synthesized a 
medium HS-GAG fraction with a higher charge density and degree of 
sulphation than highly metastatic B16F1D2 cells. Although increases in 
the degree of sulphation and therefore the charge density of HS-GAG may 
be interpreted as being potentially beneficial since many GAG-binding 
activities are charge-dependent, the level of HS-GAG sulphation, whether 
increased or decreased, had no direct effect on metastatic potential. The 
effect of DMF on both HS-GAG and CS-GAG sulphation were similar to 
those observed for low cell-density, low lung-colonizing potential B16 
melanoma cells and for cells treated with retinoic acid-treated which 
inhibits lung-colonization (Edward & Mackie, 1989). Such observations 
suggest that even gross alterations in the properties of B16 melanoma 
GAG have little effect in influencing lung colonization. The mechanisms by 
which DMF and retinoic acid influence metastatic potential are not fully 
elucidated. Subsequently, their effects upon GAG biosynthesis may be a 
minor consequence of their potential to influence both gene expression and 
enzyme activity, and may represent no more than the modulation of those
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enzymes which influence, or are integral components of the GAG polymer 
modification pathway.
It is difficult to assess the role of the medium fraction proteoglycans and 
GAG in tumour cell metastasis using the artificial metastasis system. In 
washed cell suspensions their presence would be minimal, but their levels 
and properties may influence the environment, growth, and phenotype of 
the cell populations within the primary tumour and metastases by altering 
the physical and chemical properties of the pericellular matrix and by 
modulating cell interactions with the matrix in situ.
As indicated previously, HSPG are implicated in cell adhesion and growth. 
Modulation of HS-GAG charge properties by chlorate or heparin had no 
significant effect on the lung colonizing potential or growth rates of 
moderately metastatic B16F1M3 cells. Heparin had a positive effect upon 
the sulphation pattern of medium fraction HS-GAG, whereas chlorate had 
the opposite effect, reducing the degree of HS-GAG sulphation in both the 
medium and trypsin fractions. It is possible that the failure of these 
agents to affect lung colonization is a reflection of the moderate lung 
colonizing capacity of the B16F1 M3 cells. Any detectable significant 
effect that these agents may have had upon the metastatic potential of 
highly (or poorly) metastatic cell populations may be diluted out as a 
consequence of the heterogeneity of the cell line. Consequently, the 
actions of these agents on the metastatic potential of highly metastatic 
cells merits evaluation. Highly metastatic, less heterogeneous cell 
populations, such as B16F1D2, may have proved to be more informative 
since only one population of highly metastatic tumour cells would be 
evaluated, and any modification in metastatic behaviour caused by the
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modulation of cell GAG would not be masked by similar alterations in non- 
and poorly metastatic cell populations.
6-D-xyloside also affected the level of GAG sulphation by reducing the 
amount of ^^S-incorporation into medium and trypsin HS-GAG and 
CS-GAG, although this only translated into reduced sulphation in cell 
surface CS-GAG and medium HS-GAG as measured by Mono-Q-Sepharose. 
These results confirmed that the degree of GAG sulphation did not 
correspond with metastatic potential. B-D-xyloside inhibits the activities 
of the polymer modifying enzymes, uronosyl C-5 epimerase and 
4-sulphotransferase (Coster etal., 1991), without greatly altering the 
sulphation pattern, and the activities of these enzymes are believed to be 
regulated by proteoglycan core protein. This finding would explain the 
reduction in CS-GAG sulphation observed in the culture medium. The large 
and near-exclusive stimulation of CS-GAG synthesis also indicate that 
specific signals within core proteins determine the proteoglycan species, 
and that the galactosyltransferases involved in CS-GAG biosynthesis are 
less specific than those involved in HS-GAG synthesis (Stevens & Austen, 
1982).
Although the charge density properties of the GAG synthesized by the B16 
melanomas used in this study did not appear to be related to the lung 
colonizing potential, there appeared to be an important correlation with 
the level of proteoglycan expression and/or its degree of glycosylation, 
measured either as an increase in GAG chain number or size. B16F1D2 
cells synthesized cell surface GAG that was predominantly expressed as 
proteoglycan; B16F1D2 cells synthesized cell-lysate HSPG and CSPG and 
medium CSPG which eluted prior to that of B16F1H5 cells on Sepharose
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CL4B indicating a larger molecular mass. The large CS-GAG species 
present in the culture medium after pronase digestion was also larger for 
B16F1D2 cells, and B16F1D2 cells synthesized significantly more medium 
and trypsin fraction GAG than B16F1H5 cells. Consequently, it is possible 
that differences in the molecular size of the proteoglycans synthesized by 
the cell clones can be attributed to differences in their levels of 
glycosylation, e.g. B16F1D2 cells may synthesize proteoglycans with an 
increased degree of glycosylation. Although this was not established per 
se for B16F1, B16F1 M3 cells and their DMF-treated counterparts, the 
increase in the levels of cell surface GAG that correlate with increased 
lung-colonizing potential may also be related to an increase in 
proteoglycan glycosylation. There is some evidence to support this theory. 
Timar & Lapis (1990) reported that a decrease in HSPG epitopes occurred 
in highly metastatic carcinoma and B16F10 cells, and was accompanied by 
an increase in total HS-GAG in the carcinoma cells. The reduction in HSPG 
epitopes was attributed to either the loss of epitopes or their masking 
through increased glycosylation. Similarly, Yeo etal. (1991) reported that 
increased CSPG glycosylation was a feature common to tumour stroma and 
healing wounds, both of which share common pathological entities.
Protein glycosylation is believed to be protective in certain respects by 
masking specific immunologically-sensitive epitopes or by protecting 
core proteins from proteolysis. The role of increased proteoglycan 
glycosylation may be to protect functionally important cell surface 
proteoglycans from proteolysis or increase their likelihood of successful 
participation in charge-dependent interactions such as the sequestration 
of GAG-binding growth factors (Roberts e/a/., 1988; Gospodarowicz etal., 
1987; Gordon etal., 1988; Luikart etal., 1990). Increased glycosylation of
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cell surface proteoglycans or increases in GAG chain length would have 
the to potential influence the hydration properties of both the cell surface 
and the pericellular matrix which may contribute to successful 
metastasis. On an immunological basis, the masking of epitopes through 
glycosylation may be critical. The HSPG transferrin receptor (Fransson et 
al., 1984), has been postulated as a target for human NK cells (Perl etal., 
1986) and the loss of HS-GAG chains may expose epitopes recognized by 
NK cells. Conversely, reduced B16 melanoma cell susceptibility to NK cells 
has also been attributed to a reduction in the level of cell surface 
HS-GAG, and may suggest that GAG chains themselves represent epitopes 
recognized by the immune effector system. Therefore alterations or 
perturbations in the enzymes that facilitate GAG polymer modifications 
may result in the expression of sensitive epitopes. This however remains 
to be resolved.
The failure in this study to associate distinct qualitative differences in 
GAG biosynthesis does not necessarily suggest that such changes are not 
relevant in tumour cell metastasis. Subtle alterations in the degree or 
types of O-sulphation or the degree of epimerization or N-sulphation may 
be significantly important. The undersulphation of HS-GAG that can 
accompany viral or spontaneous transformation is usually the consequence 
of reduced O-sulphation (Underhill & Keller, 1977; Winterbourne & Mora, 
1981; Smith etal., 1987). Specific oligosaccharide sequences may confer 
specialized functions. Kure etal. (1987) demonstrated that reduced cell 
surface HS-GAG correlated with increased B16 melanoma metastatic 
potential, and that cells selected for reduced cell surface HS-GAG levels 
possessed an increased potential. The criterion for selection was a 
HS-GAG-specific monoclonal antibody suggesting that the loss of a
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specific HS-GAG epitope correlated with increased metastatic potential.
As expected, sodium chlorate had an inhibitory effect on the charge 
density of the HS-GAG synthesized by B16F1M3 cells. It is reported that 
sodium chlorate inhibits both O-sulphation, GlcLIA C5-epimerization and 
the subsequent N-sulphation of deacetylated GlcN (Keller etal., 1989). In 
agreement with other reports (Greve etal., 1988; Humphries & Silbert,
1988; Walters etal., 1988), sodium chlorate also reduced the charge 
density of the CS-GAG synthesized, supporting the view that the 
sulphotransferases involved in CS-GAG synthesis are more sensitive to 
the action of sodium chlorate. In contrast, heparin induced an increase in 
the degree of sulphation of the medium fraction HS-GAG. Heparin has been 
shown to specifically stimulate the degree of sulphation of the HS-GAG 
synthesized by rabbit endothelial cells with an enrichment of uronic acid 
sulphation (Nader etal., 1989). The findings that it was possible to 
chemically induce gross alterations in the charge density properties of 
cell-derived GAG without significantly affecting colonization suggests 
that the extent and nature of these alterations plays a minor role in the 
latter stages of lung colonization. The GAG modifications associated with 
neoplastic transformation and/or acquisition of a metastatic phenotype 
may be beneficial to that phenotype, but would appear to be an effect of 
the altered cell phenotype rather than a cause.
Sepharose CL4B GPC indicated that both B16F1D2 cells and their 
13-D-xyloside-treated counterparts synthesized proteoglycans and GAGs 
with similar elution profiles. Size exclusion analysis of these structures 
suggested that B-D-xyloside did not appear to significantly alter the size 
of the proteoglycans synthesized but reduced their levels of expression on
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the cell surface. Consequently, the reduction in lung colonization 
attributed to 3-D-xyloside-treatment suggests that the underexpression 
of proteoglycans is the basis of this reduction in metastatic potential. A 
change in GAG chain length cannot be ruled out since Yeo etal. (1991), 
reported that an increase in CS-GAG glycosylation in tumour stroma and 
healing wounds could be attributed to an increase in CS-GAG chain size. 
The effect of alterations in GAG chain length on proteoglycan functioning 
and properties and cell behaviour is poorly understood. Increased chain 
length may result in the local modification of tumour microenvironments 
ranging from increased ligand binding, to modulation of degradative 
enzyme-inhibitor balances to variance in the biophysical and biochemical 
properties of the tumour extracellular matrix.
Comparison of the cell surface proteoglycan profiles of the two lots of 
B16F1D2 cells used in the studies with 3-D-xyloside-treated cells and 
B16F1H5 cells revealed a reduction in the relative proportion of 
proteoglycan to free GAG chains. This may reflect the effect of the polar 
solvent, DMSO, which was used to dissolve the (3-D-xyloside, and was 
present in the medium of control B16F1D2 cell cultures at a concentration 
of 0.17%.
The Sepharose CL4B GPC results also suggest that 3-D-xyloside does not 
affect the level of proteoglycan glycosylation: there was no distinct peak 
to indicate the presence of partially-glycosylated proteoglycan forms. 
3-D-xyloside only appears to suppress the numbers of fully glycosylated 
proteoglycans although non-glycosylated proteoglycan core proteins may 
have been synthesized and expressed. If naked core proteins are expressed 
in the plasma membrane, they may represent epitopes recognized by NK
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cells, and thereby prove to be a potential mechanism for the reduced 
lung-colonizing potential observed for B-D-xyloside-treated cells. The 
failure to detect partially-glycosylated proteoglycans might indicate that 
the proteoglycan biosynthetic apparatus is capable of synthesizing and 
expressing only fully glycosylated proteoglycan (or naked core protein).
The presence of apparently mature proteoglycans in the plasma membrane 
of B-D-xyloside-treated cells emphasizes the importance of these 
structures for the normal biological functioning of cells.
GAG-deficient BHK cells have been observed to exhibit altered adhesion 
responses and fail to form stress fibres and focal contacts (Couchman et 
ai,  1988; LeBaron etal., 1988). HSPG are involved in cel I-substrate 
attachment (Gill etal., 1986). Proteoglycans, in particular HSPG, are 
implicated in tumour cell metastasis since the process can be perturbed 
by the heparin-binding domain of fibronectin (McCarthy etal., 1988). The 
inhibitory effect of B-D-xyloside on cell attachment to collagen IV 
suggests that cell attachment to this protein may be mediated, in part, by 
proteoglycans. Both B16F1 M3 cells and their DMF-treated counterparts 
possess more cell surface GAG than B16F1 cells and show an increased 
rate of cell attachment to collagen IV. Cell surface proteoglycans may 
therefore be involved in cell attachment to collagen IV as appears to be 
the case for attachment to laminin and fibronectin, at least in the initial 
phases of the process. The level of cell surface GAG however, does not 
reflect the final level of cell attachment to collagen IV since B16F1, 
B16F1M3 and DMF-treated cells possessed similar levels of attachment 
after 90 mins. GAG may possess multiple roles in cell attachment. Since 
the GAG side-chains are highly flexible molecules and possess a large 
volume to size ratio, they may represent primary, non-integrin adhesive
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mechanisms: GAG may represent the first molecules to interact with 
matrix proteins through their GAG-binding domains, and the resultant 
receptor-ligand interaction may prove stable enough temporalily, to 
permit the later interactions between integrins and matrix proteins.
Further, the GAG side-chains may stabilize this receptor-ligand complex 
and assist in the formation of adhesion plaques and cytoskeletal 
reorganization and stabilization.
Although G-D-xyloside suppresses lung colonization and the expression of 
cell surface proteoglycans, which may be related factors, and that cell 
surface proteoglycans may be a potentially important factor in this phase 
of the metastatic process, it is possible that the inhibitory effect on lung 
colonization is mediated through the effect of G-D-xyloside on the 
biosynthesis of other important glycoconjugates.
It was consistently observed among all B16 cells whose proteoglycans 
were analyzed via Sepharose CL4B GPC that although free CS-GAG and 
HS-GAG chains appeared to be released into the culture medium, only 
CS-GAG was polymerized as proteoglycan. There also appeared in the 
culture medium a large chondroitin sulphate-species which eluted from 
the GPC column in the same region as proteoglycans but which was 
pronase-resistant and chondroitinase ABC sensitive, indicative of either a 
larger molecular weight CS-GAG or a CSPG protected from proteolysis due 
to its level of glycosylation. The nature and function of this chondroitin 
sulphate was not determined and may be important. Whether a similar 
species is detectable on B16F1M3 cells and B16F1 cells and whether DMF 
influences its physical characteristics needs to be determined. Attention 
has now focussed on the CD44 CSPG, the expression of which correlates
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with metastatic potential (Gunthert etal., 1991; Faassen etal., 1992). 
Whether the metastatic B16 cells express this molecule and if so whether 
its physical properties are altered is worth evaluation. The ability of this 
molecule to confer metastatic potential is apparently related to the 
generation of different isoforms through alternative splicing. This is 
particularly intruiging since B16F1D2 cells synthesize a larger cell 
surface CSPG species than B16F1H5 cells.
Changes in GAG charge density appears to be relatively unimportant in the 
later stages of B16 melanoma metastasis. Increases in charge density and 
in particular to the degree of sulphation have been equated with 
improvements in binding activities for various macromolecules and 
growth factors. The observed differences in charge density and degree of 
chain sulphation, whether naturally occurring or chemically induced, are 
inconsistent with the observed metastatic potentials and adhesion 
characteristics to defined ECM components. Many binding properties of 
GAG can be substituted for by increases in GAG chain numbers since 
charge is often the major determinant of GAG binding activity. The 
observation that all metastatic cell lines express elevated levels of total 
cell GAG when compared with the poorly metastatic cell lines corresponds 
with this, and it may be that although increases in the charge density of 
specific GAG may provide a selective advantage, these may be countered 
by increases in the total cell surface GAG charge density by the increase 
in GAG chain numbers. Increases in cell surface GAG may result in an 
increase in the total cell surface negative charge. Whether this has 
important consequences on cell phenotype and properties also merits 
further evaluation.
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An Increase in GAG biosynthesis has the potential to alter the 
physicochemical properties of the ECM surrounding cells. Increased GAG 
levels would affect the hydration properties of the pericellular matrix and 
ECM, and may also increase the availability of GAG-binding growth factors 
and strengthen, or interfere with, the cellular interactions with ECM 
components. The effect of B16 cell-derived GAG on other cell types has 
not been evaluated. Tumour cells, including B16 melanomas, can induce 
other cell types to remodel and alter the physicochemical properties of 
the ECM, either by producing factors which induce collagenolysis (Biswas 
& Nugent, 1987) or stimulate alterations in GAG biosynthesis (Edward et 
al., in press). Therefore the effect of melanoma-derived ECM and 
proteoglycans upon the behaviour of normal cells also merits further 
study.
The reduction in total GAG present in the cell surface, whether as 
proteoglycan or free GAG chains would appear to correspond with the 
reduction in lung colonization ability. It may be that a reduction in GAG 
results in the loss of some cell surface factor, or a reduction or loss of 
some GAG-dependent activity important for lung colonization, or the 
subsequent early events that occur after lodgement.
In conclusion, the effects of the chemical properties of proteoglycans and 
GAG properties on lung colonization appear to be minimal. The levels of 
cell surface GAG and ^^S-releasing activity though did correlate 
consistently with metastatic potential, underling the importance of both 
cell surface and matrix proteoglycans in both maintaining tissue integrity 
and regulating cell behaviour. However the importance of cellular 
preferences for ECM proteins in cell attachment is unclear, since it
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appears that different tumour cell subpopulations display marked 
differences in attachment to defined ECM substates irrespective of their 
metastatic potential.
5.1.7. Further work.
It shouldbe noted that the GAG properties and profiles observed in vitro 
may be only a consequence of cell culture. In situ, one might expect that 
the cell enviroment, a readily modulated factor, would influence the 
texpression and properties of cell-derived GAG and proteoglycan. 
Subsequently the properties of the GAG synthesized by tumour cells in 
situ need to be addressed. The expression of larger cell surface 
proteoglycans by metastatic B16F1D2 cells and the increased level of 
radioactivity associated with metastatic B16F1M3 cells and DMF-treated 
cells suggests that the proteoglycan size may be an important factor, at 
least with the cell lines used in this study. Therefore it may be 
worthwhile to further characterize the proteoglycans synthesized by both 
B16F1M3 and B16F1 melanomas and determine whether increased 
proteoglycan size is consistent with metastatic potential and whether it 
is a function of increased glycosylation, or increased GAG chain or core 
protein size. In addition, it should be determined whether these B16 
melanomas express CD44, and if so, whether there are differences in its 
expression and properties between metastatic and non-metastatic cells. 
It would also be advisable to characterize several B16F1 M3-derived cell 
clones in order to generate sufficient data to relate GAG differences to 
differences in cell adhesion and metastasis.
The observation that ^ S - r e l e a s i n g  activity but not ^H-Proline releasing 
activity correlated with metastatic potential requires that the effect of 
these activities on cell migration also be investigated. It may transpire
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that the metastatic B16 populations are more responsive to matrix 
degradation products than their non-metastatic counterparts, and that the 
levels of collagenase activity recorded are sufficient to stimulate the 
(directed) motility of metastatic cells.
Very little could be said concerning the medium fraction GAG since their 
role in the latter phases of metastasis could not be evaluated. However, 
these molecules may be influencial in situ. It is observed that tumour 
cells can directly modulate the behaviour and activities, including the 
biosynthesis of macromolecules by neighbouring cells. The modulation of 
the activities of other neighbouring cells by specific subpopulations of 
tumour cells may confer some selective advantage(s) upon those cells in 
situ. Therefore the effect of tumour cell-derived GAG and proteoglycans 
on the activities of fibroblasts, endothelial, epithelial cell and melanoma 
cell cultures also merits close examination.
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